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Introduction
J.J. Fütterer
 Prostate cancer is the most common non-cutaneous cancer in the world. In 2005, 
an estimated 232,090 new cases and 30,350 deaths of prostate cancer are expected in the 
United States alone. Parallel to these figures, approximately 1 in 10 men will die of prostate 
cancer [1-2]. In the last 15 years an exponential rise in the number of patients diagnosed with 
prostate cancer was seen. The increase in the number of older persons and the introduction of 
prostate-specific antigen (PSA) serum screening programs resulted in an increase in prostate 
cancer incidence [1, 3-6]. After prostate cancer has been diagnosed, the therapeutic options 
are determined using nomograms [7-9]. The most frequently used nomogram, the Partin 
tables, estimates the chance of organ-confined disease, capsular penetration, seminal vesicle 
invasion and lymph node metastasis, based on the results of the traditional triad of digital 
rectal examination, biopsy Gleason score and PSA value [10].
 Clinical staging to differentiate between localized (surgical candidate) and advanced 
disease stage (androgen therapy and/or radiotherapy) appear to be unreliable. Curative 
therapy can be performed only in patients with localized prostate cancer. Accurate staging is 
therefore especially important for proper disease management. Since 1984 magnetic resonance 
(MR) imaging have been applied for this purpose. However, the role of MR imaging of the 
prostate is debated extensively in the literature. Initially MR imaging was performed using a 
conventional body coil with subsequent limited anatomical detail due to insufficient spatial 
resolution [11-15].  With the introduction of new MR sequences, new coils and other technical 
developments numerous studies have attempted to improve local staging. The diagnostic 
capability of MR imaging in preoperative staging of prostate cancer is currently being 
established. The results, however, are diverse, with a diagnostic accuracy of 54% - 88% [16-
33]. 
 In a meta-analysis of all published studies evaluating the performance of MR 
imaging in the local staging of prostate cancer, a wide variation in MR imaging performance 
was demonstrated [34]. A maximum combined sensitivity and specificity of 71% can be 
obtained, which is in agreement with a previous study by Sonnad et al. (i.e. 74%) [35]. 
Extrapolating these values to apply in a clinical setting is difficult, given the range of the local 
staging performance. It is suggested that it is more appropriate to focus on high specificity 
for extracapsular extension [36-37] in order to reduce overstaging and thus allow a more 
appropriate selection of patients for prostatectomy.
 On T2-weighted MR images, prostate carcinoma represents a low signal intensity 
area in a bright normal peripheral zone. In addition to carcinoma, the differential diagnosis 
of an area of low signal intensity includes biopsy haemorrhage, prostatitis, benign prostate 
hypertrophy, effects of hormonal or radiation treatment, scars, calcifications, smooth muscle 
hyperplasia, and fibromuscular hyperplasia [38]. Detecting prostate cancer in the central gland 
is difficult because this area is often involved with benign prostate hyperplasia, which has a 
signal intensity similar to that of cancer. T2-weighted MR imaging attains a tumor localization 
accuracy in a range of 67 to 72% [39-40]. 
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 Proton MR spectroscopy is a technique that provides metabolic information of the 
prostate gland that may be used for diagnosing prostate cancer. MR spectroscopic imaging 
can thus be used for localization of prostate cancer [41-42]. The addition of MR spectroscopic 
imaging resulted in 90% sextant positive predictive value for tumors in the peripheral zone 
of the prostate gland [40]. As cancer tissue can occur anywhere in the prostate the use of a 
three dimensional (3D) method to cover the whole prostate is essential [43]. Only recently 
the usefulness of MR spectroscopic imaging of the transition zone of the prostate has been 
studied [44]. The addition of 1H-MR spectroscopy to MR imaging can improve the tumor 
visualization and determination of tumor extension [45].
 Dynamic contrast-enhanced MR imaging is reported to be an effective tool in 
visualizing prostate pharmacokinetics [46-48]. Prostate cancer demonstrated different 
enhancement patterns compared to benign tissue [49-51]. The use of four semi-quantitative 
parameters (i.e. parameters fitted to the time - relative Gadolinium-DTPA concentration 
curves; start of enhancement, time-to-peak, peak enhancement and washout) [47], and three 
quantitative parameters (volume transfer constant, permeability surface area and extracellular 
volume) may be used to increase the localization performance. The number of studies 
evaluating the use of contrast-enhanced MR imaging in staging of prostate cancer is small with 
low numbers of patients [23, 28, 33, 52-53]. The role of multi-slice dynamic contrast-enhanced 
MR imaging in staging prostate cancer has as yet not been evaluated. However, dynamic-
contrast enhanced MR imaging demonstrated prostate cancer localization accuracies up to 
80% [28, 33]. The combination of high-resolution spatiovascular information from dynamic 
contrast-enhanced MR imaging and metabolic information from MR spectroscopic imaging 
has excellent potential to improve localization of prostate cancer in a clinical setting [54]. 
 Current opinion is that localized prostate cancer can be treated successfully by 
radical prostatectomy in the patient group with life expectancy of 10 to 15 years or more. 
Nevertheless, benefits of aggressive treatment over watchful waiting in terms of quality-
adjusted life expectancy are often small, leading to controversies about the best treatment [55]. 
Due to a lack of well-controlled comparative trials between surgical and radiotherapeutical 
interventions, the choice between these treatment modalities is often difficult. New forms of 
radiation therapy, amongst which intensity-modulated radiation therapy, have been developed 
in order to improve patient outcome and decrease short- and long-term side effects. The goal 
of intensity-modulated radiation therapy is to be able to escalate radiation doses in cancerous 
tissue to up to 90 Gy while keeping doses low (70 Gy) in adjacent prostatic tissue [56].
 In the past 20 years, a magnetic field strength of 0.5 to 1.5 tesla (T) has most commonly 
been used for MR imaging in clinical practice. However, the introduction of MR machines with 
higher field strengths (> 1.5T) has resulted in improved and more sophisticated applications 
in neuroradiology [57-58]. MR imaging beyond 1.5T has opened the doors for a variety of 
improvements in clinical research applications. The signal-to-noise ratio is approximately 
two times higher at 3T compared to 1.5T. Apart from the increase in signal-to-noise ratio, 
the spectral resolution at 3T is intrinsically also increased with a factor of two. The improved 
signal-to-noise ratio can be used for several purposes. First, it is possible to enhance the spatial 
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resolution in order to achieve improved visualization of subtle morphologic changes. Second, 
the high signal-to-noise ratio can be used to shorten acquisition time. However, besides these 
attractive options there are certain factors of concern in body applications of MR imaging 
at 3T: possibly shorter T2-, and longer T1-relaxation times [59], increased susceptibility 
differences, the homogeneity of the magnetic field in the organ or tissue of interest, especially 
for body applications, and radiofrequency coil efficiency. Theoretically an MR technique with 
an endorectal coil at 3T could produce high spatial, spectral and temporal resolution images. 
This high spatial resolution images may result in increased staging performance.
The aim of this thesis
 When prostate cancer is detected imaging is important to non-invasively show 
cancer localization, the extent of cancer, and possibly in the near future also aggressiveness 
of the cancer. Knowledge about localization, extent and aggression of prostate cancer is 
important as they determine the best therapy. Question which urologists and radiotherapist 
currently want to be answered are: firstly, is a prostate tumor present and which technique 
should be used for detection? Secondly, where is the tumor located? With local therapies 
like modern radiotherapy (intensity-modulated radiation therapy, brachytherapy, or proton 
beam), the local tumor within the prostate receives an extra dose of irradiation, which may 
result in better tumor control. Thirdly, is there tumor beyond the prostate capsule? If there is 
local extension of the cancer outside the prostate, prostatectomy is no longer the appropriate 
treatment option.
 Thus far the localization and local staging performance of MR imaging is 
disappointing and therefore the implementation of MR imaging into the clinical setting is 
limited. The performance of MR (spectroscopic) imaging, although well reported, is not 
sufficiently good to warrant a successful implementation into patient management. The aim 
of this thesis was to investigate how MR (spectroscopic) imaging may be improved and to 
determine if the resulting improvements will convince the urologists and radiotherapists to 
use these advanced MR imaging techniques and if these results will further improve at high 
field strength (3 tesla). This approach is outlined in the next chapter.
Outline of this thesis
	 In	 chapter 2 a general review is presented showing the current possibilities and 
limitations of staging prostate carcinoma using MR imaging, dynamic contrast-enhanced 
MR imaging and proton MR spectroscopy. In chapter 3 anatomical detail and local staging 
performance of MR imaging in prostate cancer using a pelvic-phased array and the integrated 
endorectal pelvic phased array coils are compared in a prospective study of 82 patients 
with prostate cancer who underwent radical prostatectomy. The radiological findings were 
compared with whole mount section histopathology. In chapter 4 the localizing performance 
of the whole prostate using T2-weighted fast spin echo, 3-dimensional proton MR spectroscopy 
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and dynamic contrast-enhanced MR imaging are compared in a prospective study of 34 
patients, using histopathology as the standard of reference. In chapter 5 the local staging 
performance of T2-weighted MR imaging and dynamic contrast-enhanced MR imaging was 
evaluated in a prospective study of 99 patients, using whole mount section histopathology 
as the standard of reference. Chapter 6 describes the feasibility of prostate MR imaging, 
dynamic contrast-enhanced MR and MR spectroscopic imaging at 3T using an endorectal 
surface coil. In chapter 7 the first results of 3T endorectal MR imaging in staging prostate 
cancer are presented. Chapter 8 compares the accuracy of two image registration methods 
using gold markers as fiducials. The intensity-modulated radiotherapy treatment of a 
dominant intraprostatic lesion requires accurate integration of functional MR with treatment 
CT. Chapter 9 describes a combined approach of dynamic contrast-enhanced MR imaging 
and 3-dimensional proton MR spectroscopy method in localizing the dominant intraprostatic 
lesion for intensity-modulated radiation therapy. Chapter 10 consists of the summary of the 
thesis, the conclusions and recommendations.
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2.1  Introduction
 In the last decade an exponential rise in the number of patients diagnosed with 
prostate cancer has occured. The aging of the population and the introduction of prostate-
specific antigen (PSA) serum screening programs resulted in an increase in prostate cancer 
incidence and cancer related death rate [1-5]. Consequently, there has been a downward trend 
in the stage of prostate cancer determined at the time of diagnosis. In 2003, 85% of prostate 
cancers were localized to the prostate at the time of diagnosis compared with 72% in 1993 [2, 
6]. Treatment selection depends on patient age and general health, cancer stage and grade, 
morbidity and treatment mortality, together with the preference of the patient and physician. 
The current general opinion is that localized prostate cancer can be treated successfully by 
radical retropubic prostatectomy in the patient group with a life expectancy of 10 to 15 years 
or more. Nevertheless, advantages of aggressive treatment over watchful waiting in terms of 
quality-adjusted life expectancy are often small, leading to controversies about the adequate 
treatment.
 Clinical assessment by digital rectal examination and measurement of PSA level 
are not accurate in determining local stage, with underestimations in as many as 40 - 60% 
of cases [7]. Accurate staging with additional imaging methods is therefore an important 
issue for correct management of prostate cancer patients. Among these imaging techniques, 
transrectal ultrasound (TRUS) may enable correct assessment of locally advanced tumors but 
is not sensitive enough to detect initial extraprostatic extension across the capsule or into the 
seminal vesicles in clinically confined lesions [8, 9]. Computed tomography scanning may be 
useful to determine locally advanced cancers by showing involvement of pelvic structures 
and lymph nodes in very advanced disease, but does not provide any additional value in 
patients with clinically localized prostate cancer (stage T2b or less)  [10], which is the main 
group of all prostate cancer patients.
2.2  The role of MR imaging in prostate cancer local staging
 MR imaging is considered to play an important role in local staging of prostate 
cancer. To justify the use of an expensive imaging modality like MR imaging, patients’ 
outcome should be improved by preoperative staging. To achieve this goal staging accuracy 
should be high, the results should affect diagnostic and especially therapeutic thinking and 
the alternative therapy should increase life expectancy and quality of life. Finally, this should 
be done at reasonable cost. Furthermore, this technique should be widely implemented, based 
on this high accuracy and effect of improved treatment outcome.
 Considering the fact that there is still debate regarding the best treatment option of 
localized prostate cancer, it may be clear that the benefits of more accurate staging are very 
hard to determine.
 Despite the lack of evidence, we will give recommendations concerning the use of 
MR imaging in local staging of prostate cancer
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MR imaging as a local staging tool. These recommendations are: 1. to determine one’s own 
staging performance; 2. to consider a learning curve; and 3. to be actively participating in 
patient selection and to be aware of the impact of the MR examination results on patient 
treatment.  
1. Determining one’s own staging performance: The role of MR imaging of the prostate is 
debated extensively in the literature. Initially MR imaging was performed using a conventional 
body coil with limited anatomical resolution [11-14]. With the introduction of new MR 
sequences, new coils and other technical developments numerous studies have attempted 
to improve local staging. The diagnostic capability of MR imaging in preoperative staging of 
prostate cancer is currently being established. The results, however, are diverse, as shown in 
table I (Table I; [15-32]). 
 Engelbrecht et al. performed a meta-analysis of all published studies evaluating the 
performance of MR imaging in the local staging of prostate cancer [33]. A wide variation in its 
performance was found, with a maximum combined sensitivity and specificity of 71%. This 
result is in agreement with a previous study by Sonnad et al. [34], who found a value of 74%. 
This wide variation (Table I) could only partially be explained by the use of different criteria of 
extraprostatic disease (strict versus lacks). If that was the case, the sensitivity-specificity pair 
should be located round a virtual ROC curve. Among others, the use of different techniques 
such as field strength, sequences, coils, contrast, patient selection, and scan direction, could 
not explain the wide variation in staging results. Perhaps the ideal MR of the prostate does 
exist, however, at this point in time, it unfortunately appears to be beyond our comprehension. 
In my opinion, this variation could be explained by the lack of expertise opinion, not using 
high specificity reading and strict criteria for extracapsular extension. However, this needs 
to be validated. Thus, the statement made by Jager et al. [26] in 1996 has been shown to 
remain appropriate: “Those who perform MR imaging in cases of prostate cancer should 
determine their own standard of accuracy by carefully comparing their imaging results with 
histopathologic findings.”
2. Consider a learning curve: An important factor in MR imaging of the prostate is its steep 
learning curve. It is stated that prostate MR imaging should be performed in centers where 
at least 25-50 patients per year are examined and where results can be compared with whole 
mount section histopathology [35], in order to be able for these readers to verify their own 
results constantly.  
3. Patient selection: In general, the diagnostic capability of tests are assessed by means of 
sensitivity, specificity and accuracy. However, these are conditional probabilities which 
express the probability of a positive, respectively negative results given the fact that the 
patient has or does not have the disease (extra-capsular extension). However, clinicians are 
more interested in the probability of extra-capsular disease given a positive test result, i.e. 
the positive predictive value (PPV). This number is directly related with a priory chance of 
extra-capsular disease. The Partin tables are commonly used by urologists to determine the 
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likelihood of organ confined disease in patients with prostate cancer [36]. 
 Furthermore, sensitivity and specificity may vary depending on the criteria used 
(strict versus lacks). The choice of lacks or strict criteria should depend on the consequences 
of false negative results versus false positive results. At our institution, not operating on a 
patient with possible curable disease is considered far worse than operating a patient who is 
not curable. Therefore MR is performed with high specificity being the most important goal. 
Langlotz has calculated that MR with a sensitivity-specificity pair of 30% - 97% is more cost-
effective compared to 82 - 80% [37], although the latter has a better diagnostic capability (0.64 
versus 0.81). 
 MR imaging may play a role in different treatment strategies. For example, it may be 
the final check for a patient who is considered candidate for radical prostatectomy, or it may 
be used to select patients with a moderate risk of extracapsular disease for either radiotherapy 
or surgery. 
Table I: Reported staging performance of MR imaging of prostate cancer
Author  year n  Coil  Sequence   Accuracy  Pathology
	 	 	 	 	 	 	 													
Rifkin et al.  1990 230 B  SE  77 b
Chelsky   1993 47 ER  SE  68 b 
Kier    1993 20 PPA  TSE  85 b
Outwater   1994 30 ER  TSE  79 w 
Quinn    1994 70 ER  TSE  67 w 
Tempany   1994 213 B / ER  TSE  61 / 54 w
Hricak    1994 71 PPA / ER-PPA    TSE  68 / 77 w 
Huch Boni  1995 33 ER  TSE  88  w
Brown   1995 20 B  SE   80 n/a
Bartolozzi  1996 73 ER  TSE  82    w
Perrotti   1996  56 ER   SE  64 w
Jager   1996 34 ER  TSE  68 w
Jager          1997 57     ER  TSE   72  w
Yu   1997 77 ER-PPA  TSE  77 w
D´amico  1998 49  multicoil-ER TSE  84 w
Rorvik        1999 32     ER  TSE  58 w
Tsuda   1999 79 ER-PPA        TSE    79  w
Ogura   2001 38     ER  TSE  72 w
n	=	number	of	patients;	accuracy	in	%;	B	=	body	coil;	ER	=	endorectal	coil;	PPA	=	pelvic	phased	array	
coil;	SE	=	spin	echo	sequence;	TSE	=	turbo	spin	echo	sequence;	b	=	biopsy;	w	=	whole	mount	sections;	
n/a  = not available
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 The effectiveness of MR imaging in other strategies is related to the prevalence of 
extra-prostatic disease in the group of patients undergoing MR imaging and thus to patient 
selection. In the literature several recommendations for patient selection are made. D’Amico et 
al. [29] advised the use of MR imaging of the prostate only for patients who are at intermediate 
risk for extracapsular extension because the probability of extraprostatic disease in this group 
is high enough to warrant the use of MR imaging. This was recently confirmed by Cornud et 
al. [38], who stated that the use of endorectal MR imaging is indicated in carefully selected 
patients - specifically, those with three or more positive findings in biopsy specimens, a 
palpable tumor, or a prostate-specific antigen level that exceeds 10 ng/mL.
  With Partin’s tables (a priori chance), sensitivity and specificity on one hand, and data 
about life-expectancy, complication rate and cost models on the other, the cost-effectiveness of 
MR staging in prostate cancer can be calculated.  
 Pauker et al. [39, 40] developed the so-called double threshold method. They 
demonstrated with a decision model that if there is a high probability of having a disease 
the patient should be treated without testing, while if there is a low probability one should 
not treat and the patients should be tested. Thus, it is possible to determine two thresholds, 
one for testing and one for treatment without testing. These depend on the risks and costs 
of testing, the sensitivity and specificity of the test, the risks and benefits and costs of the 
treatment. Engelbrecht and colleagues [41] applied this method to MR testing. Thus, patients 
can be divided into three groups: a low-risk group who should undergo radical prostatectomy 
without MR imaging; a high-risk group of patients who should be treated by palliative 
radiotherapy without MR imaging and an intermediate risk group, patients in whom the 
selection of treatment depends on imaging results.
 If one uses sensitivity and specificity of MR imaging in the assessment of stage T3 
disease reported in the literature (64% and 72%, respectively), the calculated thresholds for 
the three categories are: radical prostatectomy without testing in the low-risk group with 45% 
pre-test probability of having T3 prostate cancer; MR imaging in the intermediate-risk group 
having a 46 - 81% pre-test probability of having stage T3 disease; and palliative radiotherapy 
in patients without MR in the high-risk group has a pre-test probability that exceeds 81%. 
Thus far, the only practical way to determine a patient’s pre-test probability of having stage 
T3 disease is to use the Partin tables [36, 42], the most widely used and validated nomogram 
[43, 44]. To be placed in the intermediate-risk group (for whom MR imaging is cost-effective), 
a patient should have a PSA level exceeding 10 ng/mL, a Gleason grade greater than 6, or a 
stage T3 tumor found on digital rectal examination. 
 In conclusion: data from literature suggest that high specificity MR imaging is cost-
effective in the intermediate risk group. However, if results of imaging are improved such as 
for example reported by Fütterer et al. [45] (sensitivity of 65% and specificity 98%) the number 
of patients with a T3 tumour even in the low risk group (13/49) is high enough to justify 
MR imaging in these patients. This means with such an improved sensitiviy and specificity, 
all patients who are considered candidates for a radical prostatectomy should undergo MR 
imaging and their final treatment selection can be based on MR imaging findings.
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2.3  Prostate cancer pathophysiology
 Prostate cancer is a multifactorial disease. Age and a positive family history of prostate 
cancer are the main risk factors. Other factors are the type of diet, lifestyle-related factors, 
and certain genetic defects [46]. There is also a distinct geographical and racial difference in 
prostate cancer incidence with higher rates in Western countries and among black men, as 
compared to Asian countries and white men, respectively [3, 4].
 On a cellular and molecular level the main task of the prostate gland is to lubricate 
the sperm produced in the testes during ejaculation. In healthy prostatatic epithelial cells, the 
enzyme aconitase is inhibited by high levels of zinc present in the cells. This, in turn, blocks 
the oxidation of citrate in the Krebs cycle, thus accumulating citrate in the prostatic lumina. 
Zinc levels decrease in prostate cancer, thereby decreasing the citrate levels. However, the 
causes of the loss of zinc have not yet been established and are likely to be multifactorial. [42, 
48, 49]. The decrease in citrate levels is an important characteristic in spectroscopic detection 
of prostate cancer. (see below)
 The earliest determinable pathological changes in characteristics of the healthy 
prostatic cells are atrophic and inflammatory changes. A cascade of these and other factors 
may lead to the histopathologically defined precursors of proliferative inflammatory atrophy 
and prostatic intraepithelial neoplasia [50]. 
2.3.1  Prostate anatomy
 Knowledge of the zonal anatomy of the prostate is very useful considering that 
many prostatic diseases have a zonal distribution. More than 70% of adenocarcinomas of 
the prostate arise in the peripheral zone, whereas about 20% emerge in the transitional zone 
and 10% in the central zone.  Most central gland tumors have additional tumor foci in the 
peripheral zone [51-53]. Since many cases of prostate cancer are multifocal, combinations of 
these tumor localizations frequently occur within the same patient [54]. At our institution, 
the prostate is divided into a central gland (the transitional and central zones) and peripheral 
zone (Figure 1). 
 There is still debate about the prostate having a capsule or not. The prostate is 
surrounded by a thick layer of fibromuscular tissue corresponding to the capsule. The ‘true’ 
prostatic capsule, however, is a thin (0.5-2mm) layer of connective tissue located external 
to the peripheral zone. Around this layer there is the pelvic fascia, often called the “false” 
prostatic capsule. Sattar et al. considered the prostate capsule as an extension of the prostate 
parenchyma itself [55, 56].
 The periprostatic venous plexus surrounds the gland and drains into the internal 
iliac veins and the presacral veins. The neurovascular bundle courses along the posterolateral 
aspect of the gland (Figure 1) and is a preferential path for tumor spreading due to small 
nerve branches penetrating the prostate capsule in this area. The periprostatic fat shows high 
signal intensity on T2-weighted MR images, thus clearly delineating the rectum, muscles, 
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Figure 1. Normal prostate in a 28-year-old man. T2-weigthed 
MR image shows peripheral zone (PZ) with intermediate to 
high signal intensity. Small central gland (CG) has lower signal 
intensity than does the peripheral zone. The neurovascular 
bundle is located at the posterolateral aspect of the gland 
(curved arrow).
Figure 2. 56-year-old man with stage T2b prostate cancer in 
the right peripheral zone. T2-weighted MR image shows that 
the tumor (T) (arrows) has lower signal intensity than the 
peripheral zone.
Figure 3. 60-year-old man with stage T3a disease (T) in the 
left peripheral zone and central gland. T2-weighted MR 
image shows invasion of the neurovascular bundle (curved 
arrow). Obliteration of the left rectroprostatic angle (arrow), 
but the right neurovascular bundle and rectoprostatic angle 
are intact.
Figure 4A. 58-year-old man with stage T3a disease (T) in 
the left peripheral zone. Extracapsular extension (arrows) is 
clearly visible on axial T2-weighted MR image.
Figure 4B. 58-year-old man with stage T3a disease (T) in 
the left peripheral zone. Extracapsular extension (arrows) is 
clearly visible on coronal T2-weighted MR image.
Figure 5. 51-year-old man with stage T3a disease in the right 
peripheral zone. T2-weighted MR image shows that tumor (T) 
has lower signal intensity than does normal peripheral zone 
and shows bulging (arrows) and broad surface contact with 
capsule.
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bones, vasculature and bladder. 
 On T2-weighted MR images, normal prostate tissue displays an intermediate to 
high signal intensity while the central gland has lower signal intensity than the peripheral 
zone. Conversely, the prostate has an homogeneous, intermediate signal intensity on T1-
weighted images. This means differentiation between peripheral and central zone cannot be 
perceived.  
2.3.2 Imaging of prostate carcinoma
 On T2-weighted MR images, prostate carcinoma displays as a low signal intensity 
area in a bright normal peripheral zone (Figure 2). In addition to carcinoma, the differential 
diagnosis of an area of low signal intensity includes post biopsy haemorrhage, prostatitis, 
benign prostatic hyperplasia, effects of hormone or radiation treatment, scars, calcifications, 
smooth muscle hyperplasia, and fibromuscular hyperplasia. Detecting prostate carcinoma in 
the central gland on T2-weighted images is difficult because this area is often involved with 
benign prostate hyperplasia, which has signal intensity similar to that of carcinoma. 
2.4 Technique
2.4.1 Imaging protocol
 Interval between biopsy and MR imaging should at least be 2 to 4 weeks. At our 
institution regular prostate MR imaging is performed at 1.5T (Sonata, Siemens Medical 
Systems, Erlangen, Germany) using an integrated endorectal pelvic-phased array coil (Medrad, 
Pittsburgh, US). Peristalsis is suppressed by i.m. injection of 1 mg glucagon (Glucagen®; Novo 
Nordisk A/S, Denmark) prior to the examination. The endorectal coil is inserted and inflated 
with approximately 80 ml of air. The patient is then placed on the scanner table in the supine 
position. The scanning protocol consists of T1-weighted sagittal and axial localizer images 
obtained to check coil positioning. Subsequently, T2-weighted turbo spin echo images are 
acquired with the following parameters: 3500/132/180° [repetition time (TR) in msec/ echo 
time (TE) in msec/ flip angle (α)], 4-mm section thickness, 0-mm intersection gap, 15-22 slices, 
280-mm field of view (FOV), 240 x 512 matrix, pixel size 0.55 x 0.55, echo train length of 15, 
two signals acquired). The direction of the phase encoding and read-out gradient are changed 
from A-P to L-R to decrease endorectal motion artifacts. In addition, axial (T1) intermediate-
weighted sequence with the following parameters is required, 200 (TR), 4.4 (TE), 8° (α) and 
280-320 mm FOV for detecting post biopsy hemorrhage.
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2.4.2  Interpretation of MR images and pitfalls
 Radical retropubic prostatectomy is considered only in patients without
extracapsular extension and seminal vesicle involvement [13, 28, 59]. Accurate staging 
is therefore especially important for the proper management of prostate cancer. The most 
reliable criteria for the detection of extracapsular extension of prostate carcinoma are 
asymmetry of the neurovascular bundle, obliteration of the rectoprostatic angle, tumor bulge 
into the periprostatic fat, broad tumor contact with the surface of the capsule, an extracapsular 
tumor, and the radiologist’s overall impression (Table II and Figure 3-5) [18, 19, 21, 28]. At our 
institution this is further supplemented with the charcoal criterion, a low-signal-intensity lesion 
with a blurring border and extension (Figure 6). The most common but misleading MR sign 
of extraprostatic extension, e.g. irregular bulging (especially in non-palpable tumors), is not 
often used. Wedge shape, diffuse extension without mass effect, and size are the morphological 
features of low-intensity lesions in the peripheral zone on pre-biopsy T2-weighted MR images 
that give the best prediction of malignancy [61]. Seminal vesicle invasion can be identified 
as an asymmetric area of low signal intensity in the seminal vesicles that is visible on T2-
weighted MR images [18, 62]. Thickening of the tubular walls and asymmetric widening of the 
seminal vesicles have to be avoided as criteria, because these are non-specific signs [63]. Senile 
amyloidosis can mimic extraprostatic spread [64]. Prostate MR imaging should be obtained at 
a minimum of 2 to 4 weeks after prostate biopsy, as haemorrhage decreases staging accuracy 
[60]. On T1-weighted images, haemorrhages usually display high signal intensity (Figure 
7). Endorectal MR imaging findings are significant predictors for detection of extracapsular 
disease when MR images are interpreted by genitourinary radiologists experienced with MR 
imaging of the prostate [65]. Engelbrecht et al. [33] suggested in their meta-analysis that the 
use of turbo spin echo MR sequences, an endorectal coil, and multiple imaging planes can 
improve staging performance of MR imaging.
Figure 6. 64-year-old man with stage T3a disease in 
the left peripheral zone. T2-weighted axial MR image 
shows a low-signal-intensity lesion with a blurring 
border (arrows) and extension (curved arrow), in our 
institution referred to as the charcoal appearance.
Figure 7. T1-weighted axial image through prostate 
demonstrates a high signal intensity lesion (arrow) in 
the right peripheral zone which represents post biopsy 
hemorrhage.
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Table II: Criteria for Predicting Extracapsular Extension
Criterion            Accuracy           Specificity            Sensitivity                 PPV
   (%)  (%)  (%)  (%)
	 	 	
Asymmetry of the 70  95  38  NA
   neurovascular bundle
Obliteration of the  71  88  50  NA
   rectoprostatic angle  
Bulge of the tumor into 72  79  46  28
   periprostatic angle  
Extracapsular tumor 73  90  15  34
PPV	=	positive	predictive	value;	NA	=	not	applicable
2.5 Radiologic experience
2.5.1 Radiologic experience in local staging
 Harris et al. [35] reported the presence of a steep learning curve in staging prostate 
cancer. A substantial improvement in overall staging accuracy of endorectal MR imaging can 
be achieved by careful pathologic correlation and by considering the anatomic features of 
prostate cancer.
 One of the first multi-institutional studies examining detection of extracapsular 
extension showed no significant difference in the area under the receiver operating 
characteristic curve for MR imaging compared to TRUS (0.67 vs 0.62, respectively) [15]. 
However, this study was performed without the use of pelvic surface or endorectal coils and 
did not unambiguously state the imaging criteria for extracapsular extension. In 1994, the 
Radiologic Diagnostic Oncology Group (RDOG) study [20] utilizing the conventional body 
coil, and/or fat suppressed sequence with body coil and endorectal coil, reported overall 
accuracies for each technique of 61%, 64% and 54%, respectively. Since then only single 
institutional studies have been performed showing improved staging accuracies. Hricak et 
al. [21] found a staging accuracy of 68% using the pelvic phased array coil, which rose to 
77% with integrated endorectal-pelvic phased array coil in a study population of 71 patients. 
In 1998, Husband et al. [66] reported superior image quality for the pelvic phased-array 
coil combination compared to the endorectal coil, which was mainly due to fewer artefacts. 
However, other groups have shown markedly improved results for endorectal coil imaging, 
with accuracies up to 88% [22]. 
 In a prospective study of 82 patients with prostate cancer performed at our institution, 
the use of an integrated endorectal phased array coil resulted in significant improvement of 
anatomical details, staging accuracy, and specificity [45]. Using an endorectal-pelvic phased 
array coil was found to significantly reduce overstaging with equal sensitivity. Local staging 
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accuracy, sensitivity, and specificity using the pelvic-phased array coil alone were 59%, 54% 
and 62%, respectively, while using the combined endorectal-pelvic phased array coil, local 
staging accuracy, sensitivity, and specificity were 83%, 65%, and 98%, respectively. 
2.5.2 The role of contrast enhanced MR imaging in prostate cancer 
staging
 Because of typical tumor contrast enhancement characteristics, cancer can be 
differentiated from normal tissue on fast dynamic contrast-enhanced MR imaging [67, 68]. 
Engelbrecht et al. [69] showed that prostate cancer demonstrated different enhancement 
patterns compared to both onset time, time to peak, peak enhancement and washout. 
Nevertheless, the number of studies evaluating the use of contrast-enhanced MR imaging in 
staging prostate cancer are limited, results are conflicting and difficult to compare. Fütterer 
et al. [70] concluded in a study of 103 patients that the use of MR imaging in prostate cancer 
can be incorporated in clinical practice and that multi-slice dynamic contrast-enhanced MR 
imaging did show significant improvement in staging performance for the inexperienced 
readers (88% accuracy). 
2.5.3 The role of 1H-MR spectroscopy in prostate cancer staging
 Image-guided proton nuclear MR spectroscopy is a technique that provides metabolic 
information about the prostate gland that may be used for diagnosis of prostate cancer. 
Prostate cancer has been shown to be characterized by a decreased level of citrate and an 
increased level of phosphocholine [71]. Correlations have been reported between metabolite 
ratios (e.g. choline and creatine over citrate ratio) and the histologic grade of prostate cancer 
[72]. The addition of 1H-MR spectroscopy to dynamic MR imaging can improve the tumor 
visualization and determination of tumor extension [73]. The addition of 1H-MR spectroscopy 
to MR imaging has been shown to increase staging accuracy [74] for less experienced readers 
and reduce interobserver variability [73].  
2.6 Limitations
 Hemorrhage due to biopsy can produce areas of low signal intensities that can result 
in discrepancies between MR imaging results and histopathology results. This has to be taken 
into account whenever interpreting MR images. In many papers this issue is not addressed, 
which is inappropriate. 
 An important issue in the evaluation of the data in the literature is the presence 
or absence of positive surgical margins. The incidence of the latter has been reported to be 
as high as 40% in some studies. This has major implications on the results of these studies. 
Are positive surgical margins T3 disease, or is this still stage T2 in case of only focal disease? 
Currently, no consensus has been established. In our opinion, positive surgical margins in 
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prostates with large tumors are considered stage T3. However, stage T2 is assigned in cases of 
focal disease.
 There are several limitations associated with local staging of prostate cancer by 
MR imaging. The most important of these, as suggested by all authors, is the detection of 
microscopic invasion [16, 19, 45, 57]. However, none of the available imaging modalities 
allow the detection of microscopic invasion [75]. Positive surgical margins can contribute 
to the inconsistencies between imaging and pathology results. Cornud et al. [38] reported 
that pathologically staging tumors with positive surgical margins as stage T3, despite the 
fact that they appear within the limits of the prostate on MR imaging, would result in an 
unjustified lower accuracy of MR imaging. Epstein et al. [76] reported that patients with focal 
extracapsular extension showed no evidence of progression on long-term follow-up after 
surgery. In addition, it has been shown that endorectal MR imaging results that are negative 
or positive for extracapsular extension or seminal vesicle invasion help to separate patients 
with clinically confined disease and intermediate risk of extraprostatic spread into groups 
with a 78% vs. 21% 3-year rate of freedom from PSA failure [38, 77].
2.7 Future developments
 One limitation of dynamic MR imaging is that the variety of MR scanners and 
sequences used produce different gadolinium concentration-time curves and subsequently 
different parametric images providing true quantitative information (Ktrans, Kep and extracellular 
volume). Therefore, development of a robust calibration method is essential. This calibration 
may be performed by integrating the arterial input function for correction into the imaging 
protocol.
 As mentioned in the limitations section, the major limitation at the moment is the 
inability to detect microscopic invasion. The use of high magnetic field strengths offers 
new possibilities in prostate cancer imaging. Higher field strengths increase the signal-to-
noise ratio, which may lead to a higher spatial resolution and subsequently better staging 
performance (see also chapter 8.8 Fütterer). Fütterer et al. [78] explored how the potential 
benefits of higher field strength, e.g. 3T, balances with the potential limitations for MR of the 
prostate. The authors stated that it is likely that imaging with an endorectal coil at a magnetic 
field strength of 3T expands potential clinical applications in evaluating the prostate. A voxel 
volume reduction from 1.21 mm3 to 0.13 mm3 could be obtained. These developments may be 
used to detect microscopic invasion of the prostate capsule.
2.8 Conclusions
 Endorectal MR imaging is the most accurate modality in staging prostate cancer and 
can be incorporated in the clinical work up of prostate cancer. However, several parameters 
have to be taken into account (Table III). The most reliable criteria for the detection of 
extracapsular extension of prostate cancer are asymmetry of the neurovascular bundle, 
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Table III: Key features for MR imaging of the prostate
 . Selected patient group
 . > 25 patients per year
 . At least 2 weeks between MR and biopsy
 . State of the art technique (endorectal coil)
 . Criteria for extraprostatic extension
 . Correlation of MR findings with histopathology
obliteration of the rectoprostatic angle, tumor bulge into the periprostatic fat, broad tumor 
contact with the surface of the capsule, an extracapsular tumor, and the radiologist’s overall 
impression. 
 The literature reports a wide variation in the performance of MR imaging in local 
staging of prostate cancer. Factors contributing to improved prostate cancer MR imaging are 
the use of turbo spin echo MR sequence in at least two planes (axial and sagittal), an integrated 
endorectal-pelvic phased array coil and correlation of MR imaging result with histopathology 
results. MR imaging should be limited to patients with an intermediate to high probability 
of having extraprostatic disease. The integrated endorectal-pelvic phased array coil adds 
anatomical detail and improves performance of MR imaging in local staging by significantly 
increasing specificity. 
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    Abstract
Purpose: To compare the visibility of anatomical details and prostate cancer local staging 
performance of pelvic phased-array coil and integrated endorectal-pelvic phased-array coils 
MR imaging, with histologic analysis serving as the reference standard.
Material and methods: MR imaging was performed in 81 consecutive patients with biopsy-
proved prostate cancer, prior to radical prostatectomy, on a 1.5T scanner. T2-weighted fast 
spin echo images of the prostate were obtained using phased-array coil and endorectal-pelvic 
phased-array coils. Prospectively, one radiologist, retrospectively, two radiologists and two 
less experienced radiologists working in consensus, evaluated and scored all endorectal 
pelvic phased-array imaging, with regard to visibility of anatomical details and local staging. 
Receiver operator characteristics (ROC) analysis was performed.
Results:  Anatomical details of the overall prostate were significantly better evaluated using 
the endorectal-pelvic phased-array coils setup (P < 0.05). The overall local staging accuracy, 
sensitivity and specificity for the pelvic phased-array coil was 59% (48/81), 54% (20/36) and 
62% (28/45), and for the endorectal-pelvic phased-array coils 83% (67/81), 64% (23/36) and 98% 
(44/45), respectively, for the prospective reader. Accuracy and specificity were significantly 
better with endorectal-pelvic phased-array coils (P < 0.05). Area under the ROC curve (Az) 
was significantly higher for endorectal-pelvic phased-array coils (Az = 0.74) compared to 
pelvic phased-array coil (Az = 0.57), for the prospective reader. 
Conclusion: The use of endorectal-pelvic phased array coils resulted in significant 
improvement of anatomic details, staging accuracy and specificity. Overstaging is reduced 
significantly with equal sensitivity when an endorectal-pelvic phased-array coils is used.
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    Introduction
 Prostate cancer is the most common non-cutaneous cancer in the world. In 2005, an 
estimated 232,090 new cases and 30,350 deaths of prostate cancer are expected in the United 
States alone [1]. Curative therapy can be considered in cases of localized disease, for example, 
radical prostatectomy is only performed in case of stage T2b or less [2, 3] based on the TNM 
staging system [4]. Accurate staging is an important issue for correct management (prognosis 
and treatment choice) of prostate cancer patients.
 Endorectal MR imaging in local staging of prostate cancer is debated extensively 
in literature [5]. Initially MR imaging was performed using a conventional body coil with 
subsequent limited anatomical detail due to insufficient spatial resolution [6-10]. The 
spatial resolution was increased by using an endorectal coil, a pelvic phased-array coil, or 
combination of both coils. However, the local staging accuracy ranged from 54 to 93% [11-
30]. The Radiologic Diagnostic Oncology Group study [16] in 1994, utilizing the conventional 
body coil, and/or fat suppressed sequence with body coil and endorectal coil, reported an 
overall accuracy for each technique of 61%, 64% and 54%, respectively. Hricak et al [17] found 
in a study population of 71 patients a staging accuracy of 68% using the pelvic phased-array 
coil, rising to 77% with an integrated endorectal-pelvic phased-array coil setup. Husband 
et al [31] reported superior image quality for pelvic phased-array coil compared to the 
endorectal coil, mainly due to fewer artifacts. However, other groups have shown improved 
results for endorectal coil MR imaging, with accuracies up to 88% [18]. Nevertheless, due 
to various factors such as lack of standardized criteria for extracapsular extension, different 
reader experience levels and patient populations, staging accuracies still show variability, and 
therefore its general acceptance for staging is still debated.
 Combining high resolution fast spin echo (FSE) sequences and integrated endorectal-
pelvic phased-array coils may improve local staging performance further [24, 27]. Thus far, 
only one prospective study has been published comparing local staging performance of pelvic 
phased-array and integrated endorectal-pelvic phased-array coils [17]. This paper showed 
increased sensitivity. However, other papers suggest that it is more appropriate to focus on 
high specificity for extracapsular extension [32, 33], in order to reduce overstaging and thus 
allow a more appropriate selection of patients for prostatectomy. Thus, the purpose of our 
study was to compare the visibility of anatomical details and prostate cancer local staging 
performance of pelvic phased-array coil and integrated endorectal pelvic phased-array coils 
MR imaging, with whole-mount section histopathology serving as the reference standard, 
and to see if specificity can be improved.
    Material and methods
 Between January 1999 and May 2002, 88 consecutive patients with biopsy-proved 
prostate cancer, who were candidates for radical retropubic prostatectomy, underwent 
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MR imaging of the prostate. Exclusion criteria were previous androgen deprivation 
treatment, positive lymphadenectomy results, incomplete MR examination datasets, and 
contraindications to MR imaging. The study protocol was approved by the institutional 
review board, and informed consent was obtained from all patients.
 Patient age ranged from 41 to 78 years (median, 65.4 years). The median prostate 
specific antigen (PSA) levels and median Gleason score were 14.1 ng/mL (range, 4-78 ng/
mL) and 6.3 (range, 3-9), respectively. The time interval between transrectal ultrasonography-
guided sextant biopsy and MR imaging, which was performed after biopsy, was 2 – 11 weeks 
(mean, 5 weeks). The time interval between MR imaging study and surgery was 1 - 7 weeks 
(median 3 weeks). 
MR Imaging
 MR imaging was performed at 1.5-T (Vision; Siemens Medical Systems, Erlangen, 
Germany) using both a pelvic phased-array and integrated endorectal-pelvic phased-array 
coils (MRinnervu®; Medrad, Pittsburgh, Pa). In all patients, peristalsis was suppressed by 
intramuscular injection of 1 mg glucagon (Glucagen®; Nordisk, Gentofte, Denmark) before 
the MR examination. An additional dose of 1 mg glucagon was given after insertion of the 
endorectal coil. The scanning protocol consisted of two parts:
 First, multisection T2-weighted FSE sequences with a pelvic phased-array coil 
(repetition time msec/echo time msec, 3500-4400/132; flip angle, 180°; 4-5-mm section thickness; 
0.1-mm intersection gap; 11-15 sections obtained; 280-mm field of view, 240 x 512 matrix; pixel 
size 0.55 x 0.55; echo train length, 15; two signals acquired) were performed. 
 Second, the endorectal coil was inserted and inflated with approximately 80 mL air. 
T1-weighted localizing images were obtained to check coil and patient position. Multisection 
axial T2-weighted FSE sequences were performed with identical scanning parameters as 
in the first part. The direction of the phase encoding and read-out gradient was changed 
from A-P to L-R to decrease endorectal motion artifacts. In addition, transverse two-
dimensional intermediate-weighted spoiled gradient-echo sequence (200/4.4; flip angle 8°) 
was performed.
Scoring and Evaluation of Data
 All images were evaluated by one experienced radiologist (A; J.O.B.) prospectively, 
with knowledge of clinical data (PSA, biopsy Gleason score and digital rectal examination 
findings). Retrospective MR imaging evaluation was conducted by four radiologists (B, B.K.; C, 
R.H.; D, M.R.E.; E, J.J.F.), who were divided in two groups (B/C and D/E), in which one group 
(B/C) was unaware of the clinical data and the other group (D/E) was aware of these data. In 
these two groups, the readers evaluated the images separately. When there was disagreement, 
the case was discussed by both readers and the stage was decided in consensus. Anatomical 
details were assessed retrospectively by four independent readers (A – C, E). Data were 
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entered on a standardized form developed for this study. The five radiologists had different 
levels of experience in evaluating prostate MR images. Reader A was the most experienced, 
having more than 10 years experience (approximately 650 studies) in MR imaging of the 
prostate, reader B had 10 years of experience (approximately 250 studies), reader C had 3 
years of experience (approximately 50 studies), reader D had less than 2 years of experience, 
and reader E had no experience. 
 Anatomical details were assessed using two approaches used by McCauly et al [34]. 
First, side-by-side comparison of the pelvic phased-array and the endorectal-pelvic phased-
array images was obtained for each patient. Each reader determined whether the pelvic 
phased-array images were better, the endorectal-pelvic phased-array images were better, or 
had equal quality. Second, independent numerical rating of image quality with the ratings 
of the pelvic phased-array images was performed one week apart from the ratings of the 
endorectal-pelvic phased-array images. Images were evaluated for motion artifact and coil 
related artifacts, prostate anatomy (visualization of the peripheral zone, central gland, and 
anterior margins), and overall image quality, according to a 5-point scale (1 – poor, to 5 – 
excellent). 
 In each prostate half, the presence of extracapsular extension was evaluated based 
on five specific features described in literature as being indicative of extracapsular extension. 
These findings were asymmetry of the neurovascular bundle [9-10], obliteration of the 
rectoprostatic angle [10], bulge in the contour of the prostate, overall impression [14], and 
extracapsular tumor [14]. The pelvic phased-array and the endorectal-pelvic phased-array 
images were read at random order by all the readers. T1-weighted images were used to 
rule out false-positive findings caused by post-biopsy hemorrhage, if a low signal intensity 
lesion on a T2-weighted image matched a high signal intensity, than this area was considered 
as biopsy haematoma [35]. The criterion used for seminal vesicle invasion was: abnormal 
asymmetric low signal intensity within the lumen on T2-weighted images [14, 17]. The readers 
expressed their findings of extracapsular extension and seminal vesicle invasion on a five-
point confidence level scale. A rating of “1” indicates the criterion extracapsular extension, 
seminal vesicle invasion or stage T3 disease was not present; “2” probably not present; “3” 
possible; “4” probably present; or “5” definitely present. 
Histologic Examination
 The prostatectomy specimens obtained at radical retropubic prostatectomy were in 
toto fixed overnight (10% neutral buffered formaldehyde) and coated with India ink. Seminal 
vesicles were separated from the prostate and examined separately. Transverse whole-mount 
step-sections were obtained at 4-mm intervals in a plane parallel to that in which transverse 
T2-weighted sequences were performed. After dividing each step-section into three or four 
parts (for technical reasons), all sections were routinely embedded in paraffin. All tissue blocks 
were labeled according to location for whole mount reconstruction. Tissue sections of 5µm 
were standard prepared and stained with hematoxylin and eosin. The presence and extent of 
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cancer were outlined on the glass cover by one experienced pathologist (C.A.H.v.d.K., with 
11 years of experience), who had no knowledge of imaging results. For each tumor lesion, 
seminal vesicle and extra capsular extension were determined and recorded. Staging was 
based on the TNM classification system [4]. 
Statistical Analysis
 mage quality data from the side-by-side comparison were analyzed with a one sample 
contingency table to determine if there was a significant difference between the number of 
times the pelvic phased-array was rated superior versus the number of times the endorectal-
pelvic phased-array was rated superior. A two-tailed Student t-test for paired data was used 
to determine significance between pelvic phased-array and endorectal-pelvic phased-array 
image quality and visibility of anatomical details.
 The sensitivity, specificity, positive predictive value, negative predictive value and 
overall accuracy in prediction of tumor stage, extracapsular extension and seminal vesicle 
invasion were calculated by dichotomizing the readings. Scores of 4 and 5 were considered 
“present” (i.e. extracapsular extension, seminal vesicle invasion, and stage T3 disease). The 
comparison of results from pelvic phased-array and endorectal-pelvic phased-array coils was 
performed with the McNemar test. 
 The statistical analysis included evaluation of interobserver agreement by using 
non-weighted kappa (κ) statistics. The following qualitative terms associated to the strength 
of the various κ values were used: 0.0-0.2 = poor agreement, 0.21-0.4 = fair agreement, 0.41-
0.6 = moderate agreement, 0.61-0.8 = substantial agreement, and 0.81-1.0 = almost perfect 
agreement. [36]
 Based on the Partin tables [37], patients were categorized in two subgroups with 
low risk (49 patients, PSA < 10 ng/ml and biopsy Gleason score 2-7 or PSA 10.1–20 ng/ml and 
biopsy Gleason score 2-5) or intermediate/high risk (33 patients, PSA > 10 ng/ml and biopsy 
Gleason score > 5 or PSA > 20 ng/ml) of having extracapsular disease. 
Receiver operating characteristic (ROC) curves were generated for the probability of 
extracapsular extension and seminal vesicle invasion by both technique and radiologist. The 
diagnostic performance was then assessed by calculating the area under the curve (Az). The 
statistical significance differences in the Az were determined using the x2 test. All statistical 
analyses were performed with Rockit 0.9B (Department of Radiology, University of Chicago, 
Chicago, Ill) [38] and SPSS, version 10.1 (SPSS, Chicago, Ill). All reported P values are from 
two-sided tests, a P value of .05 or less was considered to indicate a significant difference.  
	
    Results
Surgical Pathologic Findings
Seven patients were excluded as a result of androgen deprivation treatment (n = 4), positive 
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lymph node at frozen section during the operation (n = 2) and incomplete MR examination 
(n = 1). Five patients with positive findings on MR imaging, who were initially planned for 
prostatectomy, underwent ultrasound-guided seminal vesicle biopsies preoperatively, all of 
which were positive. Subsequently, the scheduled prostatectomy was cancelled. Eighty-one 
patients were enrolled in this study. Pathologic examination of the prostatectomy specimens 
revealed that 45 (56%) of 81 patients had disease confined to the prostate. Pathologic staging 
demonstrated stage T2a in 16 patients and T2b in 29 patients. The remaining 36 (44%) 
patients had extraprostatic disease. Stage T3a was found in 26 patients and T3b in 10 patients. 
Microscopic invasion into, but not through, the capsule was found in six patients which were 
also classified as having stage T2 disease [38]. In 8 cases capsular penetration was less than 
1-mm. 
MR Imaging Findings
Anatomical	 Details – Side-by-side comparison of pelvic phased-array versus endorectal-
pelvic phased-array images yielded a statistically significant difference (P < .05) in benefit for 
endorectal coil for all the four readers (A-C, E). With endorectal-pelvic phased-array coils, 
image quality was judged superior in 54 to 73 patients (readers A-C, E). Using the independent 
numerical rating scale endorectal-pelvic phased-array images were significantly better for all 
the readers (P < .05) in 2 out 4 categories: overall image quality  and visibility of prostate 
anatomy (Figure 1). Endorectal-pelvic phased-array coil images were in 5 cases degraded 
by near-field endorectal coil profile. Assessment of interobserver agreement yielded fair to 
almost perfect agreement (kappa = range .43 – .96).
Local Staging Performance – Staging accuracy was significant higher using endorectal-pelvic 
phased- array coils (P = .02; Table I) for the most experienced reader A. Staging accuracy was 
almost similar for the all the readers (83%, 78% and 79%; reader A, B/C and D/E). For reader 
A, consensus readers B/C and D/E, interpretation of pelvic phased-array and endorectal-
pelvic phased-array images demonstrated significant improved specificity (P = .0002) with 
endorectal-pelvic phased-array coils (96% - 98%; Table I) and equal sensitivity (56% - 65%). At 
prospective evaluation by experienced reader A of the pelvic-phased array images, stage T2 
was overstaged in seventeen patients and T3 was understaged in sixteen patients. Evaluation 
using the endorectal-pelvic phased-array images resulted in two false-positive findings, which 
reduced overstaging significantly (P = .0002). The interobserver variability between reader A, 
and consensus readers B/C and D/E, resulted in substantial agreement (kappa = .63 to .77). 
 Accuracy in detection of extracapsular extension (Figures 1 and 2) was significant 
higher using endorectal-pelvic phased-array coils (P = .01; Table II) for all readers. Accuracy in 
detection of extracapsular extension was similar for all the readers (80%, 83% and 76%; reader 
A, B/C and D/E; P = .50). The specificity in detection of extracapsular extension was statistically 
significantly higher using endorectal-pelvic phased-array images for all the readers (P = .009; 
Table II) compared to pelvic phased-array images. Sensitivity did not significant increase
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          Single reader              Consensus readers      Consensus readers
   (A)               (B/C)               (D/E)     
           PPA    ER-PPA PPA    ER-PPA               PPA    ER-PPA
Sensitivity 20/36 (56)  23/36 (64) 22/36 (61)  20/36 (56) 17/36 (47)  21/36 (58)
Specificity        28/45 (62)  44/45*(98) 31/45 (69)  43/45*(96) 31/45 (69)  43/45*(96)
Accuracy         48/81 (59)  67/81*(83) 53/81 (65)  63/81 (78) 48/81 (59)  64/81 (79)
PPV  20/37 (54)  23/24 (96) 22/36 (61)  20/22 (91) 17/31 (55)  21/23 (91)
NPV  28/44 (64)  44/57 (77) 31/45 (69)  43/59 (73) 31/50 (62)  43/58 (74) 
-	Numbers	in	parentheses	are	percentages;	PPA	=	pelvic	phased-array	coil;	ER-PPA	endorectal-pelvic	phased-array				
		coils.	PPV	=	positive	predictive	value;	NPV	=	negative	predictive	value
*	Differentiation	between	pelvic	PPA	and	ER-PPA	coils	was	significant	(p<0.05,	McNemar	two-tailed	test)
Table I:  Sensitivity, Specificity, Positive Predictive Value, Negative Predictive Value and 
 Accuracy of Staging Accuracy
Figure 1. Stage T3a carcinoma of the prostate in 54-year-old patient. (A) Axial pelvic phased-array T2-
weighted FSE MR image is graded 2 for image quality and 2 for extracapsular extension. Peripheral 
zone, central gland and capsule are not adequately visualized. (B) Corresponding axial endorectal-pelvic 
phased-array T2-weighted FSE MR image shows low-signal-intensity lesions suggestive for prostate 
cancer (T). Bulging in the right lateral peripheral zone (arrows) indicates extracapsular extension. This 
image is graded 4 for image quality and 5 for extracapsular extension. (C) Whole-mount section at 
corresponding location shows tumor (T) with capsular penetration (arrows).
T
T
A B
C
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using the endorectal-pelvic phased-array coil setup (P = .54). The interobserver variability 
between reader A, readers B/C and readers D/E, image interpretation resulted in substantial 
agreement (kappa = 0.71 to .76). The superior performance of the endorectal-pelvic phased-
array coil setup is demonstrated in Figure 3, which summarizes the results of ROC analysis. 
There was a statistical significant greater Az for reader A using endorectal-pelvic phased-
array coils compared to the pelvic phased-array coil (Az = .74 vs .57; P = .031). The Az was not 
significantly different between reader A (Az = .57 vs. Az = .74; pelvic phased-array – endorectal-
pelvic phased-array), consensus readers B/C (Az = .67 vs. Az = .76), and consensus readers D/E 
(Az = .61 vs. Az = .70) for both coils.
 The results of seminal vesicle invasion are presented in Table III. Accuracy in 
detection of seminal vesicle invasion was higher for reader A than for consensus readers B/C 
and D/E (98% vs 91% and 90%). For reader A the overall specificity in detection of seminal 
vesicle invasion (Figure 4) was significantly increased using endorectal-pelvic phased-array 
coils (99%, P < .001). Interobserver agreement was substantial (kappa = range .67 to .72). 
Because of the low number of pathologic positive cases of seminal vesicle invasion (n = 10), 
however, ROC analysis was rejected. 
Subgroup Analysis
 Table IV shows the total number of patients found to have extracapsular extension 
and/or seminal vesicle invasion with MR imaging (reader A) and histopathology stratified 
by low and intermediate/high risk group of having extra capsular extension. Of the 48 study 
patients in the low risk group, 13 (29%) had extracapsular extension and 1 (2%) had seminal 
vesicle invasion (Table IV). Respectively, in 28 (58%) and 42 (87%) of 48 patients (P = .035) 
the presence or absence of extracapsular extension and/or seminal vesicle invasion was 
correctly identified on the preoperative pelvic phased-array and endorectal-pelvic phased-
	
      Single reader  Consensus readers Consensus readers
                (A)                (B/C)            (D/E)
      PPA     ER-PPA     PPA     ER-PPA      PPA     ER-PPA
Sensitivity  15/30 (50)  17/30 (57) 18/30 (60)  19/30 (63) 13/30 (43)  14/30 (47)
Specificity  33/46 (72)  44/46*(96) 32/46 (70)  44/46*(96) 33/46 (72)  44/46*(96)
Accuracy  48/76 (63)  61/76*(80) 50/76 (66)  63/76*(83) 46/76 (61)  58/76*(76)
PPV   15/28 (54)  17/19 (89) 18/32 (56)  19/21 (21) 13/26 (50)  14/16 (88)
NPV  33/48 (69)  44/57 (77) 32/44 (73)  44/55 (80) 33/50 (66)  44/60 (73)
-	Numbers	in	parentheses	are	percentages.	PPA	=	pelvic	phased-array	coil;	ER-PPA	endorectal-pelvic	phased-array		
		coils.	PPV	=	positive	predictive	value;	NPV	=	negative	predictive	value
*	Differentiation	between	PPA	and	ER-PPA	coils	was	significant	(p<0.05,	McNemar	two-tailed	test)
Table II: Sensitivity, Specificity, Positive Predictive Value, Negative Predictive Value and
   Accuracy of Extracapsular Extension  
45
Local	staging	accuracy	of	pelvic	phased	array	coil	and	integrated	endorectal	pelvic	phased	array	coils
 Table III: Sensitivity, Specificity, Positive Predictive Value, Negative Predictive Value and 
    Accuracy of Seminal Vesicle Invasion
        Single reader   Consensus readers Consensus readers
                (A)                                       (B/C)                                       (D/E)
      PPA    ER-PPA    PPA    ER-PPA   PPA    ER-PPA
Sensitivity    5/10 (50)    9/10 (90)   3/10 (30)    4/10 (40)    5/10 (50)    8/10 (80) 
Specificity  57/71 (80)  70/71*(99) 67/71 (94)  70/71 (99)           64/71 (90)  65/71 (92)
Accuracy  62/81 (76)  79/81 (98) 70/81 (86)  74/81 (91)           69/81 (85)  73/81 (90)
PPV    5/19 (26)    9/10 (91)     3/7 (43)    4/5   (80)             5/12 (41)    8/14 (57)
NPV   57/62 (92)  70/71 (99) 67/74 (91)  70/76 (92)           64/69 (93)  65/67 (97)
-	Numbers	in	parentheses	are	percentages.	PPA	=	pelvic	phased-array	coil;	ER-PPA	endorectal-pelvic	phased-array	
		coils.	PPV	=	positive	predictive	value;	NPV	=	negative	predictive	value
*	Differentiation	between	PPA	and	ER-PPA	coils	was	significant	(p<0.05,	McNemar	two-tailed	test)	
Figure 2. Stage T2a carcinoma of the prostate in a 60-year-old-patient. (A) On the axial pelvic phased-
array T2-weighted FSE MR image, the tumor (T) in the left peripheral zone demonstrates bulging (arrows) 
that resulted in a misdiagnosis of extra capsular extension (score 4). (B) Axial integrated endorectal-
pelvic phased-array T2-weighted FSE MR image obtained at the same anatomic section as image in a 
demonstrates a low signal intensity lesion in the left peripheral zone (score 2). (C) Whole-mount slice at 
corresponding level shows that no tumor (T) penetrates the capsule on the left side.
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Table IV: Patients Stratified in Low and Intermediate/High Risk Group and the Sensitivity, 
Specificity, Positive Predictive Value, Negative Predictive Value and Accuracy of these Cases 
Correctly Identified on the Preoperative PPA and ER-PPA MR Imaging
               Low risk (n = 48)   Intermediate/high risk (n = 33)
ECE / SVI  ECE n = 13 (27) / SVI n = 1 (2) ECE n = 17 (52) / SVI n = 9 (27)
     PPA  ER-PPA      PPA  ER-PPA 
Sensitivity   5/13 (38) 7/13   (54) 16/24 (67) 17/24   (71)
Specificity 22/35 (63) 34/35 (97)*   5/9   (56)   9/9   (100)
Accuracy 28/48 (58) 42/48 (87)* 21/33 (64) 26/33   (79)
PPV    5/18 (28)   7/8   (88) 16/20 (80) 17/17 (100)
NPV  22/30 (73) 34/40 (85)   5/13 (38)   9/16   (56)
-	Numbers	in	parentheses	are	percentages.	PPA	=	pelvic	phased-array	coil;	ER-PPA	endorectal-pelvic	phased-array	
		coils.	PPV	=	positive	predictive	value;	NPV	=	negative	predictive	value
*	Differentation	between	PPA	and	ER-PPA	coils	was	significant	(p<0.05,	McNemar	two-tailed	test)
Figure 3. Receiver operating characteristic curves for the experienced reader A and consensus readers 
(B/C and D/E) for the presence of extracapsular extension. Statistically significantly greater area under the 
curve using endorectal-pelvic phased-array coils (ER-PPA) for the experienced reader (P = .031) compared 
to pelvic phased-array coil (PPA). No significant difference was found for the less experienced readers 
(D/E; P = .24).
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array MR imaging (Table IV). Specificity in this group increased significantly from 64% to 97% 
(P = .009) for endorectal-pelvic phased-array MR imaging. Seventeen (52%) patients in the 
intermediate/high risk group had extracapsular extension and 10 (30%) had seminal vesicle 
invasion, respectively, extracapsular extension and/or seminal vesicle invasion were identified 
in 64 with pelvic phased-array MR imaging, and 79% with endorectal-pelvic phased-array 
MR imaging, respectively.
	
				Discussion
 Available diagnostic staging modalities, transrectal ultrasound and biopsies are not 
accurate enough for staging [39]. Local staging of prostate cancer in terms of patient prognosis 
and treatment options is important for the therapeutic decision making process. More accurate 
staging is needed for adequate therapy planning. The role of MR imaging herein is still under 
investigation because of limited availability, high costs and variability in results [5, 23]. 
 Since Rifkin et al [11] demonstrated the limited value of body coil MR imaging in
staging prostate cancer, several studies have addressed the use of endorectal and pelvic phased 
array coils [11-30]. Although these developments resulted in improved image resolution, 
the subsequent staging accuracy of prostate MR imaging still is not high enough. Factors 
responsible for this variation of results are patient population size, use of an endorectal coil, 
MR sequences such as FSE and reader experience [33]. Hricak et al [17] combined endorectal 
and pelvic phased-array coils which improved local staging. Jager et al [32] developed a 
decision analytic model which supported the opinion that MR staging in preoperative work-
up of prostate cancer is cost-effective and should be performed with a high specificity. Langlotz 
et al [33] emphasized this need for high specificity in prostate MR imaging to ensure that as 
few patients as possible will be unnecessarily turned down of potentially curative therapy on 
the basis of false-positive MR imaging results. D’amico [25] et al advised to use MR imaging 
in patients with intermediate risk only, because in this group the probability of extraprostatic 
disease is high enough to warrant the use of MR imaging. This was recently confirmed by 
Cornud et al. [41], who stated that endorectal MR imaging is indicated in carefully selected 
patients-specifically, those with three or more positive biopsy specimens, a palpable tumor, 
and/or a PSA level greater than 10 ng/ml.
 The results of our study showed that the use of an integrated endorectal-pelvic 
phased-array coil resulted in a significant improvement of anatomical details and visibility of 
the prostate anatomy compared to pelvic phased-array coil alone. This is in disagreement with 
Husband et al [31], who showed that pelvic phased-array coil produces better image quality 
than endorectal coil alone. However, the current study is comparing pelvic phased-array coil 
with integrated endorectal-pelvic phased-array coils, which resulted in superior quality for 
the combination of both coils. Improved results in our study could also be explained by the 
fact that Husband et al investigated a small patient group (n = 21) and used different criteria 
for anatomical details, with fair to moderate interobserver agreement which reflects the 
difficulties in attempting to quantify degree of artifacts.
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 In the present study, superior results were noted for the endorectal-pelvic phased-
array coils in local staging compared to the pelvic phased-array coil. Our overall staging 
accuracy of 78 - 83% for differentiation between stage T3 and T2 disease by endorectal coil 
imaging, fall within the range of published studies (accuracies, 54% to 93%), but are higher 
than reported in the Radiologic Diagnostic Oncology Group study [16]. The difference 
between results of this study and our study may be related to differences in techniques and 
the use of whole mount section histopathology. Langlotz et al [33], reported possible effect of 
inconsistent image quality in the Radiologic Diagnostic Oncology Group study due to variations 
in technique between institutions. Also, our study included T2-weighted FSE images and 
integrated endorectal-pelvic phased-array coils, whereas the Radiologic Diagnostic Oncology 
Group study technique consisted of conventional spin echo and the use of an endorectal coil 
without a pelvic phased-array coil. Rifkin et al [11] reported a staging accuracy of 77% using 
a body coil, however biopsy results were used for correlation with MR imaging results. The 
results of the pelvic phased-array coil images, however, are inferior to those of Kier et al. [13]. 
In part, this may reflect the difference in study design. Our study used whole-mount section 
histopathology; the study of Kier et al used biopsies. Also, our sample size is three times 
Figure 4. Seminal vesicle invasion in 64-year-old patient.(A) Transverse pelvic phased-array T2-weighted 
FSE MR image through the seminal vesicles shows no abnormality. This case was rated as probably not 
present (score = 2) (B) On the corresponding transversal endorectal-pelvic phased-array T2-weighted 
FSE MR image, this case was rated as definitely presence of seminal vesicle invasion (arrows, score = 5) 
(C/D) Invasion of prostatecarcinoma into muscle wall of the left seminal vesicle. The inset shows cancer 
(on the right site) approaching the seminal vesicle glandular epithelium with characteristic golden brown 
pigment (left corner; arrows). (400x; HE).
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larger. Studies with small sample sizes may result in higher staging performance [5]. Huch 
Boni et al [18] demonstrated a high staging accuracy of 88%, however with a small sample size 
of 33 patients. A possible limitation of our study relates to the order in which pelvic phased-
array and endorectal-pelvic phased-array examinations were interpreted. Pelvic phased-array 
examinations were always interpreted before endorectal-pelvic phased-array examinations. 
It is possible therefore that reader was biased towards endorectal-pelvic phased-array coil 
images.
 Our results concur with Hricak et al [17] who also combined both coil types. The 
overall staging accuracy for differentiation between T2 and T3 disease by endorectal MR 
imaging are almost similar compared to Hricak et al. (77% vs. our results of 77 - 83%). 
However, our study used TNM classification for staging like all recent studies, whereas 
Hricak et al used two different staging systems (TNM classification and the Jewitt-Whitmore 
staging criteria). This resulted in a low staging accuracy of 60% and higher accuracy of 77% 
for the TNM classification and Jewitt-Whitmore staging criteria, respectively. Furthermore, 
the specificity and positive predictive value in our study are higher compared to Hricak et al. 
This can be explained by the fact that our study focused on high specificity reading, which 
resulted in low false positive findings. Thus we have more reliable results.
 Finally, our results do not support the conclusion of the Radiologic Diagnostic 
Oncology Group study by Tempany et al [16], that experienced readers were significantly better 
than less experienced readers [17, 24]. As our study showed, the accuracy of interpretation was 
only slightly better when read by a more experienced reader A. ROC analysis demonstrated 
greater area under the curve for experienced reader compared to the less experienced 
consensus readers, however, this difference was not significant. An explanation for this could 
be that one less experienced reader (reader D) had already 2 years experience and that both 
less experienced readers (D/E) learned prostate MR reading from the experienced reader A. 
Also the less experienced readers work together in consensus, which is reported to improve 
performance compared to a single reader [5]. The knowledge of clinical data (PSA and Gleason 
score) did not increase the diagnostic performance of reader A and consensus readers D/E 
compared to consensus readers B/C.
 In 8 out of thirty cases, capsular penetration was only less than 2-mm resulting in 
false negative findings, which shows the limits of resolution of MR imaging at this moment. 
However, recent reports suggest that minimal capsular penetration of less than 1-mm does 
not adversely affect surgical cure rate [40, 42]. 
 The use of MR imaging to detect seminal vesicle invasion is considered to be a useful 
tool [11, 26]. This is in agreement with the results of this study (accuracy of 98%, sensitivity 
of 91% and a specificity of 99%, respectively). We concur, as 5 (6%) of our patients, who were 
initially planned for prostatectomy, underwent ultrasound-guided seminal vesicle biopsies 
preoperatively, all of which were positive. Subsequently the prostatectomy was cancelled. The 
ability of MR imaging to diagnose seminal vesicle invasion with fairly good sensitivity and 
specificity is an important advantage of this technique in the local staging of prostate cancer, 
because this information can rarely be obtained by using transrectal ultrasound [11].  
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 Our results suggest that MR staging is accurate in a population at low risk for having 
extraprostatic disease. In this low risk group, endorectal-pelvic phased-array MR imaging 
identified in 7 patients correctly stage T3 disease with a high specificity (97%), which may 
be used to save the patient an unnecessary prostatectomy. Using the results from our study, 
MR imaging is considered useful at an a priori chance between 0.08-0.86 (range low-risk – 
high-risk) [32]. In clinical practice this means that in our local situation both patients with 
low risk and with an intermediate-high risk of non-organ confined disease may benefit from 
treatment selection by MR imaging. Although MR imaging and histopathology results are 
not compared with the Partin table, our results suggest that Partin table underestimated 
extracapsular extension in our patient group. This makes it more difficult for the referring 
clinician in selecting patients for radical prostatectomy and subsequently pre-operative MR 
imaging. The effect of this underestimation in patient outcome has to be studied in future 
studies.
 In conclusion, we demonstrated that use of endorectal-pelvic phased-array coils 
resulted in significant improvement of anatomic details, staging accuracy and specificity. 
Overstaging is reduced significantly with equal sensitivity when an endorectal-pelvic phased-
array coils is used. This technique may be a useful tool even in patients who are at low risk of 
extraprostatic disease.
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    Abstract
Purpose: To prospectively determine the prostate cancer localization performance in prostate 
cancer patients of T2-weighted MR imaging, dynamic contrast-enhanced MR imaging (DCE-
MRI) and quantitative three-dimensional (3D) proton MR spectroscopic imaging (MRSI), of 
the whole prostate, using whole mount sections as the reference standard.  
Material and methods: In a prospective study 34 consecutive patients were examined. Mean 
age and prostate specific antigen level were 60 years and 8 ng/ml, respectively. Median biopsy 
Gleason score was 6. T2-weighted MR imaging, DCE-MRI and 3D MRSI were performed 
and based on these image data, two readers with different levels of experience prospectively 
recorded the location of suspicious peripheral zone and central gland tumor nodules on a 
standardized division of the prostate (14 regions of interest (ROI)). The degree of diagnostic 
confidence for each ROI was recorded on a five-point scale. The localization performance and 
ROI based receiver operating characteristics (ROC) were calculated. 
Results: For both readers, the area under the ROC curve for T2-weigthed MR imaging, 
DCE-MRI and 3D MRSI were 0.68, 0.91 and 0.80, respectively. DCE-MRI reading performed 
significantly better for tumor localization than quantitative MRSI (P < 0.01). Both DCE-MRI 
and MRSI were significantly better than reading T2-weighted imaging (P < 0.01). 
Conclusion: The use of  DCE-MRI and 3D MRSI showed significant improvement in localization 
performance in prostate cancer patients compared with T2-weighted MR imaging.
56
4
    Introduction
 Prostate cancer is the most common non-cutaneous cancer in the western countries. 
In 2005, an estimated 232,090 new cases and 30,350 deaths of prostate cancer are expected in 
the United States [1-2].
 Systematic sextant ultrasound guided biopsy localization sensitivity was only 39-
52% compared with radical prostatectomy [3-4]. The sensitivity of this technique is low, due 
to the fact that more than 40% of prostate cancer lesions are isoechoic [5, 6] and that central 
gland tumors are difficult to detect. Use of MR imaging may result in higher localization 
rates. With T2-weighted MR imaging, prostate cancer often appears as an area of low signal 
intensity in a bright normal peripheral zone. Detecting prostate cancer in the central gland 
is difficult because this area often contains benign prostatic hyperplasia, which has signal 
intensities similar to that of cancer. Previous studies using T2-weighted MR imaging obtained 
accuracies in a range of 67 to 72% in localizing tumors [7-8]. 
 Proton MR spectroscopic imaging (MRSI) provides quantitative metabolic data 
based on the citrate, choline and creatine levels as well as their ratios. MRSI can be used 
for the detection and localization of prostate cancer [9-10]. Proton MRSI spectra of prostate 
cancer tissue reveal a reduction or depletion of citrate levels and an increased level of choline 
compared to healthy or benign tissue. The addition of MRSI resulted in 90% sextant positive 
predictive value for tumors in the peripheral zone of the prostate gland [8]. As cancer tissue 
can occur anywhere in the prostate the use of a three dimensional (3D) method to cover the 
whole prostate is essential [11]. Only recently the usefulness of MRSI to detect and localize 
cancer in the transition zone of the prostate has been addressed [12].
 Dynamic contrast-enhanced MR imaging (DCE-MRI) is reported to be an effective 
tool in visualizing the pharmacokinetics of gadolinium uptake in the prostate [13-15]. Prostate 
cancer demonstrated different enhancement patterns compared to benign tissue [16-18]. DCE-
MRI revealed prostate cancer localization accuracies up to 80% [19-20].
 The combination of high-resolution spatiovascular information from DCE-MRI and 
quantitative metabolic information from MRSI has excellent potential to improve prostate 
cancer localization in a clinical setting [21]. To our knowledge, there are no reported studies 
that evaluated prostate cancer localization using T2-weighted MR imaging, DCE-MRI and 
MRSI techniques in the peripheral, transitional and central zone, all applied to the same 
patient. Thus, the purpose of our study was to prospectively determine the prostate cancer 
localization performance of T2-weighted MR imaging, DCE-MRI and MRSI, of the whole 
prostate, using whole-mount sections as the reference standard.  
57
Combined	DCE-MRI	and	MRSI	in	localizing	prostate	cancer
    Materials and Methods
Patient characteristics
 From April 2002 until June 2004, 34 consecutive patients (mean age, 60 years; range, 
50 - 69) with biopsy-proven and clinically localized prostate cancer underwent endorectal coil 
MR examinations prior to radical prostatectomy. MR imaging was performed at least 3 weeks 
after the last transrectal ultrasound-guided sextant biopsy. Patients who were scheduled for 
radical prostatectomy within 6 weeks (range: 1-41 days; median 10 days) after MR imaging 
were included in the study. Patient exclusion criteria were previous hormonal therapy, 
positive lymphadenectomy, contraindications to MR imaging (e.g. cardiac pacemakers, 
intracranial clips) and contraindications to endorectal coil insertion (e.g. anorectal surgery, 
inflammatory bowel disease). The present study was approved by the institutional review 
board and informed consent was obtained from all patients.
MR imaging acquisition protocol
 The MR images were obtained with a 1.5T MR system (Sonata, Siemens Medical 
Systems, Erlangen, Germany) using a combination of an endorectal (Medrad®, Pittsburg, 
PA, USA) and a pelvic phased-array coil. The endorectal coil was inserted and inflated with 
approximately 80 cc of air. In all patients peristalsis was suppressed by intramuscular injection 
of 1 mg glucagon (Glucagen®; Nordisk, Gentofte, Denmark) before the examination. The 
imaging protocol – after quick validation of the patient and coil positioning with fast gradient 
echo imaging – included the following: 
 First, multi-slice T2-weighted multiple spin echo images were obtained with an in 
plane resolution of 0.55 x 0.55-mm (TR 3500-4400 ms/ TE 132 ms; flip angle 180°; 11-15 slices; 
4-mm slice thickness; echo train length of 15; 280-mm field of view (FOV) and 240 x 512 
matrix) in three orthogonal planes covering the prostate and seminal vesicles.
 Second, 3D MRSI of the whole prostate was performed with a slice-selected box, 
positioned tightly around the prostate, by a Point Resolved Spectroscopy Sequence (PRESS) 
[22]. The nominal voxel size before apodization was 6 x 6 x 6 mm3; TR was 650 ms and TE 120 
ms. Hamming weighted signal averaging was performed with 5 acquisitions in the center of 
k-space, resulting in a total measurement time of 12 minutes. For details see [11]. 
Third, 3D T1-weighted spoiled gradient echo images (TR 34ms/TE 1.6 ms; flip angle 14°; 10 
axial partitions in 3D slab; 4-mm thickness; 280-mm FOV, 77 x 256 matrix) were acquired 
during an intravenous bolus injection of paramagnetic gadolinium chelate (0.1 mmol/kg, 
gadopentetate, Magnevist®; Schering, Berlin, Germany) using a power injector (Spectris, 
Medrad®, Pittsburgh, PA, US) with an injection rate of 2.5 ml/second followed by 15 ml saline 
flush. With this sequence the 3D volume with ten partitions was acquired every 2 seconds 
for 120 seconds, with same positioning angle and center as the axial T2-weighted sequence 
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covering the whole prostate. Before contrast injection the same axial 3D T1-weighted gradient 
echo sequence was used to obtain proton density images but with TR 800 ms/TE 1.6 ms and 
flip angle 8°, with identical positioning to allow calculation of relative gadolinium chelate 
concentration curves.
Data post-processing
 The MRSI data was filtered with a Hamming filter in the three spatial dimensions and 
zerofilled to a 16 x 16 x 16 matrix before Fourier Transformation in the spatial dimensions. The 
residual water was removed from the spectral data (by fitting a low-frequency, exponentially 
decaying sine/cosine function to the time point moving average signal in the time domain), 
a Hamming filter was applied in the time domain, and Fourier Transformation and phase 
correction was performed with Siemens Syngo software on the MR scanner. Resonance areas 
were determined by an automatic Gaussian curve fitting routine.
 Functional DCE-MRI parameters were estimated as follows. Each MR signal 
enhancement - time curve was first fitted to a general exponential signal enhancement model 
as described previously [14]. This reduced a curve to a 5 parameter model: baseline; start 
of signal enhancement, which defines the onset of the exponential curve; time-to-peak (ttp), 
the exponential constant; peak enhancement, the signal amplitude at which the exponential 
curve levels off; and latewash, defined as the slope of the late part of the exponential curve. 
The reduced signal enhancement-time curve was converted to a reduced tracer concentration 
[mmol/ml] - time curve [14, 23] effectively converting peak enhancement to concentration 
gadolinium (Cgd). The reduced plasma concentration time curve was estimated using 
the reference tissue method [24]. Deconvolution of the plasma profile and estimation of 
pharmacokinetic parameters conforms to the theoretical derivations [25] but is implemented 
in the reduced signal space as: ve=Cgdplateau_tissue/Cgdplateau_plasma, kep=1/(ttptissue-ttpplasma) and K
trans= 
ve . kep. Where ve is an estimate of the extracellular volume [%], Ktrans the volume transfer 
constant [1/min], and kep the rate constant [1/min] between extracellular extravascular and 
plasma space. The subscript ‘tissue’ points to a measurement in the tissue under investigation 
and subscript ‘plasma’ to the reference tissue plasma estimates. The reference tissue was 
automatically determined by selecting the set of voxels in the whole pelvic volume that had 
moderate enhancement.
 The DCE-MRI parameters were color coded and rendered semi-transparently over 
T2-weighted images. This DCE-MRI post-processing procedure (10 minutes per patient) was 
performed by an MR technologist.
Scoring and evaluation of data
	
 All T2-weighted MR imaging, MRSI and DCE-MRI datasets were prospectively 
evaluated and scored without prior knowledge of the prostate-specific antigen level and 
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biopsy results. Two radiologists (A; J.J.F. / B; S.W.T.P.J.H.) interpreted and scored all three 
datasets. The two radiologists had different levels of experience in evaluating prostate MR 
images. Radiologist A was the most experienced (4 years of experience, with approximately 
350 studies total) in prostate cancer MR imaging at the beginning of this study. Radiologists B 
had 2 years of experience with approximately 150 studies. 
 For tumor localization the prostate was divided into apex, mid-gland and base. Both 
the apex and base were divided into quadrants and the mid-gland into sextants. Thus, each 
case was divided in 14 regions of interest (ROI). Readers reported the confidence they had 
that tumor was present in each of these ROIs on a five-point scale: definitely no tumor present 
(1), probably no tumor (2), possible tumor (3), probably tumor (4) definitely tumor present 
(5). 
The image interpretation session consisted of three parts:
 First, the two readers independently interpreted and scored the T2-weighted MR 
images in random order with respect to a low signal intensity area using the aforementioned 
five-point scale. Pre-contrast T1-weighted images were additionally evaluated to rule out 
false-positive findings caused by post-biopsy hemorrhage [26]. 
 Second, in a different reading session, all MR spectra were independently interpreted 
in all included patients. The spectra of each ROI were interpreted and scored along a five-
point scale as being benign or malignant essentially as described by Jung et al [27]. For the 
definition of the 5 categories of this scale (Table 1) we used mean values of metabolite ratios and 
standard deviations from the initial results of a multi-center study using the same acquisition 
method [28]. In this study, the mean values (± SD) for the choline + creatine / citrate ratio for 
benign tissue in patients was 0.36 ± 0.15, which can be separated into the different tissues: 
0.30 ± 0.14 for the benign peripheral zone, 0.38 ± 0.14 for the benign central gland (combined 
central zone and transitional zone), 0.41 ± 0.17 for the benign (peri-)urethral zone. This five-
point scale was adapted to be used for the peripheral zone and central gland. Assessment of 
the choline-to-creatine ratio was also included in the analysis. The readers were allowed to 
assign MR spectra as unusable if they showed significant lipid contamination, poor spectral 
signal-to-noise ratio or baseline misalignment. 
 Third, in a different reading session, maps of the following DCE-MRI parameters 
Table I:  Choline + Creatine / Citrate Ratios for the Different Tissues in the Prostate on a 
 Five-Point Scale [28]
Rating      peripheral zone central gland
1  definitely benign tissue       ≤ 0.44   ≤ 0.52
2  probably benign tissue     0.44 - 0.58  0.52 – 0.66
3  possibly malignant tissue      0.58 - 0.72  0.66 – 0.80
4  probably malignant tissue    0.72 - 0.86  0.80 – 0.94
5  definitely malignant tissue  > 0.86   > 0.94
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were assessed: contrast latewash, ve, kep and K
trans as derived from the reduced tracer time 
curve. The parametric scale was subjectively evaluated. Each reader separately scaled the 
parametric values into a five-point scale. Based on asymmetry and degree of enhancement 
these four DCE-MRI parameters were evaluated in random order. Thus, the readers gave 4 
ratings for DCE-MRI, one for each parameter. These cannot be regarded as independent, but 
nevertheless different characteristics of these parameter images are reflected in these ratings. 
An additional mean pharmacokinetic score (MPKS) was constructed by computing the mean 
of the pharmacokinetic parameter scores of the observations. The readers were allowed to 
assign DCE-MRI parameters as unusable if they showed severe motion artefacts or if the 
parameter was not calculated appropriately. MRSI and DCE-MRI were assessed in conjunction 
with the T2-weighted images.
Histopathologic Analysis
 Three experienced urologists (18 years (J.A.W.), 11 years and 5 years of experience, 
respectively) performed all radical prostatectomy procedures with knowledge of the 
MR results. The prostatectomy specimens were fixed overnight (10% neutral buffered 
formaldehyde) and coated with Indian ink. Seminal vesicles were separated from the prostate 
and examined separately. Axial whole-mount step-sections were made at 4-mm interval in 
a plane parallel to the axial T2-weighted sequence. All sections were routinely embedded 
in paraffin. Tissue sections of 5 µm were prepared and stained with hematoxylin and eosin. 
The presence and extent of cancer were outlined on the glass slide cover by an experienced 
genitourinary pathologist (C.A.H.K.), with 13 years of experience, who was blinded to the 
MR imaging results. The prostatectomy specimens were staged according to the present TNM 
classification [29]. The volumes of all independent carcinomas were calculated (by C.A.H.K) 
as the sum of surface areas for a given carcinoma multiplied by the slice thickness. Volumes 
were expressed in cubic centimeters.
Data analysis
 The ROIs were compared to the histopathological analysis by two radiologists in 
consensus (A and B) after evaluation (1 month) of the data. The T2-weighted MR images 
were aligned with the whole-mount sections. The morphology of the central gland, peripheral 
zone, apex and base of the prostate, cysts, calcifications and urethra were used as landmarks. 
Aligning MR images and whole-mount sections is considered difficult [19]. Although no 
literature is available on this subject, we were however confident to be within an accuracy 
of 8 mm (2 slices). An ROI detected with MR imaging was considered true-positive in case 
the imaging results correlated with the histopathologic conclusion as mentioned above. To 
provide reasonable allowance for differences in registration, as well as morphology between 
imaging and histopathologic evaluation, the tumors were considered to be of comparable 
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sizes if the maximum transverse diameter measured at MR imaging was within the range of 
50%–150% of the maximum transverse diameter at histopathologic evaluation [30]. All other 
nodules detected at MR imaging were considered false-positive findings.
Statistical Analysis
 The statistical analysis included calculation of sensitivity, specificity, positive 
predictive value, negative predictive value and overall accuracy in the localization of 
prostate tumor by dichotomizing the readings. Scores of 3 to 5 were considered “present”, 
i.e. prostate tumor. Comparison of results from T2-weighted MR imaging, MRSI and DCE-
MRI was performed using the McNemar test. The analysis was repeated for nodules with a 
histopathologic volume greater than 0.50 cm3, because tumors less than 0.50 cm3 are clinically 
considered less relevant [31, 32].
 Receiver operating characteristic (ROC) curves comprehensively summarize the 
performance of multiple modalities at different operating levels. A summary measure of the 
ROC curves is the area under the curve (Az) for which statistical test have been developed 
for ROC analyses. ROI-ROC analysis accounts for the ROI sampling and allows comparison 
of multiple modalities and readers using bootstrapping [33, 34]. ROI-ROC has been used in 
the pre-market approval of a lung CT Computer Aided Diagnosis evaluation study for the 
FDA (PMA: P030012, July 8, 2004) and recently in sextant localization of local prostate cancer 
recurrence [35].
 All p-values reported were from two-sided tests; a P-value of 0.05 or less was 
considered to be statistically significant. Statistical analyses were performed using R (Version 
2.1.0) [36] and SPSS software package (version 12, Chicago, Ill, U.S.).
    Results
 No patients were excluded. Table 2 provides a summary of patient characteristics 
and pathologic findings. For each technique, a total of 476 ROIs (34 patients x 14 ROIs) were 
evaluated. A total of 71 prostate cancer nodules were observed. Sixty-nine percent (49/71) of 
these tumors were observed in the peripheral zone and 31% (22/71) in the central gland.
MR Imaging, MRSI and DCE-MRI
 A typical example of a complete dataset of a patient is presented in Figure 1. Axial 
T2-weighted MR images of the prostate did not reveal a suspicious low-signal-intensity 
lesion. DCE-MRI showed an increased Ktrans in the central gland (oval in B). Moreover, in 
the left half of the central gland kep was higher (C) compared to the right half, and marked 
latewash was present (circle in D). In the same region MRSI showed a markedly reduced 
citrate signal and an increased choline+creatine/citrate ratio (red box in E). The combination 
of DCE-MRI and MRSI resulted in this patient that the tumor was correctly localized, which
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Table 2: Patient Characteristics 
Pre operative characteristics
Mean age, years (range)   60 (50 - 69)
Mean PSA level, ng/ml (range)  8.0 (3.2 -23.6)
Median Gleason score (range)  6 (5 - 8)
Post operative characteristics
Pathologic stage
 T2 (T2a / T2b)   27  (9 / 18)
 T3 (T3a / T3b)   7 (7 / 0)
Tumor localization
Number of tumor nodules   71
 Peripheral zone, % (tumor nodules) 69  (49/71)
 Central gland, % (tumor nodules) 31 (22/71)
Mean tumor volume, ml (range)  0.98  (0.01 – 6.4)
Mean Gleason score (range)  6  (4 – 9)
Table 3: T2-weighted MR imaging, MRSI and DCE-MRI Tumor Localization Results on a 14 
               Region-of-Interests Basis for Tumors ≥ 0.5 cm3
   Sensitivity (%)  Specificity (%)  Accuracy (%)  PPV (%)     NPV (%)
T2-weighted MR imaging      
    Reader A 67 (75/112)         73 (264/364)      71 (339/476) 43 (75/175)   88 (264/301)
	   Reader B 52 (58/112)         74 (270/364)      69 (328/476) 38 (58/152)   83 (270/324)
MRSI
    Reader A 80 (78/98)           87 (249/286)      85 (327/384) 68 (78/115)   93 (249/269)
    Reader B 77 (75/98)           84 (226/268)      82 (301/366) 64 (75/117)   90 (226/249)
DCE-MRI
	 latewash	
Reader A  69 (76/110)         96 (325/338)      89 (401/448) 85 (76/89)     91 (325/359) 
Reader B  75 (79/106)         96 (322/334)      91 (401/440) 87 (79/91)     92 (322/349)
 ve	
Reader A 95 (106/111)       88 (310/351)      90 (416/462) 70 (106/147) 98 (310/315)
Reader B 90 (100/111)       85 (297/351)      86 (397/462) 65 (100/154) 96 (297/308)
 kep		
Reader A  85 (94/111)         88 (310/351)      87 (404/462) 70 (94/135)   95 (310/327)
Reader B  84 (93/111)         83 (292/351)      83 (385/462) 61 (93/152)   96 (292/310)
 Ktrans	
Reader A 87 (97/111)         87 (306/351)      87 (403/462) 68 (97/142)   96 (306/320)
Reader B 85 (94/111)         80 (282/351)      81 (376/462) 58 (94/163)   94 (282/351)
Note:	Numbers	in	parentheses	are	ROIs;	PPV	=	positive	predictive	value;	NPV	=	negative	predictive	value
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Figure 1. MRI data and histopathology of the corresponding slice of the prostate of a 71-year-old prostate 
cancer patient (PSA = 16.4 ng/ml; Gleason sum score 6). (A) Axial T2-weighted MR image of the prostate. 
(B) to (D) Pharmacokinetic maps of calculated parameters mapped on top of the T2-weighted image: Ktrans	
(B) kep (C) and latewash (D). (E) Overlay of the volume-of-interest, MRSI matrix and spectra on the T2-
weighted MR image with the spectra of 8 voxels outlined in detail. Voxels in the inset show a markedly 
reduced citrate signal and an increased choline+creatine/citrate ratio in the central gland of the prostate 
(red box). (F) Whole-mount section histopathology of the slice at a corresponding level. The tumor (T), 
indicated with a blue line, occupied almost the whole left prostate half including the central gland. In 
both the pharmacokinetic and the spectroscopic maps the tumor can be identified (red ovals in B, C and 
D and voxels with deviating metabolite ratios in E).
	
A B
C D
E F
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was confirmed by whole mount section histopathology.
 The overall accuracy of localizing prostate cancer using T2-weighted MR images was 
69% (328/476) and 67% (317/476), for reader A and B, respectively. No significant differences in 
localization performance were present between the readers. Excluding the small tumors (i.e. 
tumors less than 0.5 cm3), the localization performance increased from 67-69% to 69-71% for 
both readers (Table 3), however the difference was not statistically significant. 
In MRSI, a total of 86-116 out of 476 ROIs were assigned unusable and excluded from further 
analysis. The overall localization accuracy using MRSI was 79% (305/384) and 79% (289/366) for 
reader A and B, respectively. The localization accuracy increased significantly (P < 0.05) using 
MRSI compared to T2-weighted MR images for both readers. The localization performance 
increased from 79% to 82-85% for tumors equal to or greater than 0.5 cm3 (Table 3), however 
this was not significant.
 In DCE-MRI, a total of 14-76 out of 476 ROIs were assigned unusable and excluded 
in the further analysis. The DCE-MRI studies read in conjunction with the T2-weighted MR 
images resulted in a localization accuracy of 81-91% (Table 3) for tumors equal to or greater 
than 0.5 cm3. The diagnostic performance for tumors ≥ 0.5 cm3 increased significantly (P	 	<	
0.05) for all readers compared to T2-weighted MR images. For both readers, ve demonstrated 
the highest accuracies for tumor localization. The latewash parameter demonstrated the 
highest specificity for both readers. 
Comparison of MR approaches 
 The data of the two readers were pooled because the results were consistent. The 
presented ROI-ROC curves were based on these pooled data. The differences in performance 
of the individual DCE-MRI parameters and MPKS is shown in Figure 2. The MPKS is 
performing significantly better than the best ranking DCE-MRI parameter ve and thus better 
than all DCE-MRI parameters individually. Ktrans  and ve performed significantly better than 
latewash (P < 0.01). Comparison of per ROI and per patient analysis revealed only minor 
differences which were not significant different.
 The differences in performance of T2-weighted MR imaging, MRSI and MPKS are 
shown in Figure 3. MPKS performed significantly better than quantitative MRSI (P < 0.01). Both 
DCE-MRI and MRSI were significantly better than reading T2-weighted imaging (P < 0.01). 
Again, comparison of per ROI and per patient analysis revealed only minor differences. 
    Discussion
 This study demonstrates that using either DCE-MRI or MRSI in localizing prostate 
cancer significantly improves performance compared to T2-weighted MR imaging.
 Scheidler et al. [8] demonstrated the potential usefulness of combined morphologic 
and metabolic information to localize prostate cancer in clinical practice by MR imaging. 
A localization accuracy of 88% was obtained for tumor lateralization (right or left prostatic 
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Figure 2. The ROI-ROC curves describing the results of DCE-MRI parameters and MPKS for tumors ≥ 
0.5 cm3. A statistically significant greater area under the curve (Az) was present using MPKS (Az = 0.91) 
compared with the individual DCE-MRI parameters (P < 0.01).
Figure 3. The ROI-ROC curves describing the results of the interpretation of T2-weighted MR imaging, 
MRSI and DCE-MRI (MPKS). A statistically significant greater area under the curve (Az) was present 
using MPKS (Az = 0.91) compared with MRSI (Az = 0.80; P < 0.01). Both DCE-MRI and MRSI were 
significantly better in tumor localization than reading T2-weighted imaging (Az = 0.68).
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lobe). In their study the assessment was focused on the peripheral zone. However, in our study 
a 3D-MRSI technique was used [11] covering the whole prostate. Besides the peripheral zone, 
the transition zone and central zone were included in the analysis. Receiving MR signal from 
the central and transition zones is limited using an endorectal coil with a limited diameter. 
There is signal drop in the ventral part of the prostate (i.e. central and transitional zone) as 
a result of the distance from the coil conductors. In our study, 69% of the prostate tumor 
nodules were located in the peripheral zone. This is in concordance with reported figures in 
literature (65-74%) [37, 38]. Thus, 31% of the prostate cancer nodules would have been missed 
when focusing on the peripheral zone only. 
 In our study the MRSI localization accuracy of 82-85% fall within the range with 
previous reported accuracies of 67-88% [8, 27, 39, 40]. Our results were obtained using 
a quantitative and 14 ROI approach. However, in the latter studies [8, 27, 39, 40], only the 
peripheral zone was evaluated and a sextant approach was used. Jung et al. [27] used a cut-off 
point of ≥ 4 on a five-point scale in the evaluation of a standardized system with additional 
criteria. In our series we focused on the localization performance in the whole prostate of each 
technique separately. Although we used a cut-off point of ≥ 3 on the same five-point scale, a 
specificity of 84-87% was achieved. These findings in our study combined with those in Jung 
et al. [27] suggests that reading 3D MRSI of the whole prostate in particular is of value to 
obtain a high specificity.
 The data of the DCE-MRI parameters showed that individual pharmacokinetic 
parameters do not differ in localization performance. The MPKS is significantly better than 
individual DCE-MRI parameters and better than MRSI and T2-weighted MR imaging. 
The fact that MPKS outperforms individual DCE-MRI parameters means that each DCE-
MRI parameter has independent diagnostic information. The MPKS is a simple diagnostic 
parameter that can be readily applied. The P-values of the patient based approach hardly 
differ from the ROI based approach. This can be explained by a low intrapatient correlation 
between the ROIs. The latewash parameter is a finding with a specificity of 96% in tumors ≥ 
0.5 cm3 for all readers. This is concurrent with the finding by Engelbrecht et al. [17]. 
 ROC statistical analysis is currently the technique of choice for statistical testing 
for differences between modalities and readers. However, here we study localization and 
extent of the tumor which is important for treatment or diagnostic reasons. When location 
is involved, standard ROC techniques cannot be used. AFROC (alternative free-response 
ROC) has several techniques being developed to test for differences in modalities/readers 
[41]. AFROC has been criticised for unrealistic assumptions and as a response the Jacknife 
AFROC technique emerged [42, 43]. In ROI-ROC each ROI is evaluated by each reader for each 
modality [34]. ROI-ROC analyses allowing multiple modalities and readers to be compared 
can be performed using bootstrapping [33]. The search for the most statistically powerful 
ROC analysis that includes location and local extent of tumor is subject of investigation [44]. 
The presence of post-biopsy hemorrhage is known to degrade the T2-weighted MR images and 
the accuracy of prostate cancer evaluation [26]. T1-weighted MR images can be used to detect 
these areas of biopsy artefacts. In this study, MR imaging was performed at least 3 weeks after 
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the last ultrasound guided biopsy. The hemorrhage may not be completely absorbed after this 
period. Therefore, it is difficult to differentiate between biopsy related low-signal intensity 
and tumor on T2-weighted images, which may have introduced false positive findings. In our 
study at least one of six biopsies was positive. Patients were not excluded when post biopsy 
artefacts were present, as this is a patient group that represents daily practice.
 As expected excluding small tumors (i.e. those smaller than 0.5 cm3) from the analysis 
resulted in increased localization accuracies. These accuracies were however not significantly 
different to the analysis comprising all tumors. Tumor volume estimation performs better at 
larger tumor volumes [39]. Parallel to this finding, it is assumed that tumor localization may 
be improved in large tumors. In our study, the mean tumor volume at histopathology was 0.98 
cm3 per patient. These are rather low tumor volumes compared to those reported in previous 
studies (1.24-2.90cm3) [7, 39, 45]. 
 In this study, two functional MR imaging techniques have been evaluated. There 
are several differences between both techniques in this evaluation. The MRSI spectra 
were analyzed using a quantitative approach, which is basically independent from prior 
knowledge on the presence of tumor in the prostate and the MR image, which is used as 
background to the metabolic information. The DCE-MRI data were read in a subjective way in 
this study. This method was chosen because in literature different approaches have been used 
in the analysis of DCE-MRI data and absolute values of DCE-MRI parameters may be rather 
variable among patients [17, 21]. The precise value of a quantitative analysis of DCE-MRI 
parameters for clinical use will have to be further evaluated in the future. For these reasons 
MRSI may be used for detection and localization of prostate cancer whereas DCE-MRI can be 
used for localization in prostate cancer proven patients. As the voxel size of the MR spectra 
are larger than the parametric DCE-MRI this may have resulted in lower localization accuracy 
as compared to the DCE-MRI small tumors.
 The current study has a number of limitations. One limitation is the low number of 
patients. Nevertheless, statistically significant results were obtained using MRSI and DCE-
MRI in localizing prostate cancer. The tumor locations were compared to the histopathological 
data by two radiologists after the readings, which may have introduced information bias. 
However, this was performed one month after all the readings. Another limitation was the 
rather high number of MR spectra that were assigned as unusable by the readers, in particular 
by the less experienced reader. A more automated approach based on objective criteria for 
spectral quality may improve this situation. Furthermore, during this study, the experience 
with MRSI increased thereby resulting in an improved quality of the spectra and reduction 
of the examination time, although this was not evaluated in detail. As yet we did not evaluate 
possible relationships between prostate cancer aggressiveness observed in prostatectomy 
specimens with MRSI and DCE-MRI parameters.
 The clinical application of improved localization by DCE-MRI and MRSI in prostate 
cancer patients can be applied, firstly, in patients with rising PSA and negative biopsies 
(image guided biopsy of the suspicious lesion). Secondly, to evaluate the tumor location 
and the distance to the neurovascular bundle and prostate capsule, to determine if a nerve 
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sparing operation is possible, especially in laparoscopic procedures where there is no tactile 
information. Thirdly, for the planning of intensity-modulated radiation therapy [46]. This 
treatment requires exact localization of prostate cancer in order to administer an extra boost 
of radiation dose to in addition to the normal dose. The combination of the high specificity 
of the functional data of MRSI and latewash as well as high the sensitivity of ve, kep and K
trans 
may help to localize a prostate tumor nodule in the whole prostate more accurate. This can be 
used to aid the radiologist to focus on the high sensitivity of DCE-MRI in finding suspicious 
areas and to confirm these findings with MRSI. The proposed strategy requires confirmation 
in future studies.
Conclusions:
 In conclusion, our data indicates that DCE-MRI and MRSI of the whole prostate is 
significantly more accurate than T2-weigthed MR imaging in localizing prostate carcinoma. 
Our results suggest that if these advanced MR imaging techniques are included in the MR 
imaging protocol the localization in prostate cancer patients will improve. 
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    Abstract
Purpose: To prospectively determine the accuracy of experienced and less experienced readers 
in the interpretation of combined T2-weighted fast spin-echo (SE) magnetic resonance (MR) 
images and dynamic contrast material–enhanced MR images compared with T2-weighted 
fast SE alone, with respect to differentiation of stage T2 versus stage T3 prostate carcinoma, 
with histologic analysis serving as the reference standard. 
Material and methods: Institutional review board approval and informed consent were 
obtained, and 124 consecutive men (age range, 42–74 years; median age, 63 years) with 
biopsy-proved prostate cancer underwent MR imaging and were candidates for radical 
prostatectomy. T2-weighted fast SE MR images and multisection dynamic contrast-enhanced 
MR images with a 2-second time resolution for the whole prostate were obtained. The T2-
weighted and fused color-coded parametric dynamic contrast-enhanced MR images with T2-
weighted images were evaluated prospectively and scored with regard to local extent by one 
experienced reader and evaluated retrospectively by two less experienced readers working 
in consensus by using a five-point scale; images with a score greater than or equal to four 
were considered indicative of T3 disease. Results were correlated with whole-mount section 
histopathologic findings, and receiver operating characteristics analysis was performed. 
Results: Twenty-five patients were excluded because of positive findings in the lymph nodes 
(n = 16), preoperative biopsy-proved seminal vesicle invasion (n = 5), and an absent dynamic 
dataset (n = 4). Ninety-nine patients were included in this study. The overall sensitivity, 
specificity, and accuracy of MR staging performance in prostate cancer with dynamic 
contrast-enhanced MR imaging was 69% (24 of 35 patients), 97% (62 of 64 patients), and 87% 
(86 of 99 patients), respectively, for the experienced reader. This difference was not significant 
(P = .48) when results were compared with results from the T2-weighted images. Staging 
performance for the less experienced readers with parametric dynamic contrast-enhanced 
MR imaging, however, resulted in significant improvement of the area under the receiver 
operating characteristics curve (Az) compared with T2-weighted MR imaging alone (Az = .66 
and .82, respectively; P = .01). 
Conclusion: The use of multisection dynamic contrast-enhanced MR imaging in staging 
prostate cancer showed significant improvement in staging performance for the less 
experienced readers but had no benefit for the experienced reader.
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    Introduction
 At present, there is controversy over the role of endorectal magnetic resonance (MR) 
imaging of the prostate in the detection of extraprostatic extension of cancer. Some authors 
have reported the poor performance of endorectal MR imaging in the staging of prostate 
cancer [1,2]. Nonetheless, others have reported favorable results, with a large heterogeneity 
in local staging performance [2–7] and a limited ability to demonstrate microscopic capsular 
penetration [2]. 
 An additional MR technique, such as dynamic contrast material–enhanced MR 
imaging, is reported to be effective in the depiction of prostate pharmacokinetics [8–10]. 
Experience with this technique in patients with breast and bladder cancer indicates that 
because of neovascularization, malignant lesions demonstrate earlier and faster enhancement 
than do benign lesions [11,12]. Engelbrecht et al [13] showed that prostate cancer demonstrated 
different enhancement patterns when evaluating onset time, time to peak, peak enhancement, 
and washout. The number of studies in which the use of contrast-enhanced MR imaging in 
staging and detection of prostate cancer is evaluated is small, with low numbers of patients 
[7,14–20] (Table 1). Results are conflicting and difficult to compare. Competing examination 
strategies have been used; these strategies include postcontrast high-spatial-resolution MR 
imaging or postcontrast high-temporal-resolution MR imaging and, subsequently, low spatial 
resolution and decreased anatomic coverage, respectively [7,14–20]. 
Table I: Summary of Reports on the Staging Performance of Contrast Enhanced Magnetic 
Resonance Imaging in Prostate Cancer
Author and Year  n           Resolution    Coil  Accuracy  Histopathologic 
        Standard
Huch Boni et al. 1995 7  33         spatial     ERC 82FSE/ 86CE whole mount  
Jager et al. 1997 14   57         temporal     ERC    72FSE/ 78CE whole mount 
Namimoto et al. 1998 15 42         temporal     PPA     75FSE/ 79CE needle biopsy
Tanaka et al. 1999 16 10 / 18  temporal     ERC 92FSE/ 89CE needle biopsy
Ogura et al. 2001 17  38         temporal/      ERC 72CE                 whole mount
                spatial
n	=	Number	 of	 patients;	 temporal	 =	high	 temporal	 resolution	dynamic	 contrast	 enhanced	 imaging;	
spatial	=	high	spatial	resolution	contrast	enhanced	imaging;	ERC	=	endorectal	coil;	PPA	=	pelvic	phased	
array	coil;	accuracy	values	are	in	%;	CE	=	contrast	enhancement;	whole	mount	=	whole	mount	section	
histopathology.
 To our knowledge, no reports are available on the prospective evaluation of 
multisection dynamic contrast-enhanced endorectal MR imaging in the staging of prostate 
cancer. Thus, the purpose of our study was to prospectively determine the accuracy of 
experienced and less experienced readers in the interpretation of combined T2-weighted fast 
SE MR imaging and dynamic contrast-enhanced MR imaging compared with T2-weighted 
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fast SE MR imaging alone, with respect to differentiation of stage T2 versus stage T3 prostate 
carcinoma. We used histologic findings as the reference standard. 
    Materials and Methods
Study Design
 Between March 1999 and February 2003, 124 consecutive patients with biopsy-
proved prostate cancer underwent MR imaging of the prostate. Patients were included in this 
study if they were candidates for radical prostatectomy. The diagnosis of prostate cancer was 
confirmed with gross pathologic examination of tissue specimens obtained with systematic 
transrectal ultrasonography (US)-guided sextant biopsy. The urologist classified patients 
as having stage T2 disease on the basis of findings at clinical examination, transrectal US, 
and biopsy. Exclusion criteria were previous hormonal therapy, positive lymphadenectomy 
results, contraindications to MR imaging (eg, cardiac pacemakers and intracranial clips), and 
contraindications to endorectal coil insertion (eg, anorectal surgery and inflammatory bowel 
disease). The study was approved by the institutional review board, and informed consent 
was obtained from all patients. 
 Patient ages ranged from 42 to 74 years (median age, 63 years). Median prostate 
specific antigen (PSA) levels and median Gleason score were 7.8 ng/mL (range, 3.7–78 ng/mL) 
and 6 (range, 3–9), respectively. The mean interval between transrectal US-guided sextant 
biopsy and MR imaging, which was performed after biopsy, was 33 days ± 18 (standard 
deviation). In all patients, prostatectomy was performed within 4 weeks (range, 1–28 days; 
median, 19 days) of MR imaging. 
MR Imaging
 MR images were obtained with a 1.5-T imager (Vision; Siemens Medical Systems, 
Erlangen, Germany) and the use of an integrated endorectal pelvic phased-array coil (MR 
Innerva; Medrad, Pittsburgh, Pa). The endorectal coil was inserted and inflated to a volume of 
approximately 80 mL. In all patients, peristalsis was suppressed by intramuscular injection of 
1 mg glucagon (Glucagen; Nordisk, Gentofte, Denmark) before the examination. The imaging 
protocol included the following examinations: Multisection T2-weighted fast SE sequences 
were performed with an in-plane resolution of 0.55 x 0.55 mm (repetition time msec/echo 
time msec, 3500–4400/132; flip angle, 180°; 11–15 sections obtained; 4–5-mm section thickness, 
with a 0.5-mm gap; 280-mm field of view; 240 x 512 matrix; two signals acquired; echo train 
length, 15) in three orthogonal planes of the prostate and seminal vesicles after T1-weighted 
localizing images were obtained. 
 A multisection T1-weighted two-dimensional spoiled gradient-echo sequence (50/4.4; 
flip angle, 60°; seven sections; 7-mm section thickness, with a 0.5-mm gap; 280-mm field of 
view; 160 x 256 matrix; in-plane resolution, 1.07 x 1.07 mm) was acquired during intravenous 
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bolus injection of a paramagnetic gadolinium chelate (0.1 mmol per kilogram of body weight 
gadopentetate dimeglumine [Magnevist; Schering, Berlin, Germany]) by means of a power 
injector (Medrad) with an injection rate of 2.5 mL/sec followed by a 15-mL saline flush. With 
this sequence, seven transverse sections were obtained every 2 seconds for 90–120 seconds, 
with the same positioning angle as that used for the transverse T2-weighted fast SE sequence 
covering the whole prostate. A multisection intermediate-weighted sequence was performed 
before injection of contrast material by using the similar transverse two-dimensional spoiled 
gradient-echo sequence (200/4.4; flip angle, 8°) and section positioning to allow calculation of 
relative gadopentetate dimeglumine concentration. 
 Images were obtained with the fast SE sequence in all 124 patients and with 
dynamic contrast-enhanced MR imaging in 120 patients; images were not obtained in four 
patients because of technical difficulties with the dynamic contrast-enhanced MR sequence. 
All dynamic data sets were transferred to an independent workstation. Analyzing software 
was used to display these dynamic datasets [9]. Dynamic images were converted to four 
parameter images: start of enhancement, time to peak, peak enhancement, and washout. 
Contrast material–induced signal enhancement is converted to tracer concentration with the 
intermediate-weighted sequence data by solving a system of two low-angle gradient-echo 
signal equations with two unknowns [9,21]. Time-concentration curves were fitted to an 
exponential model extended with a late washout term [9]. The onset of the exponential curve 
is defined as the start of enhancement; the exponential constant characterizing the slope and 
height of the curve is defined as the time to peak. The peak enhancement is the concentration 
at which the exponential curve becomes level. Washout is defined as the negative slope of 
the late part of the exponential curve. The start of enhancement was calibrated by using the 
external iliac artery. The resulting parameter images depicted local flow differences in the 
feeding vascular system. Time to peak relates to permeability surface area and extracellular 
space. Peak enhancement correlates to differences in tracer-accessible extracellular volume. 
 Parametric maps were fused (three-dimensional rotation, translation, and linear 
interpolation) with T2-weighted MR images, such that the imager-provided position in any 
display mode matched exactly. The four-parameter images were displayed as transparent 
color-coded images, which were overlaid in semitransparent colors over the T2-weighted fast 
SE images. The postprocessing procedure (5 minutes per patient) was performed by an MR 
technologist. 
Scoring and Evaluation of Data
 First, the T2-weighted MR images were evaluated. The presence of extracapsular 
extension and seminal vesicle invasion was evaluated on the basis of specific features (Table 
2) described in the literature as being highly indicative of extraprostatic disease. The readers 
(J.O.B., J.J.F., M.R.E.) subjectively expressed their findings of extracapsular extension and 
seminal vesicle invasion on a five-point confidence level scale (1, not present; 5, present). 
Precontrast T1-weighted images were additionally evaluated to rule out false-positive 
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Table 2:  Criteria for Extracapsular Extension and Seminal Vesicle Invasion for T2-weighted 
 MR Images and Fused T2-weighted Parametric MR Images
Finding and Contrast     
Enhancement  Specific Features
Extracapsular Extension       
   Unenhanced  Asymmetry of the neurovascular bundle    
   Obliteration of the rectoprostatic angle     
   Irregular bulge in the contour of the prostate    
   Extracapsular tumor
   Enhanced   Asymmetric high peak enhancement, present washout 
     parameter, or both      
                  Presence of high peak enhancement, washout, and shorter
     onset time  or increased time-to-peak parameter	
Seminal Vesicle Invasion
   Unenhanced  Asymmetric low signal intensity within the lumen   
   Focal wall thickening
   Enhanced  Asymmetric peak enhancement, washout parameter within the 
     lumen, or both
   Asymmetric peak, washout, and onset time or time-to-peak 
     parameter within the lumen
findings caused by postbiopsy hemorrhage [22]. Evaluation of MR images was performed in 
all three planes. Criteria for extraprostatic extension were derived on the basis of the findings 
reported in the literature [23–26]. 
 Second, the T2-weighted fast SE images with the parametric image overlay were 
evaluated with a five-point scale (1, not present; 5, present) by using criteria defined in Table 
2. The combination of peak enhancement and the presence of washout are highly indicative 
of prostate cancer [13] for both the peripheral zone and the central gland. The presence of 
asymmetric peak enhancement, washout, and decreased start of enhancement, and/or 
increased time to peak are highly indicative of prostate cancer. 
 Reading with and without contrast enhancement was performed at a high specificity 
setting [27] for extraprostatic disease, and extraprostatic disease was rated only if the reader 
was certain of stage T3 disease. This was done to ensure that a patient with actual T2 disease 
received tailored curative therapy. The T2-weighted fast SE and the fused T2-weighted 
fast SE parametric MR images were prospectively evaluated and scored by an experienced 
radiologist (J.O.B.) and retrospectively scored by two less experienced radiologists (M.R.E. 
and J.J.F.) working in consensus. All readers were aware of the PSA level and Gleason score. 
The three radiologists had different levels of experience in the evaluation of prostate MR 
images. The radiologist who prospectively evaluated and scored images had 12 years of 
experience (approximately 750 studies) in MR imaging of prostate cancer at the beginning of 
this study. Of the radiologists who retrospectively evaluated and scored images, one (M.R.E.) 
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had 1 year of experience with approximately 50 studies, and the other (J.J.F.) had 3 months of 
experience with 25 studies. For this reason, these readers evaluated the MR examinations in 
consensus. 
Histologic Examination
 The prostatectomy specimens were fixed overnight (10% neutral buffered 
formaldehyde) and coated with India ink. Seminal vesicles were separated from the prostate 
and examined separately. Transverse whole-mount step-section specimens were obtained at 
4-mm intervals in a plane parallel to that in which transverse T2-weighted sequences were 
performed. All sections were routinely embedded in paraffin. Tissue sections of 5 µm were 
prepared and stained with hematoxylin-eosin. The presence and extent of cancer were outlined 
on the glass cover by one experienced pathologist (C.A.H., with 12 years of experience) who 
was blinded to the imaging results. For each tumor lesion, location and TNM stage (28) were 
determined and recorded. 
Data Analysis
 The extraprostatic extension that was predicted with MR imaging was correlated 
with the histopathologic analysis by one radiologist (J.J.F.) and one pathologist (C.A.H.) after 
scoring and evaluation of the data. The T2-weighted fast SE and the fused T2-weighted fast 
SE parametric MR images were aligned with the whole-mount sections. The morphology of 
the central gland, peripheral zone, cysts, calcifications, and urethra were used as landmarks. 
Aligning MR images and whole-mount specimens is considered difficult [14], and the section 
thickness used in the two MR imaging sequences is different. Although we are unaware of 
any literature on this subject, we were confident that our results were accurate within 10 mm 
(eg, two sections). If the detected extraprostatic extension in the whole-mount specimen was 
within 5 mm of the location seen on the aligned MR image and on the correct side, it was 
considered a match. Prostate cancer foci other than the tumors adjacent to the capsule were 
not evaluated separately. 
Statistical Analysis
	
 For statistical analysis, patient-by-patient evaluation was performed (ie, prostate-
by-prostate analysis). A true-positive finding was considered in case of correlation of an 
imaging score of 4 or higher and histopathologic results with respect to the extraprostatic 
extension location. In the evaluation of a true-positive finding, there was stratification into 
extracapsular extension and seminal vesicle invasion at MR imaging and histologic analysis. 
For example, if a T3 tumor was diagnosed with MR imaging on the basis of seminal vesicle 
invasion but histologic analysis showed a T3 tumor on the basis of extracapsular extension, 
this was judged as a false-positive result. The sensitivity, specificity, positive predictive value, 
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negative predictive value, and overall accuracy in the prediction of tumor stage, extracapsular 
extension, and seminal vesicle invasion were calculated by dichotomizing the readings. Scores 
of 4 and 5 were considered positive for extracapsular extension, seminal vesicle invasion, 
and stage T3 tumor. Statistical analysis included comparison of results from T2-weighted fast 
SE and the fused T2-weighted fast SE parametric MR images by using the McNemar test 
and evaluation of interobserver agreement (experienced reader vs less experienced readers) 
by using nonweighted kappa (κ) statistics. The following qualitative terms were used to 
describe the strength of the various values of κ: 0.00–0.20, poor agreement; 0.21–0.40, fair 
agreement; 0.41–0.60, moderate agreement; 0.61–0.80, substantial agreement; and 0.81–1.00, 
almost perfect agreement [29]. The area under the receiver operating characteristic curve (Az) 
was calculated by using the scores of extracapsular extension, seminal vesicle invasion, and 
staging performance. All statistical analyses were performed with Rockit 0.9B (Department of 
Radiology, University of Chicago, Chicago, Ill) [30] and SPSS, version 9.0 (SPSS, Chicago, Ill) 
software. All reported P values are from two-sided tests; a P value of .05 or less was considered 
to indicate a statistically significant difference.
    Results
	
 In 16 patients, prostatectomy was not performed because of positive findings in 
lymph nodes at frozen section analysis during the procedure. Five additional patients with 
positive findings at MR imaging were initially scheduled to undergo prostatectomy; however, 
they underwent US-guided seminal vesicle biopsy preoperatively, the results of which were 
positive in all patients. Subsequently, prostatectomy was cancelled. Of the remaining 103 
patients, histopathologic analysis confirmed that 35 (34%) patients who underwent radical 
retropubic prostatectomy had non–organ-confined disease (stage T3a or higher) and 68 
(66%) patients had organ-confined disease (stage T2b or lower). The group of patients with 
organ-confined disease comprised 28 patients with a stage T2a tumor and 40 patients with 
a stage T2b tumor. Thirty-four patients had extracapsular extension. Six of seven patients 
with seminal vesicle invasion also had extracapsular extension. In four MR examinations, no 
dynamic sequence was obtained because of technical difficulties; therefore, 99 patients were 
evaluated (age range, 42–72 years; median age, 61 years) with dynamic contrast-enhanced MR 
imaging. Although the T2-weighted MR images were degraded in 12 patients as a result of 
hemorrhage, the presence of capsular extension was assessable in all of these patients because 
these artifacts did not deform the prostate capsule. T1-weighted images were assessed to 
localize these artifacts. In Figure 1, examples of T2-weighted and fused T2-weighted fast SE 
parametric MR images are provided. 
Overall Results
	
 The overall sensitivity, specificity, accuracy, and positive and negative predictive 
values of MR staging (stage T3 vs stage T2 disease) with T2-weighted fast SE images in 
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Figure 1. Fusion of a T2-weighted fast SE transverse image in gray value with partly opaque rendered 
color overlay of four contrast enhancement parameters (see text for detailed explanation of parameters). 
(A) Transverse T2-weighted fast SE image obtained through the prostate demonstrates a low-signal-
intensity lesion (T) in the left peripheral zone with bulging (arrows) and obliteration (arrowheads) of 
the rectoprostatic angle. (B) The start-of-enhancement parameter demonstrates an earlier enhancement 
in part of the low-signal-intensity lesion (arrows) compared with the right peripheral zone. (C) Fast time 
to peak is present in the left peripheral zone (arrows) and right central gland (arrowheads). (D) Peak 
enhancement is increased markedly in the center of the lesion in the left peripheral zone (arrows) and 
right central gland (arrowheads). (E) A negative washout area is seen in the left peripheral zone (arrows) 
and right central gland (arrowheads). (F) Photomicrograph shows stage T3a disease with prostate capsule 
penetration in the left peripheral zone (arrows) and a prostate tumor lesion in the right central gland 
(arrowheads).
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Table 3:  Diagnostic Performance in Staging Prostate Cancer and Detecting Extraprostatic 
 Extension with T2-weighted MR Images
Statistic and Reader Extracapsular Extension (%) Seminal Vesicle Invasion (%)
Sensitivity
  Radiologist A  59 (20/34)   71 (5/7)
  Radiologists B/C  50 (17/34)   43 (3/7)
Specificity
  Radiologist A  96 (66/69)   99 (95/96)
  Radiologist B/C  93 (64/69)   99 (95/96)
Accuracy
  Radiologist A  83 (86/103)   97 (100/103)
  Radiologist B/C  79 (81/103)     95 (98/103) 
Positive Predictive Value
  Radiologist A  87 (20/23)   83 (5/6)
  Radiologist B/C  77 (17/22)   75 (3/4)
Negative Predictive Value
  Radiologist A  83 (66/80)   98 (95/97)
  Radiologist B/C  79 (64/81)   96 (95/99)
Note.—Data	 in	 parentheses	 are	 proportion	 of	 patients.	 Radiologist	 A	 (J.O.B.)	 had	 12	 years	 of	
experience.	Radiologists	B	and	C	(M.R.E.	and	J.J.F.,	respectively)	had	1	year	and	3	months	of	experience,	
respectively.
patients with prostate cancer were as follows: 60% (21 of 35 patients), 97% (66 of 68 patients), 
84% (87 of 103 patients), 91% (21 of 23 patients), and 83% (66 of 80 patients), respectively, for 
the experienced radiologist (J.O.B.), and 51% (18 of 35 patients), 93% (63 of 68 patients), 79% 
(81 of 103 patients), 78% (18 of 23 patients), and 79% (63 of 80 patients), respectively, for the 
less experienced radiologists (Table 3). No significant differences in staging performance were 
present. The accuracy with T2-weighted fast SE images was 83% (86 of 103 patients) and 79% 
(81 of 103 patients) for the detection of capsular extension and 97% (100 of 103 patients) and 
95% (98 of 103 patients) for the detection of seminal vesicle involvement for the experienced 
radiologist and the radiologists working in consensus (Table 3), respectively. 
 Dynamic contrast-enhanced MR images were read in conjunction with the T2-
weighted MR images by the experienced radiologist and resulted in a 69% (24 of 35 patients) 
sensitivity, 97% (62 of 64 patients) specificity, 87% (86 of 99 patients) accuracy, 92% (24 of 
26 patients) positive predictive value, and 85% (62 of 73 patients) negative predictive value 
(Table 4) in staging (stage T2 vs stage T3 disease). The results for the readers working in 
consensus were as follows: sensitivity, 71% (25 of 35 patients); specificity, 95% (61 of 64 
patients); and accuracy, 87% (86 of 99 patients) (Table 4). The sensitivity for staging increased 
from 51% (18 of 35 patients) to 71% (25 of 35 patients) when the less experienced readers used 
5
82
Figure 2. Histologically confirmed stage T2 prostate carcinoma in a 66-year-old patient with a PSA level 
of 11.4 ng/mL and a Gleason score of 6. (A) Transverse T2-weighted fast SE MR image shows a suspicious 
low-signal-intensity lesion (T) in the left peripheral zone. The experienced radiologist classified this as 
bulging (arrows) and obliteration (arrowheads) of the rectoprostatic angle and scored this as stage T3a 
disease. (B) After injection of contrast material, the time-to-peak parameter showed fast enhancement 
(arrows) in the left peripheral zone within the location of the low-signal-intensity lesion within the border 
of the capsule. (C) Peak enhancement parameter showed a high level of contrast enhancement in the left 
peripheral zone (arrows) within the contours of the prostate. The combination of T2-weighted fast SE 
and fused parametric MR images resulted in this tumor being correctly downstaged to stage T2a disease, 
which was confirmed with (D) whole-mount section histopathologic analysis. The black outline in this 
photograph of the specimen represents a tumor in the left peripheral zone.
fused T2-weighted fast SE parametric MR images; however, this increase was not significant. 
Both T2-weighted fast SE MR images and fused T2-weighted fast SE parametric MR images 
provided high diagnostic confidence in the assessment of seminal vesicle involvement. In 
one patient, seminal vesicle infiltration was missed on T2-weighted images by all radiologists 
because of the presence of symmetric low signal intensity, which resulted in a false-negative 
finding. After injection of contrast material, an asymmetric enhancement of the seminal 
vesicles was present. No significant differences in assessment of capsular penetration and 
seminal vesicle involvement were present between the experienced radiologist and the less 
experienced radiologists between T2-weighted fast SE MR imaging and fused T2-weighted 
fast SE parametric MR imaging.
A B
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Table 4:  Diagnostic Performance in Staging Prostate Cancer and Detecting Extraprostatic 
 Extension with Four Fused T2-weighted FSE Parametric MR Images 
Statistic and Reader Extracapsular Extension (%) Seminal Vesicle Invasion (%)
Sensitivity
  Radiologist A  65 (22/34)   71 (5/7)
  Radiologist B/C  74 (25/34)   71 (5/7) 
Specificity
  Radiologist A  95 (62/65)   100 (92/92)
  Radiologist B/C  94 (61/65)   100 (92/92)   
Accuracy
  Radiologist A  85 (84/99)   98 (97/99)
  Radiologist B/C  87 (86/99)   98 (97/99)
Positive Predictive Value
  Radiologist A  88 (22/25)   100 (5/5)
  Radiologist B/C  86 (25/29)   100 (5/5) 
Negative Predictive Value
  Radiologist A  84 (62/74)   98 (92/94)
  Radiologist B/C  87 (61/70)   98 (92/94)
Note.—Data	 in	 parentheses	 are	 proportion	 of	 patients.	 Radiologist	 A	 (J.O.B.)	 had	 12	 years	 of	
experience.	Radiologists	B	and	C	(M.R.E.	and	J.J.F.,	respectively)	had	1	year	and	3	months	of	experience,	
respectively.
Comparison of Readers
 The less experienced readers downstaged (ie, from stage T3 to stage T2 disease) five 
of six tumors (Figure 2) and upstaged (ie, from stage T2 to stage T3 disease) eight of 11 tumors 
correctly by using the fused T2-weighted fast SE parametric MR images in the suspicious 
area of capsular penetration. The experienced reader downstaged two of four tumors and 
upstaged four of six tumors (Figure 3) correctly.
 The interobserver agreement (experienced reader vs less experienced readers) 
in the evaluation of staging and extraprostatic extension was moderate to substantial (κ = 
0.41–0.68). The various Az values were used as indicators of diagnostic accuracy. The receiver 
operator characteristic curves describing the results of MR staging (stage T2 vs stage T3 
disease) performance by the radiologists are presented in Figure 4. The receiver operating 
characteristic curves that describe the results of the interpretation of T2-weighted fast SE (Az 
= 0.66) and fused T2-weighted fast SE parametric MR datasets (Az = 0.82) by consensus of the 
less experienced radiologists showed a significantly greater Az value with dynamic contrast-
enhanced MR imaging (P = .01) (Figure 4). There was no significant difference in the Az value 
between the experienced radiologist and the less experienced radiologists working
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Figure 3. Stage T3a disease in a 72-year-old patient with a PSA level of 10.2 ng/mL and a Gleason score 
of 5. (A) Transverse T2-weighted fast SE MR image shows a low-signal-intensity lesion (arrows) in the 
left peripheral zone, which was scored as stage T2a disease. (B) After contrast material injection, early 
start of enhancement was present in the right peripheral zone (oval). (C) In the right peripheral zone, 
faster time-to-peak enhancement was demonstrated with contrast enhancement (arrows) outside the 
capsule compared with the left peripheral zone. (D) Peak enhancement is displayed, which also showed 
an asymmetric lesion (arrows). Symmetric enhancement in the central gland was present, which turned 
out to be benign prostate hyperplasia. (E) No substantial washout was present. (F) The combination of the 
T2-weighted fast SE and fused parametric MR images resulted in this tumor being correctly upstaged to 
stage T3a disease, which was confirmed with whole-mount section histopathologic analysis. The outline 
represents prostate cancer with capsular extension (arrow) in the right peripheral zone.
A B
C D
E F
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in consensus (Figure 4). No significant difference was present for the experienced radiologist 
when comparing the fused T2-weighted fast SE parametric MR images (Az = 0.84) with the 
T2-weighted fast SE images (Az = 0.77). 
    Discussion
 In our study, the experienced radiologist showed a 97% specificity and 91% positive 
predictive value for establishing extracapsular tumor or seminal vesicle invasion. The results 
in each patient were reported to the urologist. Nonetheless, because of articles that indicate 
the poor ability to stage prostate cancer with endorectal MR imaging [2,31] and because of 
the large variability in the use of endorectal MR imaging to stage prostate cancer [6], the 
treatment decision was based on only the Partin tables, which use a combination of the PSA 
serum level, Gleason score, and digital rectal examination findings in the estimation of the 
risk of stage T2 or T3 disease [32]. Thus, MR imaging results were not used for tailored care of 
the patient. Our local ethics committee did not support this strategy, and they demanded that 
the imaging results be communicated with the urologist. In five patients, the work-up was 
altered (verification bias). 
 Jager et al [14] reported no significant improvement in staging with use of a single-
section dynamic fast low-angle shot subtraction technique. The limitations of the study of 
Jager et al were the use of a 10-mm-thick section, a single-section technique, and only an 
endorectal coil. The method used in our study is comparable to that of Jager et al; however, 
to overcome the aforementioned limitations, integrated endorectal phased-array coil, 
multisection technique, and parametric images were used in our study. This resulted in a 
significant (P = .01) improvement of the Az value for staging accuracy for the less experienced 
radiologists. 
 Reader experience is important in the staging of prostate cancer [2,27,33,34]. In our 
study, the less experienced radiologists improved their results (from an Az value of 0.66 to an 
Az value of 0.82, P = .01) by using dynamic contrast-enhanced MR imaging. The parametric 
maps helped draw the attention of the less experienced readers to areas of prostate cancer. 
These areas of prostate cancer were examined for extraprostatic spread by using the parametric 
maps and established signs on unenhanced T2-weighted MR images. As presented in the 
Results section, the less experienced readers downstaged five cases and upstaged eight by 
using dynamic contrast-enhanced MR imaging findings, whereas the experienced reader 
only up- or downstaged six cases. This suggests dynamic contrast-enhanced MR imaging 
should be used by less experienced radiologists as an additional tool in case of local staging 
of prostate cancer. 
 In our local situation, prostate MR images are interpreted by one experienced 
radiologist. Radiologists in training have the opportunity to learn MR imaging of the prostate; 
thus, less experienced radiologists interpreted the MR findings in consensus and retrospectively. 
In addition, one radiologist had only 3 months of experience in the interpretation of endorectal 
MR images of the prostate. This is a limitation of the current study; however, there is always 
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Figure 4. Receiver operating characteristic curves show the results of the interpretation of T1- and T2-
weighted dynamic contrast-enhanced MR imaging by an experienced radiologist and two less experienced 
radiologists. A significantly greater Az was present with contrast-enhanced MR imaging (Az = 0.82, P = 
.01) compared with unenhanced T2-weighted MR imaging for the less experienced readers.
a considerable learning curve in the interpretation of prostate MR images [33]. 
 The experienced radiologist did not improve his staging performance by using fused 
T2-weighted fast SE parametric MR images; this could be explained by his extensive experience 
in reading T2-weighted images. An experienced reader learns to distinguish tumorous areas 
of low T2 signal intensity from nontumorous areas in difficult cases. 
 In the evaluation of MR images in this study, the PSA level and Gleason score were 
known to the readers. It would have been interesting to determine the effect of knowledge 
of PSA and Gleason score on reading performance; however, that was not the purpose of our 
study. Sixty-six percent of the study population consisted of patients that had tumors with a 
stage of T2b or less at histopathologic analysis. According to Partin et al [32], the population 
in this study is at low to intermediate risk for having extraprostatic disease; one-third of 
these patients had extracapsular extension. Considering the five patients with seminal vesicle 
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invasion, this number will be increased. An explanation for the number of patients with 
positive capsular extension could be that the Partin et al tables [32] underestimate the risk 
of local disease in our patient populations; however, this possibility was not explored in our 
study. 
 Evaluation and scoring of the images were performed at the prostate level. The analysis 
could be improved by scoring the prostate at the octant level [35]; however, as described in 
the meta-analysis of Engelbrecht et al [6], most current examinations are performed at the 
prostate level. We evaluated patients at the prostate level, as this is the most important data 
from a clinical point of view. In case of stage T3 disease, the urologist will not perform radical 
prostatectomy. Thus, the results of our study can be compared with results of other studies. 
 Tempany [36] and Seltzer et al [37] have reported that radiologists can improve their 
diagnostic accuracy after being trained on computers afforded with examples of confined 
and nonconfined disease. As we do not have this facility in our hospital, we were not able to 
compare these techniques. 
 Our study is limited by the use of a relatively large (ie, 7-mm) section thickness for 
the dynamic sequence. This can be improved by using faster gradients and new MR software, 
should these be available. For this investigation, the attainable optimal parameters with the 
MR system were used. In general practice, this situation is not uncommon, and the obtained 
images are sufficient for the evaluation of MR images. The low number of radiologists who 
participated in this study is another limitation. It is difficult to generalize our results with only 
one experienced radiologist. 
 Jager et al [38] developed a decision analysis model that indicated MR staging in the 
preoperative work-up of prostate cancer is cost-effective and should be performed with a high 
specificity reading. The need for high specificity was also emphasized by Langlotz et al (27) to 
ensure that as few patients as possible are unnecessarily denied potentially curative therapy 
because of false-positive findings. Our prospective study has demonstrated that it is possible 
to achieve high specificity and accuracy in a large group of patients. Even for less experienced 
readers, it appeared possible to achieve these results in staging of prostate cancer with the 
additional use of contrast-enhanced MR imaging. 
 In conclusion, use of multisection dynamic contrast-enhanced MR imaging in the 
staging of prostate cancer resulted in significant improvement in the staging performance 
of the less experienced readers; however, it had no benefit to the experienced reader. Studies 
with more readers are needed to confirm our results.
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    Abstract
Rationale and Objectives: to explore the feasibility of prostate MR imaging at 3T, with the 
knowledge of potential drawbacks of MR imaging at high field strengths.
Material and Methods: MRI, dynamic MRI and MRSI were performed in 10 patients with 
prostate cancer on 1.5T and 3T whole-body scanners. Comparable scan protocols were used 
and additional high resolution measurements at 3T were acquired. For both field strengths 
the signal-to-noise ratio (SNR) was calculated and image quality was assessed. 
Results: At 3T SNR improved. This resulted in increased spatial MRI resolution, which 
significantly improved anatomical detail. The increased spectral resolution improved the 
separation of individual resonances in MRSI. Contrast-enhanced time-concentration curves 
could be obtained with a doubled temporal resolution. 
Conclusions: Initial results of endorectal 3T MR(S)I in prostate cancer patients showed 
potential advantages: the increase in spatial, temporal and spectral resolution at higher field 
strength may result in an improved accuracy in delineating and staging prostate cancer.
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    Introduction
 Magnetic resonance (MR) imaging of the prostate at 1.5 Tesla (T) is becoming 
more widely available as a routine examination in a clinical setting. The introduction of an 
endorectal coil and fast spin-echo sequences enabled the acquisition of T2 weighted images 
of the prostate and its surrounding tissues with a high spatial resolution within clinically 
acceptable examination times. Despite the relatively high spatial resolution that routinely can 
be acquired, there is still substantial room for improvement, as reflected in the large range 
of staging accuracies (54% to 88%) reported in some studies [1, 2]. Moreover, an estimation 
of tumor volume is still difficult [3, 4]. Dynamic contrast-enhanced MR imaging (DCE-MRI) 
can be used as an additional tool to visualize prostate cancer (PCa) (neo)vascularity [5-8]. 
The accuracy of this technique at a field strength of 1.5T can be improved by increasing 
the spatial and especially the temporal resolution when moving to a higher field strength: 
even a time resolution of 2 seconds has been reported to be too slow to assess cancer related 
vascular permeability and surface variations [7] and thus differentiation performance. 1H-
MR spectroscopic imaging (MRSI) has been shown to provide a high specificity for PCa 
[9, 10]. Generally signals of citrate, choline and creatine can be found in the spectra of the 
prostate, with high citrate being an important marker for healthy or benign prostate tissue 
[11] and a combination of reduced or depleted citrate together with increased choline levels 
characterizing PCa [12]. Since the line widths of the resonances at 1.5T in the prostate are 
comparable to, or often larger than, the choline and creatine chemical shift dispersion, it is 
difficult to quantify either one separately. Moving to a higher field strength the chemical shift 
dispersion will increase, which facilitates the quantification of individual signals, provided 
the increase in line width is moderate.
 MR  imaging of the brain at field strengths above 1.5T has been performed since several 
years [13, 14], whereas whole-body MR imaging beyond 1.5T was explored only recently [15-
17], mainly because proper radiofrequency (RF) coils were not available. Generally, a higher 
field strength increases the signal-to-noise-ratio (SNR), which potentially can be used to 
increase the spatial or temporal resolution of the MR measurements [18]. Potential drawbacks 
of clinical MR imaging at high field strengths are the possibly shorter T2-relaxation times, 
longer T1-relaxation times [19], increased problems with susceptibility differences, and 
the homogeneity of the magnetic field in the organ or tissue of interest, especially for body 
applications. 
 As clinical 3T MR machines are presently becoming available, their application to 
the prostate may result in a more accurate characterization of cancer in this organ. However, it 
is unknown how the potential benefits of higher field strength (3T) balances with the potential 
limitations for MR of the prostate in practice. Therefore we explored the feasibility of prostate 
MR imaging, dynamic contrast-enhanced MR and MR spectroscopic imaging at 3T using an 
endorectal surface coil. We explored the SNR limits of signals from the prostate at 3T with 
an endorectal surface coil. The first in vivo results in ten patients with prostate cancer are 
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presented. 
    Materials and Methods
Subjects
 MR imaging with an endorectal RF coil was performed in 10 patients with biopsy-
proven prostate cancer, who were recruited from the departments of urology and radiotherapy. 
The mean age was 61 years (range, 52 - 74). Mean prostate specific antigen level was 8.2 ng/ml 
(range: 3.0 - 18.0 ng/ml) and median Gleason score was 6 (range: 5 - 10). MR imaging was 
performed at least 4 weeks after transrectal ultrasound-guided sextant biopsy. This study was 
approved by the institutional ethics review board, and informed consent was obtained.
MR Imaging Protocols
 All MR measurements were performed using a commercially available 3T whole body 
scanner (Magnetom TRIO, Siemens Medical Solutions, Erlangen, Germany). A quadrature 
birdcage body coil was used for transmission and a prototype endorectal surface coil for 3T 
was used for receiving the MR signals (Medrad®, Pittsburgh, PA, US). The endorectal probe 
prototype consisted of a receiver coil mounted on the inner surface of a balloon, similar to the 
commercially available endorectal coil at 1.5T (Medrad®). Tuning, matching and decoupling 
circuitry was incorporated in an external interface at 25 cm from the endorectal coil. When 
using the endorectal coil, maximum SAR limits were lowered with a factor of two to ensure 
the patient’s safety. 
 After digital rectal examination the endorectal coil was inserted and inflated with 
demineralized water to a volume of approximately 60 ml. In all patients peristalsis was 
suppressed by an intramuscular injection of 1 mg glucagon (Glucagen®; Novo Nordisk A/S, 
Denmark) before the examination. 
 Axial and sagittal localizer images were acquired for anatomical orientation and coil 
positioning confirmation. The three-part scanning protocol is listed in order of acquisition in 
table 1 and figure 1. T2-weighted (T2-w) turbo spin echo (TSE) images were acquired in three 
planes. The scanning parameters were equal to the routinely used 1.5T protocol to acquire 
T2-w images. Additionally an axial high resolution T2-w TSE image series (1024 x 512 matrix, 
0.18 x 0.18 mm) was acquired, taking full advantage of the increased SNR of the endorectal 
coil at 3T. 
 3D-MRSI of the whole prostate was performed with measurement protocol 
comparable to that at 1.5T [20] (90°-180°-180° PRESS, PRESS localization boxed around the 
prostate, Hamming weighted signal averaging with 5 (1.5T) and 8 (3T) acquisitions in the 
center of k-space, 13 minutes total measurement time). At 1.5T the interpulse timing, defining 
the shape of the resonances of the strongly coupled citrate spin system and the echo time was 
set to 120 ms at 1.5T [21] and 145 ms at 3T, respectively. At this timing the inner lines of the 
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Figure 1. A flowchart of the MR imaging protocol in order of acquisition.
citrate resonance had a maximum positive absorptive intensity, whereas the intensity of the 
outer lines was relatively small. Water and lipid signals were suppressed with outer volume 
saturation slabs and frequency selective rf pulses [22]. These dual-band excitation pulses of 
12.8 ms duration were placed around the first refocusing PRESS-localization pulse, whereas 
in the pulse sequence for 1.5T their duration is 25.6 ms, and their positions are around the 
second refocusing pulse. Halving the pulse duration at 3T doubled the frequency range of 
excitations, and since the centers of the two excitation bands is ppm-based, the resulting 
ppm-range for signal suppression at 1.5 and 3T is comparable. Shimming was performed 
automatically by a standard shim procedure and was further improved manually focused on 
the PRESS-selected rectangular box around the prostate. 
 The contrast-enhanced imaging protocol included a T1-weighted (T1-w) 3D-FLASH 
pre- and 4 post contrast acquisitions. For dynamic analysis, an optimized T1-w turbo-FLASH 
sequence was obtained every 2 seconds over 2 minutes in which the contrast agent bolus 
passed through the prostate. Gadopentetate dimeglumine 0.1 mmol/kg b.w. (Gd-DTPA; 
Magnevist®; Schering, Berlin, Germany) was administered as the paramagnetic contrast 
material. After four patients the dynamic contrast-enhanced MR images and signal-intensity 
curves were evaluated. The high SNR obtained in these measurements allowed us to change 
the slice thickness for the 3D-FLASH sequence from 18 partitions into 32 partitions of 1.5 
mm. Since a temporal resolution of 2 seconds is too slow to estimate vascular permeability, 
as discussed earlier, we also decided to change the protocol for the turbo-FLASH sequence 
to attain a temporal resolution of 1 second (140 mm FOV, 64 x 128 matrix), resulting in 120 
sequential data sets. 
 The total examination time of the complete protocol on the scanner took approximately 
40-45 minutes. The same patient group also underwent an additional MR examination at 1.5T 
(Magnetom Sonata, Siemens Medical Solutions, Erlangen, Germany) within one week with a 
standard combination of an airfilled endorectal coil and a pelvic-phased-array coil. Deviating 
parameters for the TSE sequences (3500/132, 180°, 5.0/0.5, 280 mm FOV and 512 x 240 matrix) 
and a temporal resolution of the dynamic MR protocol of 10 partitions every 2 seconds were 
used. An important issue to be noted throughout all measurements is that at 3T we only used 
an endorectal coil for MR imaging and MRSI, while at 1.5T we used the combination of an 
endorectal coil, a two-element body array coil and one or two elements of a spine array coil 
for all imaging experiments.
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Table 1:   Scanning Parameters
Sequence    TR TE α       slice thick  FOV matrix   in plane voxelsize  
     (ms) (ms) (°)     (nr of slices) (mm)             (mm)
TSE     4100 119 180    4.0 (15) 280 512 x 256     0.35 x 0.35 
TSE (high resolution)     5630 162 150    4.0 (10) 180 1024 x 512   0.18 x 0.18 
3D-MRSI (1.5T)    640 120       PRESS 5.0 (12)  60 14 x 14      4.3x4.3 (nominal)
3D-MRSI (3T)    650 145       PRESS 6.0 (12)   80 12 x 12      6.7x6.7 (nominal)
4 patients
  3D-FLASH (pre)    8.6 4 15      2.5 (18) 190 256 x 512     0.37 x 0.37
  turboFLASH (pre)  800 1.61 8        4.0 (10) 280 192 x 256     1.09 x 1.09 
  turboFLASH (post) 34 1.61      10      4.0 (10) 280 192 x 256     1.09 x 1.09 
  3D-FLASH (post)    8.6 4 15      2.5 (18) 190 256 x 512     0.37 x 0.37 
6 patients
FLASH-3D (pre)    8.6 4 15      1.5 (32) 130 128 x 256     0.51 x 0.51  
turboFLASH (pre)    800 1.6 8       4.0 (10) 140 64 x 128      1.09 x 1.09
turboFLASH (post)   34 1.6 10     4.0 (10) 140 64 x 128      1.09 x 1.09 
FLASH-3D (post)     8.6 4 15     1.5 (32) 130 128 x 256     0.51 x 0.51 
Pre	=	pre-contrast;	post	=	post-contrast
Histologic examination
			
 Six out of the 10 patients in this study underwent a radical retropubic prostatectomy. 
The prostatectomy specimens were fixed overnight (10% neutral buffered formaldehyde) 
and coated with India ink. Seminal vesicles were separated from the prostate and examined 
separately. Axial whole mount step-sections were made at 4-mm interval in a plane parallel 
to the axial T2-weighted sequence. All sections were routinely embedded in paraffin. Tissue 
sections of 5 µm were prepared and stained with hematoxylin and eosin. The presence and 
extent of cancer were outlined on the glass cover by one experienced pathologist who was 
blinded to the imaging results.
Image Postprocessing and Analysis
 A quantitative comparison between the endorectal coil at 3T and the standard clinical 
setup of the endorectal coil and four elements of the body and spine array coil at 1.5T was 
performed by calculating the SNR in the prostate. The signal intensities in axial T2-weighted 
images through the middle of the prostate (acquired with the same parameters at both field 
strengths) were measured on an imaginary line (PA direction) starting at the center of the 
two endorectal coil conductors and pointing into the prostate. The first user-defined region-
of-interest (ROI) of which the intensity was measured was situated at the rectal wall. From 
that point signal intensities were measured in ROIs on the imaginary line in steps of one 
centimeter. Care was taken to ensure that ROIs were placed in the same place with regard to 
6
98
the internal anatomy of the prostate at both field strengths. We defined the noise strength as 
the standard deviation (SD) of the noise magnitude of several hundreds of pixels in a region 
of air outside the patient. The SNR is then calculated by dividing the mean signal intensity of 
the ROI by the noise strength.
 In addition, a qualitative assessment was performed for T2-w and T1-w post-
contrast imaging sequences. The images from both examinations (3T and 1.5T) were 
transferred to an independent work station for evaluation. Window settings were adjusted 
to minimize visual contrast differences in prostate tissue between the two sets of images. The 
images were independently analyzed by two radiologists, who were blinded to information 
on field-strength and patient data. T2-w images were evaluated for visualization of (1) the 
peripheral zone, (2) the central gland, (3) visibility of the lesion, (4) delineation of the lesion 
(low signal intensity) indicating prostate cancer if present and recognizable, (5) prostatic 
capsule delineation, (6) motion artifact, (7) coil related artifact, and (8) overall image quality, 
according to a 5-point scale (from 1: very poor; poor; moderate; good; to 5: excellent). Artifacts 
that degraded the visibility of the prostate were graded as (1) absent, (2) mild, (3) moderate, 
or (4) severe. Post-contrast T1-w images were evaluated for (1) visibility of the lesion, (2) 
delineation of the lesion, and (3) overall image quality. In image sets for which different grades 
had been obtained by the two radiologists, mean values were calculated for final calculations. 
The statistical analysis included paired Wilcoxon signed rank test to compare the qualitative 
scores and evaluation of inter observer agreement by using non-weighted kappa (ĸ) statistics. 
The following qualitative terms were used to describe the strength of the various values of κ: 
0.0-0.2 = poor agreement, 0.21-0.4 = fair agreement, 0.41-0.6 = moderate agreement, 0.61-0.8 = 
substantial agreement and 0.81-1.0 = almost perfect agreement [23]. 
 The T2-w and the (dynamic) contrast-enhanced MR datasets were prospectively 
evaluated and scored for the presence of extraprostatic disease, using a 5 point scale (1 
– not-present, to 5 – present), by one experienced observer. Results were correlated with 
whole mount section histopathology. The maximum size of the prostate cancer detected at 
both field strengths was estimated. The sensitivity, specificity, positive predictive, negative 
predictive value and overall accuracy to predict extra prostatic extension were calculated 
by dichotomizing the readings. Scores of 4 and 5 were considered “present”. For all tests, 
statistical significance was set at P < 0.05, and the SPSS® software package (version 10.1, 
Chicago, Ill, U.S.) was used for all statistical analyses.
 The spectroscopic imaging data was filtered with a Hamming filter in three spatial 
dimensions and zerofilled to a 16 x 16 x 16 matrix before Fourier Transformation in the 
spatial dimensions. The residual water was removed from the spectral data (by fitting a low-
frequency, exponentially decaying sine/cosine function to the time point moving average 
signal in the time domain), a Hamming filter was applied in the time domain, and Fourier 
Transformation and phase correction was performed with the Siemens Syngo software on the 
scanner. Spectra were evaluated for the separation of signals of citrate, choline and creatine 
and the suppression of water and lipid signals.
 All dynamic images were transferred to an independent work station. In-house 
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software was used to analyze and display contrast enhanced dynamic MR imaging datasets 
[5]. Signal intensities were converted to relative Gd-DTPA concentrations ([Gd-DTPA]) using 
PD-weighted images for calibration [24]. A robust, 4 parameter model – onset time, time to 
peak, peak and wash-out – was fitted to the curves [5] for dynamic MR imaging (the inverse 
time to peak and plateau correlate well with pharmacokinetic parameter maps [25]). The 
resulting parametric images were color-coded and fused with T2-w images. 
    Results	
 Usage of an endorectal coil at a magnetic field strength of 3T unambiguously showed 
a dramatic increase in SNR compared to the clinical setup of an endorectal coil and four 
elements of a body and spine array coil at 1.5T. This increase in SNR when moving from T2- 
weighted images of an axial slice through the prostate of a patient with prostate cancer at 1.5T 
(Fig. 2a) to images of the same slice of the same patient at 3T (Fig. 2b) allowed the FOV of these 
images to be reduced from 280 mm to 180 mm with the use of a 1024 x 512 matrix (Fig. 2c) 
in a total measurement time comparable with measurements at 1.5T. This translated into an 
increase in in-plane resolution from 0.55 x 0.55 mm (1.5T) to 0.18 x 0.18 (3T) and a reduction 
of voxel volume from 1.21 mm3 to 0.13 mm3, respectively, resulting in a detailed visualization 
of the prostate, prostatic capsule and periprostatic structures in all patients (Fig. 2). With the 
1.5T set-up, which is routinely used in clinical practice, the final image is a combination of the 
signals from all coils simply by adding the magnitude images of the individual coils. The high 
sensitivity of the endorectal coil near the prostate is in this way mixed with the relatively low 
sensitivities of the other array elements. Therefore the final SNR as a function of distance from 
the endorectal coil did not drop as sharply at 1.5 T as it did at 3T (endorectal coil only), which 
is illustrated in Figure 3. From this figure it is clear that the SNR at 3T is substantially higher 
up to the longest distance measured inside the prostate (only one out of the ten patients had 
a prostate extending ventrally to 6 cm from the rectal wall). Particularly at distances within 5 
cm of the coil conductors, the SNR of only the endorectal coil at 3T was superior to the SNR at 
1.5T. 
 Usage of an identical imaging protocol for T2-w TSE and post-contrast T1-w 
FLASH-3D images at 1.5 and 3T resulted in four imaging series that could be assessed by two 
independent readers. The results of this qualitative assessment are summarized in Table 2. The 
visibility of peripheral zone, central gland and prostate capsule on 3T images was superior 
to the visibility on images acquired at 1.5T (P < 0.05). The visibility of the lesion in T2-w TSE 
images improved in six  cases qualified as less than “good” at 1.5T to two cases at 3T (P = 
0.015). Motion artifacts based on peristaltic origin were less pronounced at 1.5T; however this 
difference was not significant. In post-contrast T1-w FLASH-3D, the visibility of the lesion was 
rated as “moderate” or better in all patients. For lesion delineation and visibility, the ratings 
in the post-contrast FLASH-3D sequences were significantly better at 3T (P < 0.023). Overall 
image quality of TSE and post-contrast FLASH-3D images was also significantly better at 3T (P 
<  0.023). The inter-observer agreement evaluating the qualitative assessment of the MR images 
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Figure 2. MRI of prostate carcinoma in a 64-year-old male. (A) T2-weighted axial TSE (3500/120 TR/TE, 
280 mm FOV, 512 x 256 matrix and 0.35 x 0.35 mm) image at 1.5T. A low signal intensity lesion in the right 
peripheral zone and central gland (arrows) is visible; this corresponds with positive biopsy findings. (B) 
Same patient at 3T, T2-weighted axial image at the same anatomical section as image in a using a TSE 
(7010/119 ms [TR/TE], 280 mm FOV, 512 x 256 matrix and 0.35 x 0.35 mm) technique. The endorectal 
coil was filled with air, because this was the first patient imaged in this study, all the other patients 
were imaged with water filled coils. The capsule at the right side of the prostate demonstrates bulging 
(arrow head) and irregular capsule suggesting invasion. (C) T2-weighted high resolution axial image at 
the same slice position as a and b using a TSE (5630/162 ms [TR/TE], 1024 x 512 matrix, 180mm FOV and 
0.18 x 0.18 mm) technique at 3T. The capsule demonstrates bulging (arrow head) and is disrupted (open-
arrow) indicating extracapsular extension. (D - F) detail (3x zoom) of A - C, respectively, shows increased 
anatomical detail of D compared to A and B.
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Table 2: Qualitative Assessment at 1.5T and 3T Field strengths
    Sequence 1.5T *    3T * p†
Visibility of the peripheral zone TSE  3.7    4.8 0.015
Visibility of central gland  TSE  3.6    4.4 0.038
Capsule delineation  TSE  3.8    4.9     0.008
Visibility of the lesion   TSE  3.3    4.4   0.015
    FLASH-3D post1	 3.3    4.4 0.023 
Delineation of the lesion  TSE  3.0    4.4 0.011
    FLASH-3D post1 3.1    4.6 0.020
Motion artifacts   TSE  1.2    1.4 NS
Coil related artefacts  TSE  1.7    1.6 NS
Overall image quality  TSE  3.6    4.8 0.015
    FLASH-3D post1 3.1    4.6 0.023
* Mean values of visual assessment criteria in all	patients	at	1.5T	and	3T	on	a	scale	of	1	to	5	for	anatomical	details	
and	on	a	scale	of	1	to	4	for	artifacts.	1T1-weighted	FLASH-3D	sequence	after	contrast	agent	administration.	p,	p-
value. † NS,	not	significant	at	the	95%	level.
Figure 3. The signal-to-noise ratio of the endorectal coil at 1.5T and 3T from all patients combined. The 
triangles and diamonds represents measurements at 1.5T and 3T, respectively. The error bars indicate the 
standard deviation in SNR from the 10 different patients. The endorectal coil at 3T shows improvement 
up to 6 cm from the coil surface compared to 1.5T. The large differences in SNR between 1.5 and 3T is the 
result of both the increase in field-strength and the non-weighted combination of multiple coil elements 
at 1.5T compared to the endorectal coil only at 3T.
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was substantial to optimal (κ = range .62 - .83). In 4 patients post biopsy artifacts were visible 
on T1-w images in both examinations, thereby not affecting the field strength comparison.
 The six patients who underwent a radical retropubic prostatectomy demonstrated 
histopathologic confirmation of organ confined disease. All patients were staged as T2a 
disease. The overall sensitivity, specificity, accuracy, positive and negative predictive value of 
MR staging in prostate cancer using T2-weighted images was n/a (0/0), 83% (5/6), 83% (5/6), 
n/a (0/0) and 100% (5/5) at 1.5T, and n/a (0/0), 100% (6/6), 100% (6/6), n/a (0/0) and 100% (6/6) 
at 3T, respectively. The overall accuracy of fused color-coded parametric datasets in staging 
prostate cancer was 83% (5/6) at 1.5T, and 100% at 3T, respectively. No significant differences 
in staging performance were present. The estimated tumor size ranged from 12 to 24 mm for 
1.5T and 9 to 26 mm for 3T (maximum diameter).
 In spectra of the 1H-spectroscopic imaging experiments at 1.5T using the pulse 
timing as described in the materials and methods section the strongly coupled citrate 
resonances appeared as one broad resonance (Fig. 4a and e, two positive absorptive inner 
lines merged into one line). The two outer lines cannot be distinguished from the noise. Apart 
from citrate also choline and creatine resonances, together with some base line distortions 
(possibly unsuppressed lipid resonances around 2.1 ppm) are present in the spectra. In the 
spectra of the 3D MRSI measurements at 3T from voxels at corresponding positions in the 
same patient (Fig. 4c and d) the increased spectral resolution was sufficient to separate the 
choline resonance (3.20 ppm) from the creatine resonance (compare Fig. 4a to Fig. 4b). The 
strongly coupled citrate resonance is centered at 2.60 ppm and appears at the used timing as 
a merged large positive absorptive inner line and two low-intense positive absorptive outer 
lines (Fig. 4b and f). Residual lipid signals around 1.3 ppm and 2.1 ppm that may extend into 
the area of citrate signals (Fig. 4e) do not overlap with the resonances of interest (Fig. 4b and 
f). Spectra from the left peripheral zone in the base of the prostate (spectra 4e and f, position 
indicated in Fig. 4d) show a large citrate signal and an intermediate choline signal intensity. 
In the peripheral zone on the right side of the prostate, moving two slices towards the apex 
(spectra 4a and b from the voxel indicated in Fig. 4c) the relative intensity of the choline signal 
increases compared to the citrate signal. 
 Apart from elaborating on one MRSI case, also the possibilities of dynamic contrast-
enhanced imaging at 3T with an endorectal coil are illustrated in detail: with dynamic contrast-
enhanced MR imaging the increase in SNR at 3T could be used to increase the temporal 
resolution of the measurements from 2 to 1 second. The relative [Gd-DTPA]-time curves 
obtained from the turbo-FLASH sequence in one pixel at the same location and patient at 1.5 
and 3T is plotted in Figure 5. 3T MR imaging enabled the increase of the temporal resolution of 
dynamic contrast-enhanced MR imaging from 2 seconds to 1 second (10 partitions). Although 
the temporal resolution was twice as high, the relative [Gd-DTPA] vs time curve demonstrated 
comparable SNR (Fig. 5). Post contrast high spatial resolution FLASH-3D images, with voxel 
size of 0.37 x 0.37 x 1.5 mm, clearly demonstrated signal enhancement in large regions of 
the prostate and extracapsular extension of the enhancing tissue (Fig. 6a and b) in the same 
acquisition time as at 1.5T. Compared with 1.5T increased signal enhancement was noted 
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Figure 4. 1H-MR spectra from voxels in the peripheral zone of a prostate at 1.5 and 3T. In (C) the position 
of the voxel of which spectrum (A) at 1.5T and (B) at 3T originate from is indicated. Spectra (E) at 1.5T and 
(F) at 3T correspond to the voxel, indicated in (D), located in a slice in the base of the prostate 8 mm above 
the slice in (C). The citrate resonance is centered at 2.60 ppm. Notice the high spectral resolution at 3T, e.g. 
in separating the lines of the citrate resonances and separation of choline and creatine peaks.
Figure 5. The uptake of Gd-DTPA contrast agent in the prostate. Curve A represents the relative [Gd-
DTPA]-time curve of one pixel in the prostate with a temporal resolution of 2 seconds at 1.5T. The relative 
[Gd-DTPA]-time curve at 3T (curve B) has a temporal resolution of 1 second and an additional offset of 10 
units. This offset was explicitly chosen for visualization purposes only (note that pixel size and distance 
to coil are equal).
A
B
E
F
C
D
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at 3T (Fig. 6). The enhancing area, indicating increased vascularity, largely coincided with 
the hypointense areas on the T2-w image (Fig. 2) and positive biopsy findings, altogether 
suggesting an increased localization and delineation of the tumor. Details of the early transient 
part of the relative [Gd-DTPA]-time curve were better visible which allows a more accurate 
assessment of pharmacokinetic parameters of Gd-DTPA uptake (Fig. 7a-d).
    Discussion
 In this report, the first results of (contrast-enhanced) MR imaging and MRSI with 
an endorectal coil at 3T are presented. Imaging at 3T with only an endorectal coil offers 
several advantages, which may allow for more accurate staging and localization of prostatic 
carcinoma, due to the achievable high spatial, temporal and spectral resolution. 
 With T1-w and T2-w imaging, the increase in SNR at 3T was used to increase the 
spatial resolution of the images. Although we have not yet specifically optimized TR and 
TE in our sequences at 3T, the improved in-plane resolution compared to images from a 
standard clinical set-up at 1.5T resulted in an increased visualization of anatomical details, 
which enabled better delineation of the prostatic capsule. Different coil and hardware setups 
are difficult to compare; we did not directly compare the use of an endorectal coil only at 
both field strengths. However, the use of an endorectal coil without a phased-array coil at 3T 
allowed an accurate visualization of the ventral part of the prostate with an even higher SNR 
compared to combined endorectal phased-array coils at 1.5T. The use of the combination of an 
endorectal and phased-array coil at 3T remains an area for further investigation and was not 
yet explored. 
 The results of the qualitative assessment of T2-w and post-contrast T1-w images 
showed a qualitative but significant improvement of image quality moving from 1.5 to 3T, 
with substantial to almost perfect inter-observer agreement. One has to keep in mind that these 
results could be biased in favor of 3T MR imaging because the observers were able to identify 
the 3T endorectal coil images by the decrease in SNR moving away from the endorectal coil. 
Still, the increase in anatomical detail of the images with the highest resolution at 3T could 
not be obtained at 1.5T within a clinically acceptable acquisition time. Potential benefits of 
high field imaging in estimating tumor size should be evaluated in a study with larger patient 
numbers. The increase in anatomical detail, and thereby a better distinction between disease 
confined to the prostate and extra-prostatic disease is important in the management of PCa, 
as this distinction is crucial for local staging of the tumor. The staging accuracy increased from 
83% (1.5T) to 100% at 3T. Although this increase was not significant, due to the low number of 
prostates evaluated with whole mount sections, it suggests a potential role for this technique 
in the determination of the local extent of carcinoma. Future studies with larger patient group 
have to be performed to prove this.
 Spectroscopic MR imaging at 3T straightforwardly benefits from an increased 
spectral resolution. We have shown that it is possible to perform MR spectroscopic imaging at 
3T using an endorectal coil. The increased spectral resolution of the 3D MRSI measurements 
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Figure 6. Same patient as fig. 2. with a poorly differentiated tumor on the right side. (A) axial T1-weighted 
FLASH3D (280 mm FOV, 0.55 x 0.55 x 2.5 mm voxel size) image at 1.5T and (B) corresponding  FLASH3D 
(190 mm FOV, 0.37 x 0.37 x 1.5 mm voxel size) image at 3T. Enhancement (arrows), disruption and 
irregularity of the capsule (arrowheads) indicating extracapsular extension is better visible at b due to the 
higher spatial resolution and improved tumor (T) contrast compared to normal tissue.
separated relevant metabolite resonances from each other and from residual water and 
lipid signals and may thereby provide an increased specificity for PCa. Pulse timing may be 
optimized with knowledge of the relaxation times of metabolic signals, but a study on this 
matter was beyond the scope of this work. Together with better shimming algorithms further 
improvement in 3D MRSI measurements is possible.
 In contrast-enhanced MR imaging at 3T the SNR increase was used to improve 
the temporal resolution of dynamic measurements and the spatial resolution of slow post-
contrast T1-weighted imaging. An increased temporal resolution allowed for a more accurate 
estimation of the parameters characterizing the transient part of the curve of relative [Gd-
DTPA] vs. time compared to 1.5T, whereas a higher spatial resolution resulted in increased 
morphologic depiction of enhancement. In addition, administration of a contrast agent 
appeared to induce more contrast in slow T1-weigthed measurements with high spatial 
resolution. Possibly the  increase in T1 relaxation times of the different tissues at 3T is an 
advantage here, where it increases the range of T1 values, and thus the dynamic range of 
contrast enhancement. Similar findings have been published in brain tumors and healthy 
tissue [14]. 
 So far, only two studies have been published about in vivo prostate imaging at high 
field strength. Kim et al. [26] have used a relatively large external transceiver coil for imaging 
the prostate. Whereas in our study, we have used an endorectal receiver coil for imaging the 
prostate, resulting in high in plane resolution imaging up to a voxel volume of 0.13 mm3. 
Future studies have to be performed to assess the optimal coil setup at high field strength. 
Dynamic contrast-enhanced MR imaging was not explored by Kim et al.. Sosna et al. [27] 
reported on volume assessment of prostates at 3T with an external phased-array coil. They 
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Figure 7. Prostate carcinoma in a 68-year-old male. (A) T2-weighted TSE (7010/119 ms, 280 mm FOV, 512 
x 256 matrix and 0.35 x 0.35 mm) axial image technique. A low signal intensity lesion in the left peripheral 
zone (arrows) is visible. (B) Axial fused image with “start of contrast enhancement” image at 3T. In the left 
peripheral zone the contrast enters the prostate earlier compared to left peripheral zone. (C) Axial fused 
image with ‘washout’ in the left peripheral zone (circle). These findings correlated with (D) whole mount 
section histopathology (T = tumor).
concluded that in vivo volume determinations were very close to ex vivo imaging volume 
determinations. However, they didn’t investigate MR imaging and MRSI in prostate cancer.
Despite the promising results, some limitations have to be considered. The number of patients 
included in this study is rather small. Shimming at high field strengths is difficult, because 
of the increased magnetic field inhomogeneities at air-tissue interfaces due to susceptibility 
differences between water and air. We tried to circumvent this at 3T by filling the balloon 
of the endorectal coil with demineralized-water. This improved our shimming results but 
indirectly increased coil related artifacts, although not significantly compared to 1.5T. We 
Initial	experience	of	3T	endorectal	coil	MR	imaging
107
didn’t use water in the endorectal coils at 1.5T because the shimming results at our routine 
MR examinations were already optimal. Another limitation of our study is the comparison of 
the different coil setups, however the SNR at 3T was superior up to 5cm from the endorectal 
coil. 
 In conclusion: it is feasible to perform endorectal MR imaging at 3T in patients with 
prostate cancer with the following advantages: an increased spatial resolution of T2-weighted 
and contrast-enhanced T1-weighted MR images, an increased temporal resolution of dynamic 
contrast-enhanced MR imaging and increased spectral resolution of MRSI. It is likely that 
imaging with an endorectal coil at a magnetic field strength of 3T expands potential clinical 
applications in evaluating the prostate.
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    Abstract
Purpose: To prospectively investigate the local staging accuracy of 3-T endorectal magnetic 
resonance (MR) imaging for prostate cancer by using whole-mount-section histopathologic 
analysis as the standard of reference. 
Materials and Methods: This study was approved by the institutional review board, and 
informed consent was obtained from all patients. In 35 consecutive patients (median age, 62.3 
years) with biopsy-proved prostate cancer, 3-T endorectal MR imaging was performed. High-
spatial-resolution endorectal T2-weighted fast spin-echo images of the prostate were obtained 
in three planes. MR images were prospectively evaluated by two experienced radiologists 
and a third radiologist who was less experienced with regard to local disease extent by using 
five established extracapsular criteria. Whole-mount-section histopathologic analysis was the 
standard of reference. Evaluation was performed according to octant and patient. Sensitivity, 
specificity, positive and negative predictive values, overall accuracy, and interobserver 
agreement were calculated. 
Results: Thirty-two patients who underwent radical prostatectomy were enrolled in this study. 
Accuracy, sensitivity, and specificity of local staging were 94% (30 of 32), 88% (seven of eight), 
and 96% (23 of 24), respectively, for both experienced radiologists, and these values were 
81% (26 of 32), 50% (four of eight), and 92% (22 of 24), respectively, for the less experienced 
radiologist. There was substantial agreement between both experienced readers (κ= 0.42–0.79) 
and moderate agreement between the less experienced reader and the experienced readers 
with respect to all extracapsular criteria. In regard to the three cases of minimal capsular 
invasion, two were detected by both experienced radiologists. 
Conclusion: In this study, high accuracy for staging of prostate cancer at 3-T endorectal MR 
imaging, with moderate to substantial observer agreement, was demonstrated. In addition, 
minimal capsular invasion could be detected. 
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    Introduction
 Prostate carcinoma is the second most frequent cause of cancer-related death in men 
[1]. The increase in the number of the aged, as well as the advent and the ever more frequent 
use of the prostate-specific antigen serum test for detection, has resulted in an increase in 
prostate cancer incidence [2,3]. Determination of the tumor extension in prostate cancer is 
important not only to allow optimal choice between the various therapeutic options but also 
to influence prognosis and treatment [4–6]. 
 Presently, the role of magnetic resonance (MR) imaging of the prostate for detection 
of extension beyond the capsule is being debated because of limited availability, high costs, 
and variability in results [7–9]. A large heterogeneity in local staging performance exists [4,9–
14]. A frequently described limitation is the inability to demonstrate microscopic capsular 
penetration [7]. 
 MR imaging at 1.5-T (the standard clinical field strength) with T2-weighted fast spin-
echo sequences and combined endorectal and phased-array coils has enabled the acquisition of 
MR images of the prostate and its surrounding tissues with high spatial resolution. Although 
a relatively high spatial resolution can be achieved within a clinically acceptable examination 
time, reported accuracy values for staging vary from 54% to 88% [4,7–15]. Jager et al [16] 
stated that staging with MR imaging in the preoperative work-up of prostate cancer is cost 
effective and should be performed with a high specificity (95%). In attaining this specificity, 
however, a low sensitivity (36%) has to be considered [17]. 
 For several years, whole-body MR imaging at high magnetic field strengths (>1.5 
T) has been used for research purposes only. At present, however, high-field-strength MR 
imaging systems are becoming more widely available in routine clinical settings. Generally, 
use of a higher field strength increases the signal-to-noise ratio linear to the magnetic field 
strength [18], thereby affording the possibility of an increase in either the spatial or the temporal 
resolution of MR imaging. Other effects of clinical MR imaging at high field strengths are the 
increased susceptibility differences in tissues that cause magnetic field inhomogeneities, as 
well as possibly shorter T2 along with longer T1 relaxation times. 
 Preliminary results with endorectal MR imaging at 3-T in patients with prostate 
cancer contributed to increased spatial resolution of T2-weighted imaging with a voxel volume 
of 13 µm3 [19]. To the authors’ knowledge, the role of endorectal MR imaging at magnetic 
field strengths of 3-T in the evaluation of local staging in patients with prostate cancer prior 
to radical prostatectomy has not yet been reported. Thus, the purpose of our study was to 
prospectively investigate the local staging accuracy of 3-T endorectal MR imaging for prostate 
cancer by using whole-mount-section histopathologic analysis as the standard of reference. 
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    Materials and Methods
Patient Characteristics
 From July 2002 until July 2004, 35 consecutive patients with biopsy-proved prostate 
cancer underwent endorectal coil MR imaging examinations at 3-T. Patients who were scheduled 
for radical prostatectomy within 6 weeks (range, 2–42 days; median, 8 days) after MR imaging 
were included in the study. Exclusion criteria were previous hormonal therapy, lymph nodes 
positive for metastases at frozen section analysis during surgery, contraindications to MR 
imaging (eg, cardiac pacemakers, intracranial clips), and contraindications to endorectal coil 
insertion (eg, anorectal surgery, inflammatory bowel disease). The study was approved by the 
institutional review board, and informed consent was obtained from all patients. 
 Median patient age was 62.3 years, with a range of 51–72 years. Median prostate-
specific antigen serum level was 8.9 ng/mL (range, 1–45 ng/mL), and median Gleason score 
was 6 (range, scores 4–7), respectively. MR imaging was performed at least 4 weeks after 
transrectal ultrasonographically guided sextant biopsy. 
MR Imaging Acquisition Protocol
 All MR images were obtained with a commercially available 3.0-T whole-body 
imager (Magnetom TRIO; Siemens Medical Solutions, Erlangen, Germany). A quadrature 
birdcage body coil was used for transmission, and prototypes of balloon-mounted disposable 
endorectal surface coils (Medrad) for 3-T MR imaging were used for receiving the MR signals. 
After digital rectal examination, the endorectal surface coil was inserted and inflated with 
demineralized water to a volume of approximately 60 cm3. Peristalsis was suppressed in 
all patients with an intramuscular injection of 1 mg of glucagon (Glucagen; Novo Nordisk, 
Bagsvaerd, Denmark) immediately before the start of the examination. 
 The protocol for acquisition consisted of a localizer and two fast turbo gradient spin-
echo measurements for patient and coil positioning and high-spatial-resolution T2-weighted 
fast spin-echo imaging in three planes. The imaging parameters for the T2-weighted images 
were as follows: repetition time msec/(effective) echo time msec, 4000/109; flip angle, 180°; 
field of view, 280 mm; matrix, 512 x 256; number of sections, 15–18; section thickness, 4 mm; 
section gap, zero. The frequency direction was anteroposterior to decrease coil motion artifacts 
over the prostate. In addition, transverse high-spatial-resolution T2-weighted fast spin-echo 
images (matrix, 768–1024 x 512; field of view, 180 mm) were acquired with a voxel volume of 13 
µm3, and this acquisition exploited the increased signal-to-noise ratio of the endorectal coil at 
3-T. Possible biopsy-related hematomas were detected with images from a three-dimensional 
T1-weighted spoiled gradient-echo pulse sequence performed with the following parameters: 
8.6/4; flip angle, 15°; number of sections, 32; section thickness, 1.5 mm; field of view, 130 mm; 
matrix, 128 x 256; and in-plane resolution, 0.51 x 0.51 mm. Total examination time for the 
aforementioned protocol and coil insertion was approximately 20–25 minutes. 
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MR Image Evaluation
 Prospectively, all MR images were independently read by three radiologists who 
were aware that patients had biopsy-proved prostate cancer and were scheduled for radical 
prostatectomy. They were unaware of the other clinical findings. The three radiologists had 
different levels of experience in interpretation of findings from prostate endorectal MR 
examinations. Radiologist A (J.O.B.) had 10 years of experience (total of approximately 700 
studies), radiologist B (J.J.F.) had 3 years of experience (total of approximately 250 studies), 
and radiologist C (S.W.T.P.J.H.), who was considered less experienced than radiologists A and 
B, had 6 months of experience (total of approximately 30 studies). MR imaging studies were 
interpreted at a digital workstation (Impax; Agfa, Mortsel, Belgium). MR image evaluation was 
performed in three planes. All MR images were rated for overall quality as good, intermediate, 
or poor. Image quality was considered to be good if the images showed high anatomic detail 
and minimal artifacts and poor if poor anatomic detail or extensive artifacts disallowed the 
evaluation of the images. All other images were considered to be of intermediate quality. 
 The readers drew lesion and extraprostatic extension locations in standard schemes 
of the prostate for comparison with the whole-mount sections. The prostate capsule was 
divided into octants; that is, the prostate was split in half (from apex to base) and then further 
divided into four areas: right and left peripheral zone and right and left central gland. The 
most likely sites of capsular extension were identified in each octant and numbered on 
the drawings. T1-weighted images were used to rule out false-positive findings caused by 
postbiopsy hemorrhage; if a low-signal-intensity lesion on a T2-weighted MR image matched 
a high-signal-intensity lesion on the corresponding T1-weighted MR image, this area was 
considered to be a hematoma due to biopsy [20]. 
 The presence of extracapsular extension was evaluated on the basis of five specific 
features described in the literature as highly indicative of extracapsular extension. These 
features were as follows: neurovascular bundle asymmetry, obliteration of the rectoprostatic 
angle, irregular bulging of the prostatic contour, tumor signal intensity within the periprostatic 
fat, and overt extracapsular tumor [8,21–23]. The criterion used for determination of seminal 
vesicle invasion was abnormal asymmetric low signal intensity within the lumen on T2-
weighted images [11,23]. 
 The readers expressed the likelihood of each criterion—extracapsular extension 
and seminal vesicle invasion—with a five-point scale. A rating with a score of 1 indicated 
that extraprostatic disease was definitely not present; that with a score of 2, that disease was 
probably not present; that with a score of 3, that disease was possibly present; that with a 
score of 4, that disease was probably present; and that with a score of 5, that disease was 
definitely present. When a score of 4 or 5 was assigned, the criterion was considered to be 
present. When a score of 1–3 was assigned, the criterion was considered not to be present. 
Reading was performed at a high-specificity setting [24,25] for extraprostatic disease (ie, only 
if the reader was certain of stage T3 disease, the disease rated as this stage). This was done to 
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prevent the withholding of potentially curative therapy because of the classification of false-
positive stage T3 disease in a patient with actual stage T2 disease. 
Histopathologic Analysis
 Three urologists, including one author (J.A.W., with 17 years of experience) and 
two other urologists with 11 years and 4 years of experience, who had knowledge of the 
MR imaging results performed the prostatectomy procedures. The prostatectomy specimens 
were fixed overnight in 10% neutral buffered formaldehyde and were coated with India 
ink. Seminal vesicles were separated from the prostate and examined separately. Transverse 
whole-mount step sections were created at 4-mm intervals in a plane parallel to the transverse 
plane used to perform the T2-weighted sequence. All sections were routinely embedded in 
paraffin. Tissue sections of 5 µm were prepared and stained with hematoxylin-eosin. The 
presence and extent of cancer were outlined on the glass cover with the tissue section by 
an experienced genitourinary pathologist (C.A.H.) who had 12 years of experience and who 
was blinded to the imaging results. Staging of the prostatectomy specimens was performed 
according to the present TNM classification [26]. 
Data Analysis
	
 The MR imaging–predicted extraprostatic extension was compared with the 
findings at histopathologic analysis by one radiologist (J.J.F., with 3 years of experience) after 
assignment of scores and evaluation of the data were performed. The T2-weighted fast spin-
echo MR images were aligned with the whole-mount sections. The morphologic characteristics 
of the central gland and peripheral zone—apex and base of the prostate, cysts, calcifications, 
and urethra—were used as landmarks. Aligning of MR images and whole-mount sections is 
considered difficult [10]. Although no literature is available on this subject, to our knowledge, 
we were confident that our alignment was within 8-mm accuracy (eg, two sections). If the 
detected extraprostatic extension in the whole-mount section was within 4 mm from the 
aligned MR image–detected location and on the correct side, this was considered a match. 
Statistical Analysis
 A finding was considered true-positive in a case in which the imaging results 
were correlated with the histopathologic findings, as mentioned previously. The sensitivity, 
specificity, positive and negative predictive values, and overall accuracy for the prediction 
of extraprostatic criteria, tumor stage, extracapsular extension, and seminal vesicle invasion 
were calculated by dichotomizing the readings. When a score of 4 or 5 was assigned, these 
features were considered to be present. When a score of 1–3 was assigned, the features were 
considered not to be present. This analysis was performed according to patient and according 
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to octant. 
 The statistical analysis included the evaluation of the interobserver agreement by 
using nonweighted κ statistics. The following qualitative terms were used to describe the 
strength of the various values of κ: 0–0.20, poor agreement; 0.21–0.40, fair agreement; 0.41–0.60, 
moderate agreement; 0.61–0.80, substantial agreement; and 0.81–1.00, near-perfect agreement 
[27]. Two-tailed tests were used to calculate all P values; a P value of .05 or less was considered 
to represent a statistically significant difference. All statistical analyses were performed with 
software (SPSS, version 9.0; SPSS, Chicago, Ill). 
    Results
Surgical Specimens
 In three patients, performance of the standard of reference was not available 
because the urologist did not remove the prostate as a result of lymph node metastases, and 
on the basis of this finding, the urologist decided not to resect the prostate. These patients 
subsequently underwent a combination of radiation and/or hormonal therapy. One of these 
three patients had clear invasion of the seminal vesicles at MR imaging, and this finding was 
reported to the urologist. The urologist then performed a biopsy of the seminal vesicle, and 
results were positive for cancer. These three patients were excluded from further analysis; 
thus, 32 patients were included in our study. Eight of 32 patients had extracapsular extension; 
in three of these patients, seminal vesicle invasion was observed. In the remaining patients, 
disease was confined to the prostate (stage T2a disease in nine patients and stage T2b disease 
in 15 patients). The image quality was good in 29 patients and intermediate in three patients. 
In six patients, postbiopsy artifacts were visible on T1-weighted images; however, the artifacts 
were not in the area of capsular extension or seminal vesicle invasion. 
Staging
 The staging results, with scores assigned according to octant, are presented in Table 
1. Two hundred fifty-six capsular sites were evaluated for extracapsular extension on the MR 
images. Of these 256 sites, 13 had capsular extension at histopathologic evaluation. Of these 
13 sites, one was not identified as a site of possible capsular extension on MR images by all 
three readers. The penetration depth of this extension was only 0.5 mm. In three sites, the 
penetration depth of the capsular extension was less than 2 mm (Fig 1). Two of these sites 
were identified by the two experienced readers (readers A and B). 
 The staging results, with scores assigned according to patient, are shown in Table 
2. The overall accuracy in prostate cancer staging (T3 disease vs T2 disease) was 94% (30 of 
32) according to patient for the experienced readers A and B and 81% (26 of 32) for the less 
experienced reader C. No statistically significant difference was present among readers A, B, 
and C.
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Table 1: Staging and Statistical Analysis Results for Three Readers according to Octant
A: Histopathologic Staging Results*
      Reader A      Reader B      Reader C
MR imaging T3   T2  T3   T2  T3   T2
Stage T3  11      3  11     3  6   15
Stage T2    2 240    2 240  5 228
B: Statistical Results
Statistic  Reader A  Reader B  Reader C
Sensitivity† 85 (11/13)  85 (11/13)   55 (6/11)
Specificity† 99 (240/243)   99 (240/243)    94 (228/243)
Accuracy† 98 (251/256)  98 (251/256)   91 (234/256) 
PPV†  79 (11/14)   79 (11/14)  29 (6/21) 
NPV†  99 (240/242)   99 (240/242)  98 (228/233) 
Note.—Readers	A	and	B	were	experienced,	and	reader	C	was	less	experienced.	PPV	=	positive	predictive	value;	NPV	
=	negative	predictive	value
*	Data	are	numbers	of	sites	with	capsular	extension.
†  Data	are	percentages.	Numbers	in	parentheses	were	used	to	calculate	percentages.
Figure 1. Histologically confirmed stage T3a prostate carcinoma in a 62-year-old patient with a PSA 
level of 8.2 ng/ml and Gleason score of 6.  (A) Transverse T2-weighted fast spin echo (4000/109) MR 
image shows a suspicious low signal intensity (open arrows) in the right peripheral zone. The experi-
enced radiologists evaluated this as irregular border (arrows) of the prostate capsule and rated this as 
stage T3a disease. (B) T2-weighted fast spin echo saggital (4124/109) MR image demonstrated disrupted 
prostate capsule in the same patient (open arrow). Histopathology (C) revealed a stage T3a disease with 
minimal capsule penetration (arrow) in the right peripheral zone.
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 The results of the readers’ observation of diagnostic features of extracapsular 
extension are given in Table 3. The mean sensitivity values for the individual criteria of 
extracapsular extension ranged from 44% to 88%. All readers obtained a high sensitivity 
for irregular bulging (Fig 1) of the prostatic contour. High specificity was established for all 
criteria (Table 3).
 In the three patients in whom seminal vesicle invasion was observed, results were 
confirmed with findings at analysis of the specimen removed at prostatectomy. All readers 
identified the invasion of seminal vesicles, and this result yielded an accuracy of 100% (Figure 
2).
Table 2: Staging and Statistical Analysis Results for Three Readers according to Patient
A: Histopathologic Staging Results*
      Reader A      Reader B      Reader C
MR imaging T3   T2  T3   T2  T3   T2
Stage T3  7     1   7     1  4     2  
Stage T2  1   23  1   23  4   22 
B: Statistical Results
Statistic  Reader A  Reader B  Reader C
Sensitivity† 88 (7/8)   88 (7/8)   50 (4/8)
Specificity† 96 (23/24)  96 (23/24)   92 (22/24)
Accuracy† 94 (30/32)  94 (30/32)  81 (26/32)
PPV†  88 (7/8)   88 (7/8)   67 (4/6)
NPV†  96 (23/24)  96 (23/24)  85 (22/26)
Note.—Readers	A	and	B	were	experienced,	and	reader	C	was	less	experienced.	PPV	=	positive	predictive	value;	NPV	
=	negative	predictive	value
*	Data	are	numbers	of	patients.
†  Data	are	percentages.	Numbers	in	parentheses	were	used	to	calculate	percentages.
Interobserver Agreement
 The results of the interobserver agreement analysis are displayed in Table 3. 
Assessment of interobserver variability showed moderate to substantial agreement (κ = 0.42–
0.79) for ratings in regard to extracapsular extension for all three readers. Agreement was best 
for ratings in regard to tumor signal intensity within the periprostatic fat and irregular bulging 
of the prostatic contour, and agreement was the worst for ratings in regard to obliteration of 
the rectoprostatic angle. 
    Discussion
 The most important findings of our study were the high sensitivity of 88% in the 
staging of prostate cancer, the retention of a specificity of 96%, and the detection of minimal 
capsular extension through the prostate capsule by experienced readers. Two of three cases of 
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minimal capsular penetration were recognized by the experienced radiologists (readers A and 
B). This finding suggests a role for prostate MR imaging at 3 T. Although we did not perform 
a comparative study between 1.5-T MR imaging and 3-T MR imaging, the results of this study 
indicated that with the 3-T technique the accuracy in staging was increased to a level that was 
higher than that reported for 1.5-T imaging, with a range in accuracy of 54%–88% [8–11,15]. 
 So far, only four studies about in vivo prostate imaging at high field strengths have 
been published, as far as we know. Kim et al [28] used a relatively large external transceive 
coil for prostate imaging without exploring staging and localization performance with MR 
imaging. In our study, we used an endorectal receiver coil for imaging of the prostate, and 
use of this coil resulted in images with a high in-plane resolution and a voxel volume as small 
as 0.13 mm3. This resolution and voxel volume would be very difficult to achieve within a 
reasonable time without the use of a local coil. Sosna et al [29] reported results of volume 
assessment of the prostate at 3-T MR imaging with an external phased-array coil. They 
concluded that in vivo volume determinations were very close to ex vivo imaging volume 
determinations. They, however, did not investigate performance of MR imaging for staging. 
Bloch et al [30] showed a proof of principle of MR imaging of the prostate at 3 T with an 
endorectal coil in a limited study with six volunteers. 
 In a concurrent study by Fütterer et al [19], patients with prostate cancer were 
examined by using an endorectal coil at 3-T MR imaging. It was shown that the increased 
signal-to-noise ratio with an endorectal coil at 3 T has great potential to improve either the 
spatial or temporal resolution of T2-weighted (dynamic) contrast material–enhanced and 
spectroscopic MR imaging of the prostate. In the current study, we applied this signal-to-
noise ratio to obtain images with high in-plane resolution for clear delineation of the prostate 
capsule. Because of this increased resolution, we were able to display minimal capsular 
extension in two of three cases. Findings in reports from the early 1990s suggested that 
minimal capsular penetration of less than 1 mm does not adversely affect the surgical cure 
rate [31,32]. No recent data in the literature, however, have confirmed these results. 
 With the demonstrated ability to detect minimal capsular penetration, the question 
arises about whether the progression from stage T2 disease to stage T3 disease should be used 
as the basis on which clinicians should choose between surgical resection of the prostate or a 
combination of radiation therapy and hormonal therapy for treatment. If minimal capsular 
penetration is detected, curative surgery will be withheld in a patient in whom the treatment 
for the disease is potentially curative. Perhaps the reported early detection of stage T3 disease, 
when it is treated as stage T2 disease, does not affect patient outcome. The effect of the 
detection of minimal capsular penetration, as well as possible implications in treatment, has 
to be evaluated in future studies. 
 In our study, we found a mean sensitivity of 62% (range, 44%–88%) and a high 
specificity for the criteria of extracapsular extension with moderate to substantial interobserver 
agreement. Outwater et al [23] found only poor accuracy for the extracapsular criteria at 1.5-T 
MR imaging. This difference in accuracy could be caused by the increased in-plane resolution 
in our study (voxel volume of 0.13 µm3) versus that of 0.61 µm3 in the study of Outwater et 
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Figure 2. Seminal vesicle invasion in a 66-year-old patient with a PSA level of 4.5 ng/ml and Gleason 
score of 6. (A) Coronal T2-weighted fast spin echo (4130/109) MR image through the prostate and seminal 
vesicles. A low signal intensity (arrows) is present in the base of the prostate which extends into the seminal 
vesicle (B, saggital view, arrows). This finding was confirmed with whole-mount section histopathology.
Table 3: Results of Readers’ Observation of Diagnostic Features for Extracapsular Extension
	 	 	 	 Sensitivity*  Specificity*  Accuracy*  NPV*   PPV*    ĸ1†       ĸ2#
neurovascular bundle asymmetry     46          99           85            87      85  .52     .45
obliteration of the rectoprostatic      44        100           86          100      85  .52     .42
  angle
irregular bulging of the prostate      88        100           97          100      96  .71     .51
  contour
tumor signal-intensity within the      63        100           91          100      89  .79     .62
  periprostatic fat   
overt extracapsular tumor      69          98           91            93      91         .62     .53
*	Numbers	are	mean	values	in	percentages	for	the	two	experienced	readers.
†	Value	signifies	interobserver	agreement	between	the	experienced	readers.
#	Value	signifies	interobserver	agreement	between	the	less	experienced	and	the	experienced	readers
al. All the radiologists read the images with the focus on high specificity [24,25]. To prevent 
overstaging, only if the reader was certain of stage T3 disease was the disease rated as such. 
 The results of the current study showed that there was a difference in accuracy 
according to experience of the reader; these results also showed a difference particularly in 
sensitivity (88% vs 50%). This difference was also found in other studies performed at 1.5-T 
MR imaging [14,33]. The sensitivity and specificity at 1.5-T MR imaging found by Yu et al 
[33] were 17% and 94% and 54% and 95% for the less experienced and experienced readers, 
respectively. This difference in sensitivity values was much smaller in the present study, where 
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sensitivity and specificity were 50% and 92% and 88% and 96% for the less experienced and 
experienced readers, respectively. 
 Despite the promising results of our study, some limitations need to be considered. 
The correlation between findings at MR imaging and the findings at corresponding whole-
mount-section histopathologic analysis was difficult to determine in most patients. This 
difficulty is a frequently encountered problem. The angle at which the whole-mount sections 
were cut in the prostate specimens was never exactly the same compared with the angulation 
of the MR images obtained in vivo. After the prostate specimens are fixed in formaldehyde, 
the specimen shrinks and deforms. We tried to overcome these problems by using all whole-
mount sections in the assessment of the corresponding level. 
 Because prostate-specific antigen serum levels and Gleason scores were low, only 
four patients with seminal vesicle invasion were included in this study. In one patient with 
seminal vesicle invasion who was excluded from this study because no results of analysis 
with the standard of reference were obtained, the urologist changed the treatment on the basis 
of MR imaging findings, and such a change suggests that the technique used in this study 
may influence a decision about treatment and patient outcome. Such a suggestion, however, 
requires confirmation in a future study. 
 The number of patients included in this study may be considered rather low. In 
their meta-analyses, Engelbrecht et al [12] and Sonnad et al [17] showed that studies with 
50 patients or fewer had more favorable results than did studies with a higher number of 
patients. In an article titled “Clinical Efficacy of MR Needs Rigorous Study” [Diagn Imaging 
1990;12:69,71,161], Kent, however, estimated that 30–70 patients would be required for a 
comparison of the diagnostic accuracy of MR imaging with that of a reference standard. In 
a future study, a multicenter approach has to be used to confirm our promising preliminary 
results. 
 The role of endorectal MR imaging in local staging of cancer of the prostate is still 
controversial. A number of articles indicated the poor capability of MR imaging in the staging 
of cancer of the prostate [7–9]. May et al [9] even suggested that treatment decisions should not 
be altered as a result of endorectal MR imaging findings. In contrast, Jager et al [16] developed 
an analytic model for decision making that supported the opinion that MR imaging for staging 
in the preoperative work-up of prostate cancer is cost effective and should be performed with 
a high specificity. Langlotz et al [24, 25] emphasized this need for high specificity to ensure 
that as few patients as possible will be unnecessarily turned down for potentially curative 
therapy on the basis of false-positive MR imaging results. D’Amico et al [34] suggested using 
endorectal MR imaging in patients with intermediate risk only; in this group, the probability 
of extraprostatic disease is high enough to warrant the use of MR imaging. If the prevalence 
of extracapsular disease is, for example, 30% and MR imaging is performed with a specificity 
of 97% and a sensitivity of 33%, then only in one of 10 patients will MR imaging results affect 
the treatment. This could be a reason why urologists do not use MR imaging as a modality for 
staging. If the results of our study are reproducible, this number could be extrapolated to one 
of three or four. 
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 With consideration of the thus far published data, results of this study indicate that 
3-T endorectal MR imaging of the prostate in staging is of additional value in patients with 
prostate cancer. MR imaging of the prostate at 3-T should be performed only in patients with 
intermediate risk of having extraprostatic disease [34], and it should be performed with high-
specificity readings by experienced genitourinary radiologists [14]. Nonetheless, it remains 
difficult for less experienced readers to interpret MR images of the prostate; however, at 3-T 
MR imaging, it may be anticipated that interpretation will improve. 
 In conclusion, in this study, high accuracy for staging with moderate to substantial 
observer agreement at 3-T MR imaging was demonstrated. In addition, minimal capsular 
invasion could be detected. These outcomes suggest a future role for high-field-strength MR 
imaging in the staging of prostate cancer. 
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    Abstract
The use of intensity-modulated radiation therapy for treatment of dominant intraprostatic 
lesions may require integration of functional magnetic resonance (MR) imaging with 
treatment-planning computed tomography (CT). The purpose of this study was to compare 
prospectively the landmark and iterative closest point methods for registration of CT and MR 
images of the prostate gland after placement of fiducial markers. The study was approved by 
the institutional ethics review board, and informed consent was obtained. CT and MR images 
were registered by using fiducial gold markers that were inserted into the prostate. Two image 
registration methods—a commonly available landmark method and dedicated iterative closest 
point method—were compared. Precision was assessed for a data set of 21 patients by using 
five operators. Precision of the iterative closest point method (1.1 mm) was significantly better 
(P < .01) than that of the landmark method (2.0 mm). Furthermore, a method is described by 
which multimodal MR imaging data are reduced into a single interpreted volume that, after 
registration, can be incorporated into treatment planning.
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    Introduction
 Radiation therapy for prostate cancer by using intensity-modulated radiation therapy 
(IMRT) improves the therapeutic ratio by directing an increased uniform dose of radiation to 
the prostate gland while sparing the surrounding organs [1]. If tumor nodules within the 
prostate or the dominant intraprostatic lesion (DIL) can be localized, then IMRT can be used to 
escalate the focal dose by delivering a boost dose to the DIL [2]. Findings from dose planning 
studies show that there is an increased probability of tumor control by administering a boost 
dose to the DIL [3]. Designing an IMRT plan requires detailed information about the prostate 
and DIL. Conventional treatment planning uses the electron density estimate obtained at 
computed tomography (CT) to calculate dose distribution. CT does not, however, provide 
good tumor localization and is inaccurate in facilitating discrimination between the base and 
apex of the prostate and the surrounding structures [4]. It is, therefore, clear that prostate 
IMRT planning requires additional imaging information to attain optimal performance. 
 Magnetic resonance (MR) imaging can facilitate prostate delineation and tumor (DIL) 
localization. In 67% of tumors, the location of the tumor can be correctly depicted at high-
spatial-resolution T2-weighted MR imaging by using a 1.5-T endorectal coil [5]. The addition 
of findings from proton MR spectroscopic imaging results in a 90% sextant positive predictive 
value [6]. Findings from multisection fast dynamic contrast material–enhanced MR imaging 
can also provide additional information [7,8]. The combination of data from T2-weighted MR 
imaging, dynamic contrast-enhanced MR imaging, and MR spectroscopic imaging has been 
previously shown to provide up to 93% localization accuracy [9]. Thus, tumor localization 
with MR imaging appears to be at a level that is suitable for use with IMRT planning. 
 Integration of MR imaging with IMRT treatment planning requires good alignment 
(registration) of CT and MR images. A common approach to image registration uses the 
correlation between gray values obtained at CT and those obtained at MR imaging (eg, 
normalized mutual information [10]). Poor visualization of the prostate at CT and the 
difference in prostate size with respect to MR imaging [4], however, render the mutual 
registration of MR imaging and CT information inaccurate, if not unreliable. Bone landmark 
methods are quick and reliable but do not account for prostate movement [11]. In this study, 
we had the opportunity to use intraprostatic fiducial gold markers. These markers are already 
used for correcting prostate position during all fractions of IMRT [12] because the markers 
do not migrate [13]. These intraprostatic fiducial markers were previously used to register 
CT and MR images [14], although, to the best of our knowledge, the registration error of this 
technique has not been studied. Furthermore, the authors [14] used a readily available manual 
single point landmark technique. We hypothesize that registration errors can be significantly 
decreased by using a surface registration technique. Thus, the purpose of our study was to 
compare prospectively the landmark and iterative closest point (ICP) methods for registration 
of CT and MR images of the prostate gland after placement of fiducial markers. 
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    Material and Methods
Patients
 The data set in this study was obtained between September 2001 and June 2002 for 21 
consecutive patients who had histologically proved prostate cancer and who were scheduled 
for radiation therapy. The patients underwent CT and MR imaging within 1 week. Mean 
prostate specific antigen level was 15.1 ng/mL (range, 6.0–27.0 ng/mL), and median Gleason 
score was 6 (range, 4–10). Seven of the 21 patients demonstrated non–organ-confined disease 
(stage T3a or higher), and 14 demonstrated organ-confined disease (stage T2b or lower); 
tumor stage was determined on the basis of the TNM classification. No hormone treatment 
was administered between MR and CT examinations. 
 At least 2 weeks prior to imaging, an experienced urologist (J.A.W., 10 years 
of experience in urology) inserted four 1 x 7-mm gold markers by using transrectal 
ultrasonographic guidance. Two markers were inserted in the base of the prostate, one in 
the apex of the prostate, and one in the central portion of the prostate. Patient positioning—
supine on a flat couch, with foam knee support—was identical for both CT and MR imaging. 
This study was approved by the institutional ethics review board, and informed consent was 
obtained. 
Data Acquisition
 The CT volume that was used for IMRT planning was acquired with a multisection 
CT scanner (AcQsim; Marconi Medical Systems, Cleveland, Ohio) (3-mm collimation, 150 mA, 
140 kV, and 12.5-mm table feed per 0.5-second scanner rotation). In 11 patients, an endorectal 
balloon was inserted and inflated with 80 mL of air to mimic MR imaging conditions and 
possibly to reduce prostate deformation differences. The endorectal balloon that was used at 
CT was a modified MR imaging balloon (MedRad, Pittsburgh, Pa) without the coil wiring. 
 MR imaging was performed by using a 1.5-T whole-body imaging system (Magnetom 
Sonata; Siemens, Erlangen, Germany). Patients were imaged in the supine position by using an 
integrated endorectal pelvic phased-array coil (Siemens). After the digital rectal examination, 
the endorectal coil (Medrad) was inserted and inflated with 80 mL of air. Peristalsis was 
suppressed by means of an intramuscular injection of 1 mg glucagon (Glucagen; Novo 
Nordisk, Bagsvaerd, Denmark) before the examination. Localization images were acquired to 
determine anatomic orientation and to confirm coil positioning. 
 MR imaging parameters are summarized in Table 1. Transverse T2*-weighted 
gradient-echo MR imaging provided clear visualization of the gold markers. T2-weighted 
spin-echo MR imaging in three perpendicular planes provided detail of the in-plane anatomy. 
Metabolic information was obtained by using 3D spectroscopic imaging [15,16]. Contrast-
enhanced functional MR imaging was performed in two interleaved modes: high-spatial-
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Table 1: Imaging Parameters for MR Imaging and Spectroscopy
                                 Dynamic
                                  Field             Volume 
                                               Repetition    Echo                    No. of                           Section                                               of       Phase-       Sampling
                                               Time             Time    No. of     Signals       Flip Angle  Thickness     Matrix      No. of     View    Encoding    Time
Modality  (msec)        (msec)   Echoes    Acquired   (degrees)        (mm)                         Sections   (mm)   Direction      (sec)
MR imaging      
 Transverse T2-
   weighted gradient-
   echo    700               18            1               2                  30                3             512 x 448       22             285      Column        NA
T2-weighted spin-echo 3500             132            15             2                180                5             240 x 512     11-22          280      Row              NA
Intermediate-weighted*
   high resolution 3D
   gradient-echo     30                 4            1               1                  10                2.5          512 x 256 x 18                280      Column        NA
Dynamic T1-weighted*
   high resolution 3D
   gradient-echo      8.2               4            1               2                  20                2.5          512 x 256 x 18                280      Column        NA
Intermediate-weighted*
   fast 3D gradient-echo   800                 1.6         1               1                   8                 4              256 x 77 x 10                 280      Column        90
Dynamic T1-weighted*
   fast 3D gradient-echo           34                 1.6         1               1                  14                4              256 x 77 x 10                 280      Column        2
MR spectroscopic imaging
   3D point-resolved
   proton spectroscopy
   with band-selective
   inversion with
   gradient dephasing            650              120          NA            8                 NA               8               12 x 12 x 12                    96      NA                NA
Note.—NA	=	not	applicable.	
*	After	contrast	material	administration,	74	dynamic	T1-weighted	fast	3D	gradient-echo	and	five	dynamic	T1-weighted	high-resolution	3D	gradient-echo	
MR	imaging	sequences	were	performed.
resolution mode and fast mode. Both modes comprised repeated T1-weighted MR imaging 
sequences and one intermediate-weighted MR imaging sequence. The imaging order prior to 
contrast material administration is presented in Table 1. After contrast material administration, 
74 dynamic T1-weighted fast 3D gradient-echo and five dynamic T1-weighted high-resolution 
3D gradient-echo MR imaging sequences were performed. A dose of 0.2 mmol per kilogram 
body weight of gadopentetate dimeglumine (Magnevist; Schering, Berlin, Germany) was 
injected by using a power injector (Spectris; Medrad) with saline flush. 
Image Registration Methods
 CT and MR image sets (Fig 1) were aligned by registering the CT volume with the 
transverse T2*-weighted MR imaging volume. Two image registration methods were applied. 
The first was a current and widely available landmark-based method. The second was a 
surface-based ICP method. The registration transform was limited to a rigid body transform 
(three translation and three rotation parameters). 
 For the landmark-based method, the operator collected pairs of conjugate points. 
Each pair corresponded to the midpoint of the same fiducial marker on CT and MR images. 
A registration (ie, a set of six rigid body parameters) that minimized the root-mean-square 
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Figure 1. Transverse CT (A) and T2*-weighted MR (B) images (see Table 1 for MR imaging parameters) 
before image registration. Markers appear as bright spots at CT (arrows) and as dark spots at MR 
imaging.
Figure 2. Fused display of transverse T2*-weighted MR (gray value) and CT (red overlay) images for 
validation of registration (see Table 1 for MR imaging parameters). CT markers overlay transverse T2*-
weighted markers completely, which confirms good prostate registration. Notice bone landmark shift 
(arrows) illustrating inability to register prostate by using bone landmarks.
distance between these point pairs was then determined [17]. 
 The ICP-based method entailed a manual segmentation of the markers. Segmentation 
was performed by using an open-source software program (3D Slicer, versions 1.2 and 1.3; 
www.slicer.org). The CT and MR marker segmentations were each converted into a surface 
model. A registration of the CT and MR marker models that would minimize the root-mean-
square distance between the surfaces by using the ICP method was then determined [18]. 
 The registration was visually inspected by observing the fused CT and MR image. 
MR features were depicted in gray, and CT features were fused in red, with the CT window 
width and window level set to reveal only the markers (Fig 2). If the fused image demonstrated 
A B
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misregistrations that were clearly visible, the registration procedure was reiterated. 
 Each CT and MR image pair was registered by three or four operators from a 
group of two radiologists, three physicists, and one radiation oncologist (J.J.F., A.W., H.J.H., 
J.A.v.D., and E.N.J.T.v.L., none of whom had previous experience in landmark and ICP image 
registration). Five operators repeated the registrations up to five times in five patients. The 
amount of time needed to perform registration was estimated by one operator (H.J.H.) by 
using a stopwatch in 10 patients for both methods. Computing time was estimated by using 
software that was built in our institution (H.J.H.) and a personal computer (Intel Pentium III 
[650-MHz]; Dell, Round Rock, Tex). 
Functional Image Postprocessing
 Postprocessing entailed two stages. First, the acquired dynamic and spectroscopic 
data were processed to extract several functional and feature images. Second, T2-weighted 
MR images and dynamic contrast-enhanced MR and 3D spectroscopic feature images were 
further reduced into a single map. 
 The 3D spectroscopic citrate and choline image volumes were calculated by using 
a workstation software program (Syngo; Siemens). This software implements filtering, zero 
filling, and spectral fitting of citrate and choline peaks [19]. For tumor localization, a derived 
feature—that is, the choline to citrate ratio—was used [20,21] (Fig 3). 
 The dynamic image volume data were converted into a tracer concentration by using 
the intermediate-weighted sequence and the inversion of the sequence signal model [22]. 
Software that was developed in-house was used to fit contrast curves robustly to a physiologic 
compartment model [23,24], and the model parameters were calibrated by using a reference 
tissue method [25]. Examples of physiologic features were extracellular volume, surface area 
permeability in low flow regions, volume transfer constant, and arrival time. Examples are 
shown in Figure 3. 
 The feature images were transparently overlaid in color onto the T2-weighted MR 
images in three perpendicular planes. A built-in 3D editor was used to delineate the tumor 
boundary. During editing, the operator switched between the feature images, with the cross 
section of the tumor model visible in all planes. The tumor model was then saved as a tumor 
image map. The registration parameters that aligned the transverse T2*-weighted MR images 
with CT data were used to align the tumor map with CT data. The aligned tumor map was 
then transferred to the radiation therapy department and used in the IMRT planning (Fig 4). 
Statistical Analysis
 Each registration resulted in a six-parameter (rigid) transform. To compare the 
registration results, each six-parameter transform was applied to two fixed target locations 
within a patient. The first target location was the marker centroid, which was estimated 
from the average of the segmented points on transverse T2*-weighted MR images for each 
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Figure 3. Images show integration of T2-weighted MR, dynamic contrast-enhanced MR, and 3D 
spectroscopic image information into a single tumor map (see Table 1 for MR imaging parameters). (A) 
T2-weighted MR image shows hypointense area in sagittal (left), coronal (center), and transverse (right) 
position fused with (B) volume transfer constant, (C) wash-out phase, and (D) choline-to-citrate ratio 
(see body text for explanation of parameters), all of which confirm DIL position. (E) Red DIL outline is 
visualized according to its cross section.
A
B
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registration method. The second target location was a simulated prostate rim point, which was 
determined by translating 20 mm left, 20 mm anterior, and 20 mm caudal from the estimated 
marker centroid. 
 The location of the centroid and rim targets could not be compared directly between 
patients to assess registration performance. Therefore, a target error vector was determined 
as follows: For each patient, registration method, and target, the average target location was 
subtracted from a target location. This can be regarded as a biased estimate of the target error. 
Because the number of registrations per patient per method was rather low (on the order of 
three to four registrations), a trimmed (25% symmetric) mean method was used to determine 
the least biased average. 
 The squared length of the target error vectors is a measure of the precision and 
follows a 2 distribution [17]. The 2 distribution is characterized according to a mean and 
standard deviation. Again, robust estimates were used. The mean was estimated by using a 
trimmed (25% symmetric) mean method. The average standard deviation was estimated by 
using the median of the absolute deviation method. The standard deviation of the landmark 
and ICP methods was compared by using the nonparametric Wilcoxon test. An analysis of 
variance test was used to analyze the influence of different factors (inter- and intraoperator 
characteristics and balloon presence) on target error. All statistical methods were validated by 
conducting additional tests on data sets with known Gaussian distributions. All statistics were 
performed by using a statistical software package (R, version 5.1) [26]. For all statistical tests, a 
P value of less than .01 was considered to indicate a statistically significant difference. 
    Results
 The operators performed a total of 179 registrations. An experienced operator was 
able to segment the fiducial markers in both modalities in an average of 5 minutes with the 
ICP method; segmentation of fiducial markers required 2 minutes with the landmark method. 
The computing time that was required to find the optimum registration was on the order of 
seconds. 
 The ICP method was significantly more precise than the landmark method (P < .01). 
This is graphically demonstrated in Figure 5, which presents the distribution of target error 
lengths for the two registration transforms at the two target locations. As anticipated, the 
precision was much better at the centroid than at the rim. The target error distributions are 
further summarized in Table 2. The average precision of the ICP method was significantly better 
than that of the landmark method (P < .01). Table 3 summarizes the number of registrations 
that had a rim target error larger than 2 or 5 mm, where 2 mm is the clinical goal and 5 mm can 
be regarded as an upper limit of acceptability. More than half of the landmark registrations 
had a target error that was larger than the clinical limit. The landmark method also yielded a 
substantial amount of unacceptable registrations. Neither the operator nor the presence of an 
endorectal balloon had a statistically significant effect on the registration error (P > .01). 
 For one patient, the DIL was outlined in consensus by expert radiologists (J.J.F., 
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Figure 5. Bar graphs demonstrate relative frequency (y axis) of prostate registration errors (x axis) for 
ICP (top graphs) and landmark (bottom graphs) registration methods at centroid (left graphs) and rim 
location (right graphs). Notice broader error distribution for landmark method.
Figure 4. Images show (A) registered tumor map 
overlaid in red on top of transverse treatment-
planning CT image and (B) radiation therapy 
treatment plan. Notice how boost dose area 
conforms to DIL area demonstrated at MR 
imaging.
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J.O.B.) by using our MR contrast analysis and evaluation package that was developed in-house 
and the whole-body imaging data previously described in the Materials and Methods. The 
outline of the DIL was carefully positioned according to information from T2-weighted MR 
images and dynamic contrast-enhanced MR and 3D spectroscopic feature images (Fig 3). The 
outline surface was converted into an image volume label map. The label map was resampled 
and transformed into the CT domain by using the ICP-obtained registration parameters. The 
CT-format tumor map was then communicated to the radiation therapy department by using 
the standard Digital Imaging and Communications in Medicine protocol. The intention of the 
IMRT plan was to deliver a uniform dose of 70 Gy to the whole prostate gland and a boost 
dose of 90 Gy to the DIL, as shown in Figure 4. 
Table 2: Summary of Prostate Image Registration Errors at Centroid and Rim
                  Centroid    Rim
Registration Method Mean (mm)    Standard Deviation           Mean (mm)    Standard Deviation
    Landmark        0.9  0.6      2.5  1.9
    ICP         0.5  0.3      1.1  0.7
Table 3: Predicted Number of Registrations That Have an Estimated Rim Target Error Larger 
than 2 or 5 mm
    Target     Target
Registration Method             Error > 2 mm                           Error > 5 mm
				
    Landmark   46/80 (58)    10/80 (13)
    ICP    14/99 (14)      3/99 (3)
    Discussion
 We were able to confirm the postulated hypothesis that registration with a manually 
segmented marker surface (ICP method) is significantly more precise than registration with 
a manually picked marker center (landmark method) (Table 2). This is in agreement with 
landmark registration theory on the effect of fiducial marker localization error [17]. As has 
also been observed by Parker et al (14), the user-defined fiducial marker surface in the ICP 
method provides better spatial information than the single user-defined fiducial marker 
center in the landmark method. Our study thus demonstrates that the localization of fiducial 
markers is important in the registration of CT and MR images for radiation therapy treatment 
planning of the prostate. 
 We have assessed the precision and have demonstrated that, in our study, the ICP 
method can be regarded as clinically acceptable because 86% of ICP registrations had a precision 
better than 2 mm at the rim of the prostate, whereas only 42% of landmark registrations had a 
precision better than 2 mm at the rim of the prostate. Image registration will never be perfect; 
image noise, spatial resolution, and many other factors impose a lower limit on the achievable 
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registration error. Findings from this study clearly demonstrate that the actual achievable 
performance varies markedly between the registration methods that are available either in 
literature or on commercial systems. Determining the performance of registration methods is 
therefore important for choosing between methods or even for deciding on the acceptability. 
 To be clinically useful, the image registration target error should not be larger than 
the IMRT treatment error. An analysis of the geometric variations during treatment by using 
offline position correction indicates that the overall systematic error (1 standard deviation) is 
approximately 1.5 mm [27,28], and the random variations range from 2.8 to 4.4 mm (1 standard 
deviation) in the three orthogonal directions. Choosing 2.0 mm (1 standard deviation) as an 
upper limit for the image registration target error limits the overall systematic error increase to 
1.0 mm (1 standard deviation). This is also typical for the geometric error allowed in treatment 
planning and dose delivery of IMRT [29]. 
 The proposed ICP-based method met the needs for this study; however, opportunities 
are present for improvement. The manual segmentation process is elaborate. Automatic 
segmentation, possibly incorporating prior knowledge regarding the fiducial marker shape, 
will reduce the time required for image segmentation and is likely to further decrease fiducial 
marker localization errors [30]. Given the results of the current study, it seems worthwhile to 
investigate such automatic fiducial marker detection strategies. A related topic of study is the 
number and size of the fiducial markers [31]. Our assumption that the intrastudy prostate 
movements were negligible also requires improvements. Currently, a manual correction can 
be performed by overlaying the images and shifting the drawing area. Future implementations 
of our software will be extended with rigid intermodality registration methods to reduce 
effects of intrastudy prostate movement. 
 The evaluation method used in this study [17] assumes that fiducial markers do 
not move relative to each other. This assumption is valid for multimodality brain image 
registration, the technique for which this method was developed, but this assumption is 
possibly not true for prostate image registration. Although marker migration is assumed to 
be low [13], a real estimate is required. We are currently researching techniques to extend the 
evaluation method to include migration and deformation effects. 
 Our results did not demonstrate that the presence of an endorectal balloon had an 
effect on the registration precision. It is expected, however, that the presence of an endorectal 
balloon affects the shape of the prostate. Thus, for clinical application, we will continue to 
use the balloon with CT. We are also aware of nonrigid registration techniques that may 
compensate for such prostate deformation. Nonrigid fiducial marker-based techniques 
would require a much denser fiducial marker sampling of the prostate, which then becomes 
clinically unacceptable. And, as we have already stated, gray value registration is not an 
option. Moreover, assessing the registration errors of nonrigid registration techniques is a 
terra incognita. We are not aware of demonstrably accurate and precise nonrigid registration 
techniques for matching CT and MR images of the prostate. 
 Findings from this study demonstrate how MR imaging information can be provided 
to a radiation therapy department for integration in the treatment plan. First, the anatomic, 
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functional, and metabolic MR features are integrated into a single tumor map. Second, this 
map is registered to treatment CT images. Tumor localization performance will obviously 
have an effect on the total achievable error that is associated with this tumor map. We and 
other groups have already demonstrated the feasibility of tumor localization [6,9] and are 
actively researching improvements. Our robust and calibrated contrast enhancement features 
[23,24] already facilitate multicenter trials. Furthermore, we expect that computer-aided 
diagnosis techniques can enhance diagnostic performance. 
 A limitation of the current study design is that it does not account for systematic 
errors in the fiducial marker localization. Such errors may occur as the result of asymmetries 
in the imaging modality or segmentation process. Because CT is the reference modality for the 
IMRT treatment plan, it is the MR imaging asymmetries that are of interest. Parker et al [14] 
estimated that the fiducial marker-induced MR asymmetry was less than 1 mm. Furthermore, 
the fiducial marker localization methods we applied are visually symmetric. Looking for the 
center or segmenting opposite sides of a fiducial marker is not likely to introduce asymmetry 
artifacts. We therefore conclude that, in our study design, the total registration error will be 
only marginally larger than the precision-derived estimate. 
 In conclusion, precise alignment of CT and MR images of the prostate is possible by 
using fiducial gold markers and dedicated registration methods. A functional MR analysis 
tool is required that can reduce multiple functional MR imaging parameters into a single 
interpreted prostatic lesion map. The registered lesion map allows a radiologist to provide 
the radiation oncologist with the information required to design an IMRT treatment plan. 
Integrated multimodal functional MR imaging information can be included in radiation 
therapy treatment planning for prostate cancer by using precise alignment of fiducial gold 
markers. 
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    Abstract
Purpose: To demonstrate the feasibility to integrate two functional prostate MR imaging 
techniques (dynamic contrast-enhanced MR imaging (DCE-MRI) and 1H-MR spectroscopic 
imaging (MRSI)), into inverse treatment planning for definition and irradiation of a dominant 
intra-prostatic lesion (DIL) as a biological target volume for high-dose intra-prostatic boosting 
with IMRT (DIL-IMRT).
Methods and materials: In 5 patients, four gold markers were implanted. An endorectal 
balloon was inserted for both CT scanning and MR imaging. A DIL volume was defined by 
DCE-MRI and MRSI using different prostate cancer specific physiologic (DCE-MRI) and 
metabolic (MRSI) parameters. The CT-MR image registration was performed automatically by 
matching 3D gold marker surface models with the iterative closest point method. DIL-IMRT 
plans, consisting of whole prostate irradiation to 70 Gy and a DIL boost to 90 Gy, and standard 
IMRT plans, in which the whole prostate was irradiated to 78 Gy (IMRT-78) were generated. 
The tumor control probability (TCP) and rectal wall normal tissue complication probability 
(Rwall NTCP) were calculated and compared between the two IMRT approaches. 
Results: Combined DCE-MRI and MRSI yielded a clearly defined single DIL volume (range 
1.1 – 6.5 cc) in all patients. In this small, selected patient population no differences in TCP were 
found. A decrease in Rwall NTCP was observed in favor of the DIL-IMRT plan, as compared 
to the IMRT-78 plan.
Conclusions: Combined DCE-MRI and MRSI functional image-guided high-dose intra-
prostatic DIL IMRT boosting to 90 Gy is technically feasible. Preliminary results indicate that 
DIL-IMRT may improve the therapeutic ratio by decreasing the NTCP with unchanged TCP. 
A larger patient population, with more variation of the number, size and localization of the 
DIL, has to be studied to extend these preliminary tumor control and toxicity estimates.
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    Introduction
 The use of defining a biological target volume (BTV) and intensity-modulated 
radiotherapy (IMRT) for advanced “dose painting”, as proposed by Ling et al. [1] is gradually 
introduced into clinical practice. This has been made possible by advanced imaging techniques. 
Prostate magnetic resonance (MR) imaging techniques can be fused with planning computed 
tomography (CT)-scans and this has been shown to enable improved target delineation 
[2,3]. Functional MR imaging techniques have developed over the years. Dynamic contrast-
enhanced MR imaging (DCE-MRI) can visualize prostate cancer (neo)vascularity [4,5]. 1H-
MR spectroscopic imaging (MRSI) has been shown to provide a high specificity for prostate 
cancer [6,7]. These techniques can lead to a more accurate staging and localization of prostate 
cancer [8-12] and are valid methods for early evaluation of radiotherapy effect [13].
   The “classical” whole-prostate dose escalation has improved treatment outcome [14-
16]. Nevertheless, intra-prostatic failures do occur and can be detected by MR imaging [17]. 
Cellini et al. [18] performed an MR-based analysis of intra-prostatic failure and concluded 
that, in all their observed cases, local recurrence originates within the initial tumor volume. 
Strategies, mainly for brachytherapy and low-size (< 50 cc) prostates, have been tested to 
detect the so-called “Dominant Intra-prostatic Lesion” (DIL) by MRSI and have been given an 
extra boost dose to this DIL, to thereby increase the therapeutic ratio [19-23]. To acquire high-
resolution anatomical MR data an endorectal coil is usually inserted causing deformation of 
the prostate gland. Consequently, accurate image registration with the initial planning CT 
scan (without endorectal coil) is often difficult. The CT-MR matching can be done by mutual 
information based automatic registration [24] or manually, by visual approximation [19,22]. To 
overcome the difficulties in registration, we developed a gold marker based 3D CT-MR fusion 
protocol [25] where an endorectal balloon (ERB) is used during CT-scanning and treatment 
that has the same dimensions as the MR endorectal coil [26]. ERBs are also used in prostate 
radiotherapy for their rectal wall sparing effect [27-29]. In our daily practice, fiducial gold 
markers are used for position verification and correction procedures [30-32]. These markers 
are clearly visible on both CT and T2*-weighted MR images. Reliable and accurate image 
fusion is feasible using above-mentioned conditions [25,33].
 To date, the combination of two functional MR imaging techniques (DCE-MRI and 
MRSI), gold markers and an ERB for biological image-guided external beam radiotherapy has 
not been described elsewhere. The purpose of this study was to demonstrate the feasibility 
of the fusion of these functional MR imaging techniques with CT, using gold markers as 
fiducials, and to integrate these images into inverse treatment planning to define a BTV for 
high-dose intra-prostatic DIL boosting with IMRT. The next goal was to make an estimation 
of the potential gains, in terms of tumor control probability (TCP) and rectal toxicity, by 
analyzing normal tissue complication probability (NTCP).
    Materials and Methods
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	Figure 1. (A) Fine gold fiducial prostate markers. (B) Prostate biopsy tool used for marker implantation, 
mounted on ultrasound probe.
 This pilot study was performed over a period of 6 months, until December 2004. 
Patients with biopsy proven prostate cancer were selected for our study. At the start of this 
study, only patients with uni-lateral prostate cancer were selected. Patient exclusion criteria 
were: previous hormonal therapy, positive lymphadenectomy, contraindications to MR 
imaging (e.g., cardiac pacemakers, intracranial clips) and contraindications to endorectal coil 
insertion (e.g., anorectal surgery, inflammatory bowel disease). Finally, five patients were 
enrolled in this study, after informed consent was given.
 In each patient, four fine gold markers (1-mm diameter, 7-mm length) were implanted 
in the prostate through trans-rectal ultrasound guidance by an experienced urologist (J.A.W.) 
(Fig. 1a). Two markers were inserted in the base, one in the apex and one in the central part 
(next to the urethra) of the prostate gland. A standard 18-gauge prostate biopsy tool was 
used (Micro-invasive topnotch, Boston Scientific, Natick, MA, US.) (Fig. 1b) and prophylactic 
antibiotics were given (ciprofloxacin 500 mg, BID, for 3 days).
 After at least 1 week, to resolve swelling of the gland after marker implantation, 
patients underwent both CT and MR imaging on the same day, within 4 hours. Patient 
positioning during both CT and MR examinations was identical to that during treatment: 
supine on a flat couch that was covered with a thin disposable paper sheet. Only a pillow 
and a foam knee support were used for relaxed positioning of the head and legs, respectively. 
Prior to the imaging sessions, patients used a laxative diet and a laxans (Microlax clysma 5 
mL, Pharmacia B.V. Woerden, The Netherlands), and were intended to have a full bladder by 
drinking 500 ml of water.
CT and MR imaging protocol
 The planning CT scan was obtained at 3-mm slice thickness with a multi-slice CT 
scanner (150 mA, 140 kV, feed 12.5 mm, rotation 0.5s) (AcQsim spiral CT; Philips Medical Systems, 
Bothell, WA). An ERB was inserted and inflated with 80 cc of air to mimic MR imaging conditions 
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Figure 2. (A) Endoretal balloon used during CT and MR imaging. (B) Sagittal MR T2-weighted image 
(FSE) (left panel) and CT image (right panel) with endorectal balloon inserted. Prostate and outer rectal 
wall are highlighted. (C) Transverse MR T2*-weighted (MEDIC) image (left panel) and CT (right panel) 
image, gold marker is indicated (arrow)
and reduce prostate deformation differences. The ERB used during CT imaging is a modified 
MR endorectal balloon without the coil wiring and has the same dimensions and shape as the 
MR endorectal coil (MedRad, Indianola, PA, US) [26,29] (Fig. 2a).
 MR imaging was performed using a 1.5T MR scanner (Magnetom Sonata, Siemens, 
Erlangen, Germany). Patients were imaged in supine position with a combination of a body 
phased-array coil and an endorectal coil (Medrad, Indianola, PA, US). After digital rectal 
examination the endorectal coil was inserted and inflated with 80 cc of air. Peristalsis was 
suppressed by an intramuscular injection of 1 mg glucagon (Glucagen; Novo Nordisk A/
S, Denmark) prior to the examination. Localizing images were acquired for anatomical 
orientation and to confirm coil positioning. The three-part scanning protocol is listed in order 
of acquisition in Table 1. Firstly, for anatomical information, T2-weighted fast spin echo (FSE) 
images were acquired in three planes (Fig. 2b). A transversal T2*-weighted gradient echo 
sequence (MEDIC) provided clear visualization of the gold markers (Fig. 2c). Secondly, MRSI 
was obtained using a 3D chemical shift imaging sequence. Thirdly, DCE-MRI was performed 
using one intermediate weighted and a series of repeated T1-weighted image volumes during 
2 minutes. A dose of 0.2 mmol/kg gadolinium-DTPA (Magnevist, Schering, Berlin, Germany) 
was injected using a power injector (Spectris, Medrad, Indianola, PA, US) with saline flush.
A B
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Imaging registration
 CT and MR imaging sets were aligned by registering the MEDIC MR volume to 
the CT volume, using an in-house developed application as described by Huisman et al. 
In summary, the markers, displayed on T2*-weighted (MEDIC) MR and CT, were semi-
automatically segmented and converted into 3D surface models (Fig. 3a, b). The 3D surface 
models from both datasets were then registered by minimizing the root-mean-square distance 
between the surfaces using the iterative closest point (ICP) method [25]. The registration 
was visually verified by observing the fused CT and MEDIC MR images. The MR marker 
surface model was depicted in green while the CT marker surface model was overlaid in red 
with CT window and level set to reveal only the markers (Fig. 3c). In case the fused display 
demonstrated clearly visible mis-registrations the registration procedure was reiterated.
DIL delineation
 The radiologist (J.F.), performing the DIL delineation, was unaware of the tumor 
characteristics (local staging by digital rectal examination, PSA or Gleason score) during the 
evaluation of the images. Post-processing entailed two stages. First, the acquired DCE-MRI 
and MRSI data were processed to extract functional feature images. We started with analyzing 
the DCE-MRI dataset to identify regions of neo-vascularity based on multiple physiologic 
parameters, such as the Kep, quantifying the permeability surface area, K
trans, defined as the 
volume transfer constant and ECV, for quantification of the extracellular volume [5,9]. Then, 
based on these findings, the MRSI dataset was evaluated to make the final diagnosis of prostate 
cancer or benign prostate tissue, by analyzing the 1H-MR spectra of the prostate gland voxels. 
A conservative threshold of choline + creatine/citrate ratio > 0.9 was considered to be positive 
for prostate cancer
	
 In the second post-processing stage, these DCE-MRI and MRSI feature images and the 
T2-weighted prostate images were fused; the functional images were overlaid in transparent 
colors on T2-weighted MR images in 3 perpendicular planes. A 3D editor, build within the 
registration application, was used to delineate the boundary of the DIL (Fig. 4a). During the 
editing process of the DIL, the radiologist was able to switch between the DCE-MRI and 
MRSI feature images and the T2-weighted MR images with the cross-section of the resulting 
tumor model visible in all planes. The definitive tumor model was then saved as a binary DIL 
volume. The registration parameters that aligned the MEDIC MR data and the CT data were 
used to align the DIL volume with the CT data. The aligned DIL volume, together with the 
MEDIC MR images and the T2-weighted MR images were then transferred and imported into 
the radiotherapy treatment planning system. An illustrated case example is described in the 
Results section.
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Table 1.   Scanning Parameters
Sequence    TR TE α       slice thick  FOV matrix   in plane voxelsize  
     (ms) (ms)          (nr of slices) (mm)             (mm)
FSE     4100 119        180          4.0 (15) 280 512 x 256     0.35 x 0.35 
MEDIC       700   18  30          3.0 (22)  285 512 x 448     0.56 x 0.56
3D-MRSI        640     120       PRESS     5.0 (12)    60   14 x 14        4.3 x 4.3
turboFLASH (pre)       800         1.61 8            4.0 (10) 280 192 x 256     1.09 x 1.09 
turboFLASH (post)       34     1.61     10          4.0 (10) 280 192 x 256     1.09 x 1.09 
Pre	=	pre-contrast;	post	=	post-contrast
Figure 3. Marker registration by iterative closest point (ICP) method. Markers are semi-automatically 
segmented on (A) T2*-weighted MR image (MEDIC) and on (B) CT image. (C) MR (green) and CT (red) 
marker surface models registered by minimizing the root-mean-square distance of the separate models.
IMRT treatment planning
 The radiation oncologist (E.V.L.) and the radiologist (J.F.) reviewed the MEDIC MR 
images, the T2-weighted MR images and the aligned DIL volume. Together they delineated 
the prostate gland in the MEDIC and the T2-weighted MR images. The resulting contours 
were automatically transferred to the corresponding CT slices and defined as the prostate 
clinical target volume (CTV). They reviewed the registered DIL volume in the image fusion 
window of the Pinnacle3 treatment planning system (Philips Medical Systems, Andover, 
MA) and defined the DIL CTV. (Fig. 4b). On each CT slice the normal surrounding structures 
were outlined: bladder, urethra, femoral heads and rectal wall. The rectal wall (Rwall) was 
defined as the difference between the inner and outer rectal wall contour [34]. The Rwall 
was delineated from the ischial tuberosities up to the rectosigmoid flexure. For each patient, 
two IMRT treatment plans were made to compare the tumor control probability (TCP) and 
predicted rectal toxicity, as estimated by the NTCP. First, the DIL-IMRT plan was made, 
irradiating a PTV70 and a PTV90. The PTV70 was defined as the prostate gland  + 7 mm isotropic 
margin (prescription dose 70 Gy). The PTV90 consisted of the DIL + 5 mm isotropic margin 
(prescription dose 90 Gy). Next, a more standard IMRT plan (IMRT-78) was constructed, 
in which PTV78 consisted of the prostate gland + 7 mm isotropic margin. For this plan the 
prescription dose was 78 Gy (14). For both plans, the dose per fraction was 2 Gy.
A B C
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Figure 4. (A) 3D editor for delineation of the DIL volume. DIL is highlighted in red (B) DIL volume 
(highlighted in red) is transferred into treatment planning system and displayed on a transversal MR 
T2-weighted image (top panel) and on a CT image (bottom panel). In yellow the central gold marker is 
indicated.
Table 2. IMRT treatment planning objectives and planning weight factors for the normal 
tissues.
ROI  Objective Dose level (Gy) Volume (%) Weight factor
Rectal Wall Max Dose 75  100  50
Rectal Wall Max DVH 60  10  20
Rectal Wall Max DVH 50  20  10
Rectal Wall Max DVH 40  30  10
Bladder  Max DVH 70  2  3
Bladder  Max DVH 60  15  2
Urethra  Max DVH 80  50  1
Urethra  Max Dose 85  100  1
Left Femur Max Dose 50  100  1
Right Femur Max Dose 50  100  1
ROI	=	region	of	interest,	Max	Dose	=	maximum	allowable	dose,	DVH	=	dose	volume	histogram
 For both plans, the step-and-shoot IMRT plan consisted of 7 coplanar, non-opposing 
10 MV photon energy beams. One beam was oriented posterior-anterior (PA) while the other 
6 beams were configured with equidistant gantry angles.
 For both plans, equal DVH and maximum dose objectives for the normal tissues 
were defined (Table 2). In addition, the maximum allowable dose outside the delineated 
structures was set to 38 Gy (weight factor = 1). For the DIL-IMRT plan and IMRT-78 plan the 
following target volume objectives were defined. In brackets the weight factor (W) for the 
corresponding objective is noted. Objectives regarding the CTV were: minimal allowable dose 
of 90 % of the prescription dose (W=10), maximum allowable dose 110 % of the prescription 
dose (W=10). Objectives for the PTV were: minimum dose 90 % (W=2), maximum dose 110 % 
A B
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(W 5) and dose uniformity (W 1). For the PTV, also DVH objectives are defined:  > 99 % of the 
PTV volume should receive a minimal dose of 95 % of the prescription dose (W=10). For the 
DIL-IMRT plan, the maximum allowable dose within the DIL was set on 94 Gy (W=1).
 For comparison of the IMRT-78 and the DIL-IMRT plans, the mean doses for the 
prostate and DIL were calculated. For the Rwall, the NTCP for serious (≥ grade 3) rectal 
toxicity was computed, applying the Lyman-Kutcher-Burman model with Emami parameters 
(n=0.12, m=0.15 and TD50=80 Gy) [35-37]. The resulting spatial dose distribution over the inner 
surface of the rectal wall, representing the rectal wall mucosa, was visualized by generating 
inner rectal wall dose surface maps [38].
 For TCP calculations we used the Poisson-based model of Webb and Nahum, 
taking the interpatient variation in radiosensitivity over a representative cohort of patients 
into account [39].  The model parameters used were taken from Nahum et al. [40]: a mean ± 
standard deviation radiosensitivity (mean and alfa beta, respectively) of 0.26 ± 0.06 Gy-1 and 
an alfa/beta-ratio of 8.3 Gy were used. Furthermore, it was assumed that the initial clonogenic 
cell density for the DIL was 107 cells/cc, and for the remainder of the prostate this was 105 
cells/cc. Proliferation effects were ignored in the calculations.
				Results
Imaging and post-processing
 The marker implantation posed no problems. This procedure took five minutes 
per patient on the urology outpatient clinic. The ERB was tolerated well and no problems 
arose during the imaging procedures. The planning CT-scan took 15 minutes totally, while 
the MR imaging at the radiology department took one hour (10 minutes patient preparation 
and 50 minutes imaging), which was rather strenuous for this elderly patient population. 
In one patient the MR imaging was interrupted due to lower back pain, but eventually the 
MR procedure could be finished. The post-processing was performed by an experienced 
radiologist in 40 minutes; DCE-MRI evaluation 10 minutes, MRSI evaluation 20 minutes, DIL 
delineation 5 minutes and files preparation for transmission to the radiotherapy department 5 
minutes. The next day, the radiation oncologist and the radiologist reviewed the images. The 
target volumes and normal tissues were delineated in 60 minutes. The inverse DIL-IMRT and 
IMRT-78 treatment planning were performed in 1.5 – 2 hours.
Intra-prostatic IMRT boosting with DCE-MRI and MRS image guidance
 In all 5 patients a DIL could be determined by the combined functional MR imaging 
techniques. The initial PSA level ranged from 5.8 to 8.2 ng/ml and the prostate volume ranged 
from 41 to 106 cc (Table 3). The DIL volumes ranged from 1.1 to 6.5 cc and all were localized 
in the right or left peripheral zone.
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Table 3. Patient characteristics, and DIL-IMRT and IMRT-78 treatment planning results.
                   DIL-IMRT 70-90 Gy     IMRT-78 Gy
                   Mean Dose (Gy)                             Mean Dose
Pat. No. PSA             Gleason   Stage   DIL            prostate                                                NTCP         TCP     Prostate        NTCP        TCP
 (ng/ml)       score   vol. (cc)    vol. (cc)      Loc.               DIL prostate      Rwall (%)   (%)     (Gy)              Rwall (%)   (%)
1 7.8                7               T1c     79               1.1           R-PZ              90.0 71.3 2                89     77.7       4               88
2 8.2                6               T2a   106               1.8           L-PZ              91.2   71.6 3                85     77.8       6               85
3  7.7                5               T2a     74               6.5           R-PZ              90.5 71.5 6                86     78.4       6               83
4  5.8                7               T2a     41               2.2           R-PZ              90.8 71.4 5                89     78.1       6               87
5 7.0                8               T2a     51               1.8           L-PZ              90.7 71.5 3                88     78.6       6               87
DIL	=	dominant	intra-prostatic	lesion,	L-PZ	=	left	peripheral	zone,	R-PZ	=	right	peripheral	zone,	DIL	Loc.	=	DIL	localization,	NTCP	=	normal	tissue	
complication	probability,	TCP	=	tumor	control	probability.
	
Figure 5. DCE-MRI and MRSI results of patient no. 4. (A) Axial T2-weighted MR image with decreased 
signal intensity in the right peripheral zone (arrows), without evidence of capsular invasion. DCE-
MRI results are displayed in B-C. (B) The start-of-enhancement parameter demonstrated an earlier 
enhancement in part of the low-signal-intensity lesion (arrows) compared to the left peripheral zone. (C) 
The volume transfer constant (Ktrans) was elevated in the low-signal intensity lesion (arrows) indicating 
tumor tissue. (D) MRSI detected elevated choline and low citrate peaks in 8 voxels. The blue box indicates 
the voxel, of which the spectrum, as displayed in E, originates from. (E) 1H-MR spectrum from a voxel 
in the right peripheral zone.. An increased choline+creatine/citrate ratio indicates prostate cancer. Cho = 
choline, Cr = creatine and Ci = citrate. (F) A strongly interpolated (choline + creatine) / citrate map was 
used to visualize the MRSI-based tumor nodule. The scale of this map ranges from 0.9 (tumor threshold) 
to the maximum Cho+Cr/Ci value in this patient. The numbers in the map indicate the ratio value of the 
corresponding voxel.
 An example of a comprehensive MR examination and DIL volume delineation 
procedure of a 71-year-old prostate cancer patient (Pat. no. 4 from Table 3) is shown in Fig. 5. 
He presented with a PSA of 5.8 ng/ml and a palpable tumor in the right prostate lobe, staged 
on digital rectal and ultrasound examination as T2. A total of 8 ultrasound-guided biopsies 
were taken, 4 from the left and 4 from the right prostatic lobe. Two right peripheral biopsies 
revealed a Gleason sum 7 adenocarcinoma. The T2-weighted MR images showed a decrease 
of signal intensity in the right peripheral zone, without capsular invasion (Fig. 5a). Evaluation 
A B C
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of the DCE-MR imaging showed contrast kinetic parameters, suggesting malignancy on the 
right side (Fig. 5b-c). MRSI confirmed these findings. An increased choline+creatine/citrate 
ratio was found in 8 voxels of the right peripheral zone (Fig. 5d-e), and a choline+creatine/
citrate map was constructed to visualize the MRSI based tumor nodule (Fig. 5f). Based on the 
combined DCE-MRI and MRSI data, this prostate tumor was staged as T2a located in the right 
peripheral zone. The DIL volume was delineated within the 3D editor and transferred to the 
treatment planning system. The DIL volume was 2.2 cc and a 3D margin of 5 mm was drawn 
for PTV90. The prostate gland measured 41 cc and a 3D margin of 7 mm was drawn for PTV70	
(Fig. 6). The DIL-IMRT planning resulted in a dose distribution as displayed in Fig. 7a. For 
this plan a TCP of 89% was estimated and an NTCP Rwall of 5%. The IMRT-78 treatment plan 
(Fig. 7b) yielded a TCP of 87% and an NTCP Rwall of 6%. 
 A summary of the comparison of DIL-IMRT and IMRT-78 data for the investigated 
patients is given in Table 3. Overall, in this small selected number of patients, the TCPs, 
ranging from 83% to 89% did not differ between the two IMRT plans. But in 4 out of 5 
patients, DIL-IMRT reduced the NTCP Rwall, ranging from 1 to 3%. For every individual 
patient, the therapeutic (TCP/NTCP) ratio was increased by the DIL-IMRT plan. An example 
of the different dose distribution pattern of the inner rectal wall surface for the two treatment 
plans is displayed in Fig. 7c-d. The combination of DIL-IMRT and a daily inserted ERB, which 
dilates the rectal wall, gives a different dose distribution over the inner rectal wall (Fig. 7c), 
compared to the IMRT-78 plan and ERB (Fig. 7d). In case of DIL-IMRT, a smaller area is 
exposed to a dose > 80 Gy, surrounded by a larger area of about 70 Gy and the dorsal rectal 
wall is exposed to doses < 40 Gy.
				Discussion
 In this study, we have shown the feasibility of using combined functional imaging 
techniques of the prostate gland to integrate them into inverse treatment planning and to 
define a biological target volume (BTV) [1] for high dose intra-prostatic IMRT boosting. This 
MR-based BTV was then superimposed onto a treatment planning CT with a CT-MR gold 
marker-based fusion protocol. With two different IMRT plans and commonly used TCP and 
NTCP models, preliminary data were produced to investigative the potential gains of the 
DIL-IMRT concept.
 Pickett et al. [21] were the first to report on the possible advantages of incorporating 
MR imaging, both anatomical and functional, into a static field prostate IMRT plan. In 
their case report the feasibility of treating a single lobe to 90 Gy, by MRSI guidance, was 
demonstrated. Previous investigations have shown that using anatomical MR images for more 
accurate prostate delineation resulted in 30 % reduction of prostate volume and a reduction 
of the proportion of irradiated rectal wall [2,3]. This is demonstrated in Fig. 6, where, as a 
result of the MR, a sharp delineation of the ventral part of the gland tissue on the CT can be 
made. Integration of anatomical prostate MR imaging with the described CT-MR marker-
based fusion method is now implemented into our daily clinical practice. 
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Figure 6. DIL-IMRT treatment volumes of patient no. 4. 3 panel (transversal, saggital en coronal view) 
CT treatment planning image:  the DIL volume (red colorwash) and prostate (black line) were delineated 
with a margin of 5 and 7 mm, for PTV90 (red line) and PTV70 (orange line), respectively. In yellow the 
central gold marker is indicated.
 Due to the increasing availability and improvements in MR imaging, its role 
in prostate radiotherapy has developed rapidly over the past years. With high sensitivity 
and specificity, both DCE-MRI and MRSI can provide accurate tumor staging [4, 5, 8-12]. 
MRSI has shown to provide a high specificity for prostate cancer [7,41]. This technique has 
proven to be capable of accurately detecting prostate cancer in the peripheral zone [9,10,12]. 
However, the availability of this imaging modality is still limited. Only a few institutions 
have the opportunity and the experience to use MRSI clinically. Experience with DCE-MRI 
in breast and bladder cancer indicates that, due to neo-vascularization, malignant lesions 
demonstrate an earlier and faster enhancement compared with that of benign lesions [42,43]. 
This technique is wide-spread available and is capable of detecting regions of prostate cancer 
in both the peripheral and the central prostate gland zone [4,5,9,10]. In summary, DCE-MRI 
can identify regions of neo-vascularity, suggestive for prostate cancer, while MRSI can detect 
malignant tumor nodules on voxel-size with high specificity.
 Functional prostate MRS imaging can also help to assess local tumor control in an 
early stage [13]. MR-based analysis in 118 prostate cancer patients, irradiated to a dose of 65 
– 70 Gy, revealed that all twelve observed intra-prostatic recurrences originated within the 
initial tumor [18]. This supports the concept of intra-prostatic boosting, with a dose higher 
than 70 Gy, while maintaining the dose to the remainder of the prostate at an intermediate 
dose level (around 65 – 70 Gy). The concept of a BTV for prostate cancer means detection and 
localization of dominant tumor nodules with higher tumor cell density, the so-called DIL, 
in contrast to non-DIL prostate tissue where the tumor cell density is lower and therefore a 
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Figure 7. Transversal dose distribution: for (A) DIL-IMRT 70-90 and (B) IMRT-78 plan of patient no. 4. 
Inner rectal wall dose surface maps resulted from the (C) DIL-IMRT plan and from (D) the IMRT-78 plan. 
The dose distribution of the inner rectal wall surface is displayed by virtual rectum unfolding (i.c. the 
rectum is virtually cut open along the posterior wall). On the horizontal axis the distance from anterior 
(towards the prostate and seminal vesicles) is displayed. On the vertical axis the distance from the most 
caudal delineated CT-scan is given. 
lower irradiation dose may be sufficient. Based on that hypothesis, we tested the DIL-IMRT 
70-90 Gy treatment planning in a small selected patient population and compared it with a 
more standard whole-prostate IMRT 78 Gy plan. Our data suggest a comparable high TCP, 
ranging from 83% to 89%, for both IMRT plans. The DIL-IMRT plan produced in 4 out of 
5 patients a lower Rwall NTCP, as compared to the IMRT-78 plan and in all patients the 
therapeutic (TCP/NTCP) ratio was increased.
 Nutting et al. [20] performed an IMRT planning study in six patients in which the DIL 
volume and localization were derived from prostatectomy specimens that were projected into 
planning CT scans. An IMRT plan (70 Gy whole prostate + 20 Gy boost on DIL) was compared 
with a whole homogeneous irradiated prostate with IMRT to 70 Gy. With the DIL boosting 
the estimated TCP increased from 64.4% to 95.6%. Instead of 70 Gy we choose for 78 Gy, as a 
result of the positive MD Anderson randomized trial [14]. Nutting et al. [20] observed a 1.8% 
increase of the rectal NTCP, to a mean value of 7.7% for the DIL-boost plan. The rectal volume 
was delineated as the rectal wall plus content, so a direct comparison with our NTCP data is 
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difficult. With our DIL-IMRT plan the estimated Rwall NTCP decreased for the individual 
patients with 1 – 3 %, to a mean NTCP of 4 %. In our study the CTV-PTV margins were smaller 
(7 and 5 mm), while Nutting et al. [20] applied 10 mm margins, which also can explain the 
differences in NTCP.
 The TCP/NTCP ratio, as observed by Nutting et al. [20], was very dependent on the 
localization of the DIL: anteriorly in the prostate or posteriorly, close to the anterior rectal 
wall. In our pilot study, we detected the DILs in the posterior part of the peripheral zone of the 
prostate in all five patients. According to extensive pathological examinations, this is also the 
localization where the highest portion (74 %) of the cancer foci is located  [44]. Nevertheless, 
we have to expand our patient population to obtain more variation of DIL localization and 
different DIL volumes to further investigate the impact on the TCP/NTCP ratio. Currently, 
we are enrolling more patients for this study. Also the effect of this novel approach on other 
surrounding radiosensitive structures, such as the neurovascular bundle, penile bulb and 
urethra has to be investigated. This will be topic of future investigations. 
In prostate brachytherapy, the MR image-guided DIL boosting concept has been tested for 
patients with a prostate gland volume < 50 cc [19,22,23]. Only MRSI was used for DIL detection 
and localization. Zaider et al.[23] registered MRSI and ultrasound images for boosting of the 
intra-prostatic tumor regions. In a single patient, three different DIL volumes (1.36  – 3.71 
cc) were defined: one from actual MRSI information and two hypothetically constructed. 
Depending on the size of the DIL, the image-guided boost yielded TCP values ranging from 
94.3% to 96.5%, without increasing the maximum urethral dose. In comparison, standard 
brachytherapy treatment resulted in TCP values ranging from 64.9% to 76.1%. An endorectal 
probe, filled with 100 cc of air, was used for MRSI, causing gland deformation and therefore 
difficulties arose with the registration procedure. They have developed an algorithm to 
overcome this problem and achieved absolute 3D-positional errors of 2.2 mm ± 1.2 (mean ± 
1SD) [24]. In our study, we used the ICP method in which the gold marker surface models 
are automatically registered. With this method, a MR-CT fusion precision of 1.1 mm was 
achieved in a dataset of 21 patients using 5 operators [25]. Dibiase et al [19] and Pouliot et 
al.[22] encountered also problems with precise MR-CT registration due to gland deformation 
by the endorectal coil. MRSI-determined prostate boost volumes were manually entered into 
the planning system and the gland distortion was addressed only visually. In our study, we 
used for CT-scanning an endorectal balloon (ERB), filled with 80 cc of air, identical to the MR 
endorectal coil. This resulted in almost equal deformation of the prostate gland in MR and CT 
scanning, resulting in an accurate DIL projection onto the CT scan. ERBs are used in prostate 
radiotherapy for their rectal wall sparing effect and are well tolerated by most patients [27-
29,38]. The ERB is often referred to as a prostate immobilizer, but due to presence of gas and 
stool surrounding the ERB, the day-to-day interfraction prostate displacements can be high, 
up to 4.7 mm (1 SD) for the anterior-posterior direction [26]. Therefore, we now use the ERB 
in combination with a gold marker based portal imaging verification and correction protocol 
[26,30-32].
 The presented DIL-IMRT plan, in combination with a daily inserted ERB, which dilates 
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the rectal wall, gives an interesting dose distribution over the inner rectal mucosa (Fig. 7c). 
A relatively small area is exposed to high doses (> 80 Gy), surrounded by a larger area of 
intermediate doses and a low dose over the dorsal rectal wall. Recent data have shown that 
this type of spatial dose distribution and also the amount of rectal wall surface irradiated to 
low doses may further reduce the Rwall NTCP [34]. Therefore, in treated DIL-IMRT patients, 
the actual Rwall late toxicity may even be lower than the estimations calculated in this study, 
based on the Lyman-Kutcher-Burman model with Emami parameters [35-37]. Execution of the 
DIL-IMRT concept and thorough follow-up may also provide us with additional information 
to construct more accurate Rwall NTCP models.
 Regarding the TCP calculations, it should be remarked that there is still an ongoing 
debate in the literature on the LQ parameter values especially whether the alfa/beta ratio 
is low, i.e. in the range typical for late responding tumors [44-46]. For the TCP calculations 
we have applied parameters comparable to those applied by Nutting et al [20], i.e. an alfa/
beta value typical of early responding tissues (as applied by Nahum et al [40]) and further 
assuming a heterogeneous distribution of radiation sensitivities (alfa) and assuming a ratio 
of 100 in the clonogen densities between DIL  (107 cells/cm3) and the rest of the prostate 
(105 cells/cm3). An extensive comparison of different TCP models is beyond the scope of this 
paper. However, we have verified that choosing a low-alfa/beta TCP model does not alter 
the conclusions. If parameters proposed by Wang et al. (45) are used  (i.e. alfa/beta = 3.1 Gy, 
alfa = 0.15 ± 0.04 Gy-1, Tpot = 42 days and number of clonogens is in the range 106-107), the 
absolute TCP values change, but the relative values for the DIL-IMRT and IMRT-78 plans are 
comparable and did not differ.
 The issue of multi-focality of prostate cancer is not addressed in this technical 
feasibility study. In a large pathology study, 83% of the prostatectomy specimens had more 
than one cancer focus [47]. For this feasibility study we selected patients with uni-lateral 
palpable, ultrasound detected and biopsy-proven tumors. This was done to avoid possible 
extra difficulties in interpreting and executing the implementation of the described CT-MR 
fusion and DIL-IMRT planning. Pouliot et al. [22] have reported on multiple DIL volumes 
and it was possible to deliver separate boost volumes on these tumor nodules with MRS-
guided brachytherapy, without compromising the surrounding normal tissues. In another 
study, a multiple boost implant in one patient with 4 tumor foci was shown infeasible (19). 
For all other patients an MRSI-guided brachytherapy boost was given successfully with 
toxicity comparable to conventional treatment. The goal of our study was to demonstrate 
the feasibility of incorporating two MR imaging techniques in a (single) external beam DIL-
IMRT concept for a wide range of prostate gland volumes (41-106 cc). The next step will 
be to include more patients, also with more than one DIL and to investigate the possible 
advantages or disadvantages, in terms of tumor control probability and toxicity. Xia et al. 
[48] have already demonstrated the feasibility of planning two DILs up to 90 Gy with IMRT 
on a selected patient case, but their DIL volumes were derived from MRSI only and, due to 
ERB induced gland deformation in the MRS study, the MR-CT image fusion was a visual 
approximate process. The DIL-IMRT concept may not be applicable in the case of more than 
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two or three DILs localized near the rectal wall or urethra, due to unacceptably high estimated 
toxicity scores. Currently, we are enrolling also bi-lateral prostate tumors with multiple DILs 
and we are further evaluating the presented intra-prostatic IMRT boosting under DCE-MRI 
and MRSI guidance.  
 In this study, the feasibility was demonstrated to integrate two functional prostate 
MR imaging techniques into inverse treatment planning, for the definition of a dominant 
intra-prostatic lesion (DIL) for high-dose intra-prostatic boosting with IMRT (DIL-IMRT). In 
all patients the combination of DCE-MRI, identifying regions of neo-vascularity, suggestive 
for prostate cancer, and MRSI, detecting tumor nodules with high specificity, yielded a 
clearly defined single DIL volume. This DIL volume could be accurately transferred to the 
radiotherapy treatment planning system, by CT-MR image registration based on matching 
3D gold marker surface models and usage of the same type of ERB for CT and MR imaging. 
Compared to the IMRT-78 plan, the DIL-IMRT plan estimated a similar TCP, but a decreased 
Rwall NTCP. This resulted in an increase of the therapeutic (TCP/NTCP) ratio, in favor of 
the DIL-IMRT plan. Also the typical Rwall spatial dose distribution, as a result of the DIL 
boosting, may indicate a further reduced actual rectal toxicity.
 Before bringing DIL-IMRT into clinical practice, a larger patient population, with 
more variation in the number and localization of the DIL, has to be studied to extend these 
preliminary tumor control probabilities and toxicity estimates.
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Summary 
and 
Conclusions 
    Summary
 Magnetic resonance (MR) imaging, 1H-MR spectroscopic and dynamic contrast-
enhanced MR imaging techniques allow us to investigate patients with prostate cancer. These 
techniques can be used for tumor localization and local staging. The aim of this thesis was 
to evaluate how these advanced MR techniques will improve localization and local staging 
performance in prostate carcinoma and if these results will further improve at high field 
strength (i.e. 3 tesla). Clinical consequences of these new techniques were also discussed. 
	 Chapter 2 presents a literature review of the role of MR imaging in prostate cancer 
staging. MR imaging is considered to play an important role in local staging of prostate 
cancer. However, only 0.9% to 7.5% of all patients undergo MR imaging [1, 2]. Based on an 
urologist expert opinion: firstly, “MR imaging is not accurate enough in local staging (due to 
the large reported variability and expertise dependency)”. Secondly, “it is an expensive tool” 
and thirdly, “I don’t have this tool”. Therefore, to justify the use of an expensive imaging 
modality like MR imaging, patients outcome should be improved through the use of imaging 
technique e.g. to better assess the preoperative chance of having extracapsular extension. To 
achieve this goal, staging accuracy of imaging should be high, results should have a positive 
effect on therapy decision and the altered therapy should decrease morbidity, increase life 
expectancy and quality of life, preferably with reduced costs. 
In this review recommendations concerning the use of MR imaging as a local staging tool are 
summarized: 
1. “Those who perform MR imaging in cases of prostate cancer should determine their own 
standard of accuracy by carefully comparing their imaging results with histopathological 
findings” [3]. 
2. MR imaging of the prostate has a steep learning curve. MR imaging should be performed 
in centers with at least 25-50 patients per year and where results will constantly be compared 
with whole mount section histopathology [4] in order to improve the imaging accuracy. 
3. MR imaging should be performed with high specificity reading and is cost-effective in the 
intermediate-risk group of having extraprostatic disease [5]. 
 Despite extracapsular extension signs [6-8], the sensitivity of local staging is rather 
low. This may be explained due to low in plane resolution and the lack of a surface coil near 
the prostate. The use of an endorectal coil may improve staging sensitivity and anatomical 
details. This is presented in chapter 3. 
	 In	chapter 3 it was found that the use of a combined endorectal-phased array coil 
resulted in a significant improvement of anatomical details, local staging accuracy (T2 vs. 
T3), and specificity. Using an endorectal-phased array coil was found to significantly reduce 
overstaging with equal sensitivity. Local staging accuracy, specificity and sensitivity using the 
endorectal-pelvic phased array coil were 83%, 65% and 98%, respectively. The less experienced 
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readers obtained almost similar staging results (area under the ROC curve = 0.70) compared to 
the experienced reader (area under the ROC curve = 0.74). This suggests that, due to the high 
anatomical details with an endorectal coil, the less experienced readers will improve. In the 
low-risk group seven out of thirteen patients were correctly staged with stage T3 disease with 
one false-positive finding (sensitivity 54%; specificity 97%). These results justify MR imaging 
in a low-risk patient group. This means that all patients who are considered candidates for a 
radical prostatectomy should undergo MR imaging with high specificity, their final treatment 
selection being based on MR imaging findings.
	
	 In	 chapter 4 the outcomes indicate that the use of proton MR spectroscopic 
and dynamic contrast-enhanced MR imaging of the whole prostate is more accurate than 
unenhanced T2-weighted fast spin echo MR imaging in localizing prostate carcinoma. 
These results suggest that these advanced MR imaging techniques can be included in the 
MR imaging protocol in the evaluation for tumor localization in prostate cancer patients. 
Whereas the overall localization accuracy using T2-weighted fast spin echo MR images was 
68%, proton MR spectroscopic imaging revealed an overall localization accuracy of 80%, and 
dynamic contrast-enhanced MR imaging parameters showed diagnostic accuracy up to 91%. 
The area under the ROC curve using dynamic contrast-enhanced MR imaging (range Az = 0.7 
– 0.87) and MR spectroscopy (Az = 0.80) was significantly better compared to the T2-weighted 
MR imaging (Az = 0.68).
 The combination of the high specificity of the functional data of MR spectroscopy and 
the high sensitivity of dynamic contrast-enhanced MR imaging accurately localizes a prostate 
cancer nodule in the whole prostate. The clinical application of this improved localization can 
be applied, firstly, in patients with elevated prostate specific antigen and negative biopsies 
(image guided biopsy of the suspicious lesion). Secondly, this improved localization can be 
used to evaluate the tumor location with respect to the prostate capsule in order to recognize 
T3 disease (see chapter 5). Thirdly, exact localization of the prostate cancer lesion(s) is required 
for the planning of intensity-modulated radiation therapy (IMRT) in order to administer an 
extra boost of radiation dose to in addition to the normal dose (see chapter 9).
 The study in chapter 5 evaluates the local staging accuracy of dynamic contrast-
enhanced MR imaging using whole mount section histopathology as the reference standard 
in 99 patients. On contrast-enhanced MR imaging, prostate cancer exhibits an earlier and 
rapid enhancement [9-10]. This finding can be used to improve the evaluation of extraprostatic 
extension and to increase tumor detection. The latter is described in chapter 4. In chapter 4, the 
use of multi-slice dynamic contrast-enhanced MR imaging in staging prostate cancer showed 
significant improvement in staging performance for the less experienced readers, but had 
no benefit for the experienced reader. The local staging performance for the less experienced 
readers significantly increased using parametric dynamic contrast-enhanced MR imaging 
compared to T2-weighted MR imaging alone. The area under the ROC curve increased from 
Az = 0.66 to Az = 0.82 (p = 0.01). The final local staging accuracy, specificity and sensitivity 
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using dynamic contrast-enhanced MR imaging was 87%, 97% and 69%, for the experienced 
reader. 
 Our prospective study has demonstrated that it is possible to achieve high specificity 
and accuracy in a large group of patients. Contrast administration helps a less experienced 
reader to achieve staging results of an experienced reader. In every day practice this may 
lead to less variable and more accurate staging results, and thus eventually to better general 
acceptance by clinicians.
	 In	chapter 6 the feasibility and potentials of 3T endorectal MR imaging in 10 patients 
was explored and the first results are presented. The use of high magnetic field strengths 
offers new possibilities in MR imaging and functional MR imaging. If noise of the sample 
dominates over coil noise the signal-to-noise ratio (SNR) is approximately two times higher 
at 3T compared to1.5T; this increase is almost linear to the main magnetic-field strength. The 
latter SNR has been used to increase the spatial, temporal and spectral resolution in this study. 
The increased spectral resolution of the 3D chemical shift imaging measurements separated 
relevant metabolite resonances from each other and from residual water and lipid signals 
and can thereby provide an increased specificity for prostate cancer. Apart from the increased 
spectral resolution, which is a major advantage of the higher field strength, the SNR of the 
individual resonances can also be higher at 3T compared to 1.5T, since the used echo time of 
75 ms is significantly shorter than the routinely used echo time at 1.5T (120 ms). Due to the 
high SNR it was possible to achieve a temporal resolution of 1 second obtaining 10 slices. 
This can be used to estimate more accurately the dynamic contrast-enhanced MR imaging 
parameters.
 The study in chapter 7 evaluates the local staging performance of 3T endorectal MR 
imaging of the prostate using whole mount section histopathology as the reference standard 
in 32 patients. The local staging accuracy, sensitivity, specificity were respectively 94%, 88% 
and 96%, for the experienced radiologists with substantial agreement between κ = 0.42 to 0.79. 
Of three cases of minimal capsular invasion (< 2mm), two were detected by both experienced 
radiologists. The results of this study demonstrated that the 3T endorectal coil MR technique 
of the prostate increased the local staging accuracy, with a high sensitivity and retaining high 
specificity and indicate that 3T endorectal MR imaging is of additional value to patients with 
prostate cancer. If the prevalence of extracapsular disease is for example 30% and MR imaging 
is performed with the aforementioned specificity and sensitivity, than in 1 out of 3 or 4 patients 
MR will affect the treatment. The outcomes of this study suggest a future role for high-field 
imaging in prostate cancer staging. MR imaging can be used in the preoperative selection, 
also in a low risk group, and may help to reduce number of positive margins as a result of the 
high anatomical resolution. 
 Functional MR imaging techniques can be used to localize prostate cancer nodules 
for the planning of IMRT. However, conventional treatment planning uses the electron 
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density estimate obtained at CT to calculate dose distribution. And thus, in chapter 8	 the	
iterative closest point method for registration of CT and MR images of the prostate gland after 
placement of fiducial markers was investigated. The iterative closest point method entails a 
manual segmentation of the markers. A registration of the CT and MR marker models that 
would minimize the root-mean-square distance between the surfaces by using the iterative 
closest point method was determined [11]. The iterative closest point method was significantly 
more precise than the landmark method (p < 0.01). This method can be used to fuse functional 
MR imaging data with CT data and transport this data to a radiotherapy planning system. 
Tumor nodules can be located with functional MR imaging techniques as described in chapter 
4. Precise alignment of CT and MR images of the prostate is possible by using fiducial gold 
markers and dedicated registration methods. A functional MR analysis tool is required that 
can reduce multiple functional MR imaging parameters into a single interpreted prostate 
lesion map. 
	 In	 chapter 9 the feasibility to integrate two functional prostate MR imaging 
techniques (dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging) 
into inverse treatment planning for definition and irradiation of a dominant intra-prostatic 
lesion as a biological target volume for high-dose intra-prostatic boosting with intensity-
modulated radiation therapy, is presented. The use of defining a biological target volume 
and intensity-modulated radiotherapy for advanced “dose painting” [12] is gradually 
introduced into clinical practice. Combined dynamic contrast-enhanced MR imaging and 
proton MR spectroscopy yielded a clearly defined single dominant prostatic lesion volume 
(1.1 – 6.5cc) in our 5 patients. In this small, selected patient population no differences in tumor 
control probability were found. A decrease of the rectal wall normal tissue complication 
probability was observed in favour of the dominant intraprostatic lesion intensity-modulated 
radiation therapy plan, as compared to the intensity-modulated radiation therapy-78 plan. 
The combination of functional MR image-guided high-dose intra-prostatic dominant intra-
prostatic lesion intensity-modulated radiation therapy boosting to 90 Gy is technically feasible. 
This may result in improved local tumor treatment and less toxicity of the surrounding 
structures. 
	
				Conclusions
The following overall conclusions can be made:
1. Based on the literature, local tumor staging of the prostate by MR imaging is cost 
 effective and should be performed with high specificity reading in centers with at 
 least 25-50 patients per year and where results can be compared with whole mount 
 section histopathology. 
2. MR imaging of the prostate should be performed with an endorectal-phased 
 array coil combination. This increases the anatomical detail and local staging 
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 accuracy and specificity.
3. Multi-slice dynamic contrast-enhanced MR imaging in staging prostate cancer 
 should be used by less experienced readers in order to obtain high accuracy and 
 specificity, comparable with T2-weighted MR imaging read by an experienced 
 reader.
4. Proton MR spectroscopy and dynamic contrast-enhanced MR imaging increases 
 the localization accuracy significantly compared to T2-weighted imaging.
5. The combination of the specificity of the functional data of MR spectroscopy and 
 washout, and the sensitivity of ve, kep and Ktrans may help to localize a prostate 
 cancer nodule in the whole prostate more accurate. 
6. It is feasible to perform endorectal MR imaging at 3T in patients with prostate 
 cancer with the advantages of an increased spatial resolution of T2-weighted and 
 contrast-enhanced T1-weighted MR images, an increased temporal resolution of 
 dynamic contrast-enhanced MR imaging and spectral resolution of MR 
 spectroscopy.
7. 3T endorectal MR imaging can be used to obtain high staging accuracy, specificity 
 and sensitivity in prostate cancer patients.
8. A voxel volume of 13-µm3 can be obtained which resulted in detection of minimal 
 capsular invasion (< 2 mm) at 3T. 
9. Precise alignment of CT and MR images of the prostate is possible by using fiducial 
 gold markers and dedicated registration methods.
10. It is feasible to integrate two functional MR imaging techniques into inverse 
 treatment planning for the definition of a dominant intra-prostatic lesion for high-
 dose intra-prostatic boosting with IMRT.
Recommendations and suggestions for further research
Future Research
 In our work advanced MR imaging techniques have been explored. Feasibility 
studies have been performed which resulted in initial results. These results and clinical 
applications have to be validated in future research. MR technology is progressing at a fast 
pace. In this thesis, we focused on high spatial resolution in order to attain high staging and 
localizing accuracies. Is the in plane resolution attainable with a body array at 3T sufficient for 
localizing and staging prostate cancer patients? The use of only a body array coil at 3T would 
be time-saving and causes less discomfort to the patient. This technique could be applied for 
screening purposes as well as IMRT treatment planning. These questions and the need for 
high spatial resolution have to be evaluated in future studies. 
 As discussed in chapter 4, in literature there is no consensus about general criteria 
which can be used for DCE-MR imaging. Also quantitative evaluation of DCE-MR imaging 
parameters has not been studied so far. Future research projects may be directed to establishing 
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criteria and accurate quantification of the Gadolinium-concentration. These criteria can be 
used to determine a prostate cancer probability map. Such a probability map contains DCE-
MR and MRS imaging parameters information displayed in one map with tumor probability. 
This map can help the urologist, in patients with rising prostate specific antigen and negative 
biopsies, in MR guided biopsy. This may also help the radiation oncologist with a more 
accurate IMRT planning.
 The insertion of an endorectal coil is time consuming and cause discomfort for the 
patient. The use of a body array coil at 3T in MR spectroscopic imaging may be used for 
prostate cancer detection. This approach has to be evaluated and compared with endorectal 
coil MR imaging in future studies.
 A potential clinical application of the investigated functional MR technique is the 
use of these techniques in patients with local recurrence. Fifteen percent of the low-risk 
patients with prostate cancer who are treated with external beam radiation therapy will have 
a prostate-specific antigen relapse after 5 years [13]. Local recurrence may be amenable to 
salvage prostatectomy, brachytherapy, thermal therapy, or cryotherapy [14]. Diagnosis of local 
recurrence with digital rectal examination and transrectal ultrasound (guided sextant biopsy) 
is challenging and difficult. MR imaging demonstrates low-signal intensity at T2-weighted 
MR imaging after radiation and hormonal therapy. This is caused by fibrosis, glandular and 
metabolic atrophy. Functional imaging techniques may help to visualize the local recurrence. 
Initial results of Pucar et al. [15] have shown that MR imaging and MR spectroscopy may 
be more sensitive than sextant biopsy and digital rectal examination for sextant localization 
of cancer recurrence after external-beam radiation therapy. Future research projects may be 
directed to investigate the usefulness of dynamic contrast-enhanced MR imaging and MR 
spectroscopic imaging with respect to imaging of prostate-specific antigen relapse.
 For the radiation oncologist the information of the prostate capsule, prostate tumor 
and seminal vesicles are important in order to define a radiation treatment planning for the 
patient. Anatomical MR images can be used to outline the prostate and seminal vesicles. This 
approach is more accurate than using CT. The soft-tissue contrast is superior with MR imaging. 
However, conventional treatment planning uses the electron density estimate obtained at CT 
to calculate dose distribution. Validation studies have to be performed to investigate if an MR-
based planning system can replace CT planning [16]. 
	
Recommendations
The following recommendations for (functional) MR imaging of the prostate are given: 
- Patients with prostate cancer who are candidates for radical prostatectomy should 
 undergo MR imaging for treatment selection. Less experienced readers should use 
 DCE-MR imaging for staging purposes.
- Patients with rising PSA and negative biopsies should undergo DCE-MR and MRS 
 imaging. The most likely tumor localization should be displayed on a standardized 
 form in order to guide the urologist for a better biopsy.
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- Patients who will undergo IMRT of the prostate will have to undergo DCE-MR and 
 MRS imaging, to determine the dominant intraprostatic lesion, prior to the 
 treatment. The sensitivity of kep, Ktrans and ve, combined with the specificity of 
 MRS imaging and washout should be used to determine this dominant 
 intraprostatic lesion.
- Institutions who have a 3T MR system should perform endorectal MR imaging in 
 prostate cancer patients who are candidates for radical prostatectomy for local 
 staging. 
- The radiological report should include: tumor stage, tumor location (relation to the 
 prostate capsule and neurovascular bundle) and a standardized digital form with 
 detailed information of the aforementioned stage and tumor location(s).
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				Samenvatting
 MRI, proton MR spectroscopie en dynamische contrast MRI zijn technieken waarmee 
onder andere patiënten met prostaat carcinoom bestudeerd kunnen worden. Deze technieken 
kunnen gebruikt worden om een tumor te lokaliseren en te stadiëren. In dit proefschrift zijn 
geavanceerde MRI technieken toegepast om te bestuderen of de lokalisatie en stadiering van 
de tumor verbeterd kan worden en of deze resultaten verder zullen verbeteren door gebruik 
te maken van hogere veldsterktes (3 tesla). De klinische consequenties van deze technieken 
werden besproken.
	 In	 hoofdstuk 2 wordt een literatuur overzicht gepresenteerd over de klinische 
relevantie van stadiëren van het prostaatcarcinoom met behulp van MRI. MRI wordt een 
belangrijke rol toegeschreven voor de lokale stadiering van het prostaat carcinoom. Echter, 
slechts 0.9% tot 7.5% van alle patiënten met prostaat kanker zullen MRI ondergaan. De 
volgende drie oorzaken zijn gebaseerd op de expert opinie van een uroloog. Ten eerste 
vindt hij MRI niet accuraat genoeg voor de lokale stadiering van het prostaat carcinoom 
hetgeen wordt veroorzaakt door de grote variatie van de resultaten en de afhankelijkheid 
van aanwezige expertise. Ten tweede is het een dure techniek en ten derde heeft niet iedere 
kliniek deze techniek tot zijn beschikking. Om het gebruik van deze dure techniek toch te 
kunnen rechtvaardigen, moet de uitkomst voor de patiënten verbeteren, dat wil zeggen dat 
door gebruik van MRI beter voorspeld moet kunnen worden wat de preoperatieve kans 
is op het hebben van doorgroei van prostaat carcinoom in het kapsel. Niet alleen moet de 
stadiering nauwkeurig zijn, maar ook moeten de resultaten een positief effect hebben op 
de therapeutische beslissing en moet de eventueel gewijzigde therapie de morbiditeit terug 
dringen en de levensverwachting en kwaliteit van leven verhogen, waarbij de kosten van de 
medische zorg dalen.
 Er worden enkele aanbevelingen gegeven over de lokale stadiering van het 
prostaatcarcinoom met behulp van MRI. 
1. “Diegene die prostaat MRI voor lokale stadiering van het prostaat carcinoom 
verrichten moeten hun eigen nauwkeurigheid bepalen en zorgvuldig hun resultaten van de 
beeldvorming vergelijken met de histopathologische bevindingen”.
2. MRI van de prostaat heeft een steile leercurve. Daarom zou MRI alleen verricht 
moeten worden in centra met minimaal 25 tot 50 patiënten per jaar, waarbij de resultaten 
voortdurend vergeleken kunnen worden met de histopathologie zodat de nauwkeurigheid 
verbeterd wordt.
3. MRI beelden moeten met een hoge specificiteit gelezen moeten worden, hetgeen 
kosten effectief is in de groep patiënten met een gemiddeld en hoog risico op het hebben van 
extra kapsulaire uitbreiding van de tumor.
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 Ondanks de verschillende criteria voor kapsel doorbraak, is de sensitiviteit van de 
lokale stadiering beperkt. Dit wordt verklaard door de lage spatiele resolutie. In de volgende 
hoofdstukken wordt besproken hoe de stadiering kan verbeterd worden.
	 In	hoofdstuk 3 wordt de meerwaarde beschreven van een geïntegreerde endorectale 
spoel en pelvic-phased array (ERC-PPA) ten opzichte van het gebruik van alleen de pelvic-
phased array spoel (PPA) voor de afbeelding van anatomische details en lokale stadiering. 
Het gebruik van een ERC-PPA resulteerde in een significante verbetering van de anatomische 
details en een afname van overstadiering bij gelijk blijvende sensitiviteit. Deze verbetering 
trad zowel op bij ervaren als minder ervaren beoordeelaars. Dit suggereert, dat door een meer 
gedetailleerde weergave dankzij de endorectale spoel, de resultaten van de minder ervaren 
beoordeelaars zullen verbeteren. Dit betekent dat meer patiënten, die in aanmerking zouden 
komen voor een radicale prostatectomie, kunnen profiteren van een preoperatieve MRI. Op 
basis van de MRI bevindingen wordt zo uiteindelijk de therapie keuze positief beïnvloed.
	 In	hoofdstuk 4 is de betekenis van de dynamische MRI - en proton MR spectroscopie 
bij het lokaliseren van het prostaat carcinoom bestudeerd. Het gebruik van deze twee 
technieken resulteerde in een verbeterde lokalisatie van het prostaat carcinoom in vergelijking 
met conventionele vaak gebruikte T2-gedomineerde fast spin echo MRI. Deze resultaten geven 
aan dat geavanceerde MRI technieken in het MRI protocol geïmplementeerd kunnen worden 
voor het beter bepalen van de tumor lokalisatie bij patiënten met prostaat carcinoom. 
 De combinatie van de hoge specificiteit van de functionele MR spectroscopie en de 
hoge sensitiviteit van de contrast MRI levert een zeer accurate lokalisatie van het prostaat 
carcinoom op. Klinische kan dit gebruikt worden voor meerdere doeleinden. Ten eerste 
bij het verbeteren van biopsie resultaten bij patiënten met verhoogde PSA waardes, maar 
herhaaldelijk negatieve biopsieën. Ten tweede om de relatie tussen de tumor en het prostaat 
kapsel aan te tonen en zo de stadiering te verbeteren (hoofdstuk 5). Ten derde kan deze meer 
exacte lokalisatie van het prostaat carcinoom gebruikt worden voor de planning van intensity-
modulated radiotherapie (IMRT) waarbij, naast de normale dosis, een extra dosis bestraling 
op de biologische actieve tumor wordt toegepast.(hoofdstuk 9).
	 In	hoofdstuk 5 wordt beschreven wat de waarde is van de dynamische MRI bij de 
lokale stadiering van het prostaat carcinoom. Bij gebruik van contrast MRI toont prostaat 
carcinoom een vroege en snelle aankleuring. Deze bevinding kan gebruikt worden om 
doorgroei van het prostaatcarcinoom door het prostaat kapsel beter aan te tonen. Het 
gebruik van dynamische contrast MRI resulteerde in een significante verbetering van de 
lokale stadiering door de minder ervaren beoordelaars, maar dit was niet het geval voor de 
ervaren beoordelaar. Het gebruik van de dynamische contrast MRI resulteerde uiteindelijk 
in een nauwkeurigheid van de lokale stadiering van 87%, een specificiteit van 97% en een 
sensitiviteit van 69%. 
10
174
 Het is dus mogelijk om ook met minder ervaren beoordelaars door het gebruik van 
contrast een hoge specificiteit en nauwkeurigheid te behalen. Dit kan leiden tot een minder 
beoordelaarafhankelijke en een meer accurate stadiering en waarschijnlijk tot een meer 
algemene acceptatie van deze techniek door de clinici.
	 In hoofdstuk 6 zijn de eerste resultaten beschreven van MRI met een endorectale 
spoel bij een hoge veldsterkte van 3 tesla (3T). Het gebruik van hogere veldsterktes biedt 
nieuwe mogelijkheden voor de anatomische en functionele MRI. De signaalruis verhouding 
(beeldkwaliteit) is met 3T ongeveer twee keer zo hoog als met 1.5T. 
 Het is mogelijk om een endorectale spoel MRI bij 3T uit te voeren bij patiënten 
met prostaat carcinoom, waarbij de volgende voordelen gezien werden: een hogere spatiele 
resolutie voor de anatomische en contrast aankleurende MR afbeeldingen en een hogere 
spectrale resolutie voor MR spectroscopie. Het werd aannemelijk gemaakt dat door gebruik 
van endorectale spoel MRI bij 3T de klinische toepassingen zullen kunnen uitbreiden. 
	 In	hoofdstuk 7 wordt beschreven wat de resultaten zijn van de lokale stadiering 
van het prostaat carcinoom met behulp van endorectale spoel MRI bij 32 patiënten bij 3T. 
De nauwkeurigheid van de lokale stadiering, sensitiviteit en specificiteit zijn, 94%, 88%, en 
96%, voor de ervaren beoordelaars met substantiële beoordelaar overeenkomst (kappa = 0.42 
tot 0.79). Bij drie patiënten waar minimale kapsel invasie bestond (<2mm), werden er twee 
door beide ervaren beoordelaars gedetecteerd. De resultaten van deze studie laten zien dat 3T 
endorectale spoel MRI van de prostaat een techniek is met een verbeterde lokale stadiering. 
Deze techniek heeft een hoge sensitiviteit verkregen met behoud van een hoge specificiteit. 
Dit houdt in dat 3T endorectale spoel MRI een toegevoegde waarde heeft bij patiënten met 
prostaat carcinoom. Als bijvoorbeeld de prevalentie van doorgroei van het prostaat carcinoom 
in het kapsel 30% bedraagt en MRI wordt uitgevoerd met de hierboven genoemde specificiteit 
en sensitiviteit, dan zal de MRI in 1 op de 3 à 4 patiënten de behandeling beïnvloeden. De 
uitkomsten van deze studie suggereren een duidelijke rol voor 3T MRI bij de stadiering van 
het prostaat carcinoom. 3T endorectale MRI kan gebruikt worden voor de preoperatieve 
selectie, ook in de groep patiënten met een laag risico op doorgroei in het kapsel en zou, door 
zijn hoge anatomische resolutie, ook kunnen helpen bij het reduceren in het aantal positieve 
resectie vlakken.
 Functionele MRI informatie kan gebruikt worden voor het lokaliseren van het 
prostaat carcinoom voor de planning van IMRT. Echter, deze planning maakt gebruik van 
CT beelden voor het calculeren van de dosis distributie. In hoofdstuk 8 wordt de iteratieve 
closest point (ICP) methode beschreven voor de registratie van CT en MR beelden van de 
prostaat na plaatsing van goud markers. De ICP methode omvat een manuele segmentatie 
van deze markers. De ICP methode kan gebruikt worden voor het fuseren van functionele 
MRI data met CT data. Deze studie heeft aangetoond dat precieze uitlijning van CT en MR 
beelden van de prostaat mogelijk is door gebruik te maken van goud markers en registratie 
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methoden. 
	 In	hoofdstuk 9 wordt de uitvoerbaarheid beschreven van het integreren van twee 
functionele MRI technieken (dynamische MRI en MR spectroscopie) in een behandelplan 
voor het definiëren en bestralen van de dominante intra-prostatische laesie (DIL) met behulp 
van IMRT. In de studie groep (n = 5) werden geen verschillen gevonden in “tumor control 
probability”. Er werd een vermindering van rectum wand “normal tissue complication 
probability” gevonden ten voordele van DIL-IMRT bestralingsplan. De combinatie van 
functionele MRI geleide hoge dosis op de DIL met behulp van IMRT boosting tot 90 Gy is 
technisch haalbaar. Dit zou kunnen resulteren in een verbeterde lokale tumor behandeling en 
minder toxiciteit op de omliggende weefsels.
	
    Conclusies
De volgende algemene conclusies worden in dit proefschrift getrokken:
1. Gebaseerd op de literatuur, is lokale stadiering van het prostaat carcinoom kosten 
 effectief bij patiënten met een hoge specificiteit, en moet uitgevoerd worden in 
 centra waar minimaal 25-50 patiënten per jaar worden onderzocht waar de 
 resultaten vergeleken kunnen worden met de histopathologie.
2. MRI van de prostaat kan het beste uitgevoerd moeten worden met een 
 geïntegreerde endorectale-pelvic phased array coil. Dit verbetert de visualisatie van 
 de anatomische details van de prostaat en de nauwkeurigheid en de specificiteit
 van de lokale stadiering.
3. Dynamische contrast MRI zou voor de lokale stadiering van het prostaat carcinoom 
 gebruikt moeten worden door onervaren beoordelaars. Dit om een hoge 
 nauwkeurigheid en specificiteit te verkrijgen welke vergelijkbaar zijn met de 
 gelezen T2-gedomineerde MR beelden door een ervaren beoordelaar.
4. Proton MR spectroscopie en dynamische MRI verbetert significant de 
 nauwkeurigheid van de lokalisatie van het prostaat carcinoom vergeleken met T2-
 gedomineerde beelden en kan hiermee ook de stadiering verbeteren.
5. De combinatie van de specificiteit van MR spectroscopie en washout, en de 
 sensitiviteit van ve, kep en ktrans resulteert in een meer accurate lokalisatie van het 
 prostaat carcinoom in de gehele prostaat.
6. Het is mogelijk om 3T endorectale MRI uit te voeren bij prostaat carcinoom 
 patiënten met de voordelen van een toegenomen spatiele resolutie van T2-
 gedomineerde en post contrast T1-gedomineerde MR beelden en een toegenomen 
 temporele resolutie van de dynamische contrast MRI en spectrale resolutie in MR 
 spectroscopie.
7. 3T endorectale MRI resulteert in een nauwkeurigere stadiering, specificiteit en 
 sensitiviteit bij patiënten met het prostaat carcinoom.
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8. Een voxel volume van 13-µm3 kan verkregen worden, welke resulteerde in de 
 detectie van minimale kapsel doorgroei (<2 mm) op 3T veldsterkte.
9. Precieze uitlijning van CT en MR prostaat beelden is mogelijk door gebruik te 
 maken van goudmarkers en registratie methoden.
10. Het is mogelijk om twee functionele MRI technieken te integreren tot een 
 behandelingsplanning voor de definitie van een dominante intra-prostatische 
 tumor voor hoge dosis intra-prostatische boosting met IMRT.
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voor de samenwerking
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en Arend Heerschap, dank voor de samenwerking.
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Heijmink en Mark Stoutjesdijk.
Tenslotte gaat mijn dank uit naar mijn ouders, mijn broer, familie en vrienden, die me gesteund hebben. 
Lieve Ninske, ik wil jou in het bijzonder bedanken voor de ruimte en het geduld die je me hebt gegeven. 
Ik weet dat ik soms in mijn enthousiasme de tijd kan vergeten....
JJ
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